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(Under the direction of Ted Bateman) 
Radiation therapy is a common clinical technique used to reduce tumor proliferation. A 
2005 study by Baxter et al. showed that women who received pelvic radiation therapy were more 
likely to experience a pelvic fracture and 90% of these fractures were hip fractures [3]. There is 
also clinical evidence that premenopausal women with gynecological tumors may experience a 
premature and permanent menopause as a result of damage to the ovaries caused by radiation 
therapy [11]. The effects of this early onset estrogen deficiency on bone health may be more 
severe since these patients likely have not reached peak bone mass.  
Both structural and material properties play an important role in the assessment of bone 
strength and fracture risk. Structural parameters, such as bone volume and trabecular thickness, 
are often studied more frequently due to the relative ease of access to imaging modalities and the 
ability to image in vivo. Changes in bone composition and material properties resulting from 
disease states or treatment methods are just as important in predicting bone function, but are 
more difficult to assess. In the first aim, a mouse model for structural changes resulting from 
fractionated radiation therapy and estrogen deficiency will be characterized at multiple skeletal 
sites. In the second aim, the efficacy of zoledronate to mitigate bone loss from radiation therapy 




model. For the final aim, the techniques developed in aim two will be applied to evaluate joint 
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CHAPTER 1: GENERAL BACKGROUND 
Introduction  
 Bone is a dynamic tissue composed of 20-40% organic matrix, 50-70% mineral, 5-10% 
water and less than 3% lipids [12]. Hydroxyapatite (Ca10(PO4)6(OH)2) is the main component of 
the mineral portion of bone, although carbonate, acid phosphate and magnesium can also appear 
in small amounts. Hydroxyapatite crystals are approximately 20-100 nm, but change in size, 
number of impurities and shape over time as they mature [12]. The organic matrix is primarily 
made up of Type 1 collagen (~90%). Other noncollagenous proteins exist in much smaller 
quantities within the organic matrix, including osteonectin, osteocalcin, osteopontin, fibronectin, 
bone morphogenetic proteins, proteoglycans and growth factors [13]. Together, the matrix of 
bone allows for energy absorption and the mineral component of bone provides support for high 
loads and resists deformation [12]. 
Bone Cells 
Osteoblasts, osteoclasts and osteocytes are the three major cell types that make up bone 
and influence bone remodeling [14]. Osteoblasts are bone-forming cells roughly 20-30 microns 
in size that are derived from mesenchymal stem cell. Among other tasks, the osteoblast is 
responsible to producing and secreting Type 1 collagen that makes up the osteoid (unmineralized 
surface) [15]. These cells can be found lining bone surfaces and their differentiation is mediated 
by bone morphogenic proteins and other growth factor-β proteins [14].  
Osteocytes are osteoblasts that have become embedded in the bone matrix and account 
for ninety percent of all bone cells [12, 14]. These cells form an extensive canalicular network 
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which connects them to both cells on the bone surface as well as other osteocytes. The area in the 
bone in which osteocytes are found are called lacunae. Through the lacunar-canalicular network, 
osteocytes can sense mechanical forces or microdamage within the bone and then signal for 
remodeling in order to repair the damage. Osteocytes are capable of responding to metabolic 
signaling as well, including changes in estrogen [15]. 
Osteoclasts are large, multinucleated cells approximately 150-200 microns in diameter 
that reside in shallow cavities of the bone surface, often referred to as Howship’s lacunae [14]. 
Osteoclasts are derived from mononuclear precursor cells of the monocyte-macrophage lineage. 
The main role of the osteoclast is to resorb bone [12]. In order to resorb bone, osteoclasts secrete 
hydrogen ions and cathepsin K enzyme. The acidity of the hydrogen ions dissolves the mineral 
portion of the bone matrix and then cathepsin K can digest the bone matrix [12]. Osteoclast 
function is mediated by numerous cytokines and factors including receptor activator of nuclear 
factor kappa-B ligand (RANKL), osteoprotegerin (OPG), macrophage colony-stimulating factor 
(macrophage CSF), interleukin-1, interleukin-6 and calcitonin [14]. 
Hierarchical Structure of Human Bone 
The organization of bone varies at different length scales, from sub-nanostructure up to 
macrostructure (Figure 1.1) [16]. At the nanostructure level, apatite crystals exist within discrete 
spaces of collagen fibrils. The collagen molecules self-assemble into a triple helix structure. 
Within the apatite crystals are certain impurities including carbonate, hydrogen phosphate, 
sodium, magnesium and others. Average crystal thickness is about 2-3 nm and the  
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average crystal lengths and widths are 50 by 25 nm [16]. A mineralized collagen fibril is 
approximately 100 nm in diameter [1]. 
 At the microstructure scale, bone lamellae are composed of tightly packed fibrils into 
bundles roughly 1 to 3 microns in diameter. Every other set of parallel bundles has a similar 
orientation and adjacent co-aligned bundles have between 40 and 80 degree angled offsets [17]. 
The fibrils and bundles create an anisotropic, cylindrical array. There is also a thin layer of 
disordered material between bundles where osteocyte canaliculi are found. An osteon is a 
concentric lamellar structure around a blood vessel [17]. Primary osteons can be differentiated 
from a secondary osteon by the absence of a cement line. A cement line is created where 
resorption stopped and new lamellae started being laid down. Secondary osteons, therefore, are 
products of bone remodeling and are about 100-200 microns in diameter with a 20-40 micron 
diameter central canal [17]. Secondary osteons are often referred to as Haversian systems and 
form parallel to the long axis of the bone.  
 In addition to the highly organized concentric structure of lamellar bone, there can also 
be woven bone. Woven bone is typically made during formation of primary bone and also during 
times of high turnover. The bone appears disorganized and is weaker than lamellar bone [12]. 
Figure 1.1: Hierarchical structure of bone. Reproduced from Liu at al. 2016 [1]
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 At the macrostructure, there is cortical and trabecular (or cancellous) bone. Cortical bone 
is dense, compact bone and can be seen as the outer surface of bone. Trabecular bone is highly 
porous bone (30-90% pores) found primarily at the ends of long bones, with bone marrow found 
in between struts. Within the human body, 80% of bone is cortical bone and 20% is trabecular 
bone). There are five main types of bones in the human body: long bones, short bones, flat 
bones, sesamoid bones and irregular bones. Long bones, such as the tibia and femur, support 
weight and provide structure [12]. Long bones can be divided into three main regions: diaphysis, 
metaphysis and epiphysis. The diaphysis contains mostly dense cortical bone and a hollow 
center. Both metaphysis and epiphysis contain trabecular bone surrounded by cortical bone, with 
the metaphysis being the wide portion of the bone below the growth plates. The epiphysis is the 
rounded portion at the end of the long bone [12]. The periosteum is a connective tissue that 
surrounds the outer cortical surface of bones except at the joints. The endosteum lines the interior 
cortical bone surface [12]. 
Bone Remodeling  
 Bone remodeling occurs in response to physiologic cues or mechanical forces in order to 
retain strength and mineral homeostasis [15]. The general process includes resorption of old bone 
and addition of new bone matrix, followed by mineralization. There are five main stages in the 
bone remodeling cycle: activation, resorption, reversal, formation and termination (Figure 1.2). 
One region of bone undergoing remodeling and including the cells involved is referred to as a 
basic multicellular unit (BMU). 
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 The activation step occurs when a hormonal or mechanical signal is received by bone 
cells. This triggers the bone lining cells to separate from the surface of the bone to expose the 
area for remodeling. Then, osteoclast precursor cells circulating in the body are recruited and 
activated. Osteoclast activation leads to osteoclast differentiation and then attachment to the bone 
surface [18].  
 The next phase, resorption, takes place over the course of 2-4 weeks [15]. The osteoclast 
secretes hydrogen ions in order to lower the pH locally and dissolve the mineral. In order to 
digest the bone matrix, cathepsin K, metalloproteinase and other enzymes are secreted. The end 
result of resorption is the formation of Howship’s lacunae (depressions on the bone surface) and 
osteoclast apoptosis [15]. The reversal phase happens when osteoclasts are replaced by 
osteoblast-lineage cells, though the exact signaling mechanism is still not fully understood [15]. 
This phase takes place over four to five weeks [18]. 
Figure 1.2: Bone remodeling cycle. Reproduced from Siddiqui and Partridge 2016 [9] 
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 During the formation phase, osteoblasts produce and secrete the osteoid matrix composed 
primarily of type 1 collagen. Then, osteoblasts aid in mineralization and eventually either 
undergo apoptosis (50-70% of osteoblasts) or become osteocytes or bone-lining cells. The 
process of bone formation takes roughly 4 to 6 months [18]. The termination phase refers to the 
process of mineralization. Mineralization occurs up to 90 days following osteoid production in 
trabecular bone and 130 days after in cortical bone [15].  
Bone Strength and Methods for Assessment of Relevant Bone Properties 
 Bone strength can be defined as the resistance to fracture. Bone structure, mass, 
geometry, composition and material properties all contribute to overall bone strength [15].  
Clinical Assessment of Bone Strength: 
Clinically, bone density is the most common method for evaluating bone strength [4]. 
The most common imaging modality to assess bone health is Dual-Energy X-ray Absorptiometry 
(DEXA) [4]. DEXA is relatively inexpensive and requires less radiation exposure compared to 
some other imaging options, such as computed tomography (CT) [19]. DEXA measures areal 
bone mineral density (BMD) and is quantified by the amount of hydroxyapatite scanned per unit 
area [20]. Compared to microCT, DEXA does not take distinguish between trabecular and 
cortical bone and does not provide information on bone geometry [21]. Quantitative Computed 
Tomography (QCT) and high-resolution quantitative computed tomography provide three 
dimensional measurements of bone geometry, macrostructure and bone mineral distribution [22]. 
Magnetic resonance imaging (MRI) can also be used to evaluate bone structure and 
microarchitecture. This modality offers the advantages of being noninvasive and not requiring 
radiation exposure, but it is expensive and has a lower spatial resolution compared to CT [23]. 
Other than converting grayscale measures of bone into an estimation for mineral density, 
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material properties are not commonly measured in humans. However, occasionally a bone biopsy 
will be taken in order to assess tissue mineralization and composition [22]. 
Bone Structure Assessment in Mouse Model: 
 In research studies, mice are often used as a model to study osteoporosis and other bone 
pathologies (Figure 1.3) [24]. Micro-computed tomography (microCT) is a standard method for 
assessing bone structure in a mouse model. MicroCT scans can have a voxel size down to 
approximately two microns, allowing for detailed quantification of cortical and trabecular bone. 
Several key parameters used to quantify trabecular structure include bone volume fraction 
(BV/TV), volumetric bone mineral density (vBMD), trabecular number, trabecular thickness 
(Tb.Th), trabecular separation (Tb.Sp) and connectivity density. Bone volume fraction is the 
ratio of the segmented bone volume to the total volume of the region of interest. Volumetric 
bone is a measure calculated by converting the linear attenuation coefficient from the target 
region into an average density of hydroxyapatite (grayscale) per unit volume. Trabecular number 
is a measure of the average number of trabeculae per length unit, trabecular spacing is the mean 
thickness of trabeculae using three dimensional assessment and trabecular separation is the mean 
Figure 1.3: Bone strength determinants and methods to assess properties that influence 
bone strength. Reproduced from Fonseca et al. 2014 [4] 
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distance between trabeculae in three dimensions [25].  Connectivity density (Conn.D) is found 
by taking the number of marrow cavities fully surrounded by bone and the number of 
connections that would need to be broken to split the structure into two parts and dividing by the 
volume [25].  
 Common parameters used to assess cortical bone morphometry from microCT scans 
include cortical porosity (Ct.Po), cortical thickness (Ct.Th), total area (T.Ar), marrow area 
(M.Ar), cortical area (Ct.Ar) and cortical area fraction (Ct.Ar/T.Ar). Cortical porosity is the 
volume of pores divided by the volume of cortical bone in the segmented region. Cortical 
thickness describes the average cortical thickness in the selected region. Total area is an average 
of the sum of both marrow area and cortical area, or all area inside the periosteal surface. The 
cortical area fraction is found by taking the cortical area (endosteal to periosteal surface) divided 
by the total area.  
 In-vivo microCT can also be used to measure structural parameters pre-treatment and 
post-treatment in mice, but leads to further complications for data interpretation [26]. By taking 
microCT images of live mice, the mice are exposed to additional radiation from the scans 
themselves [27].  
 Bone is an anisotropic material and structural changes contribute to strength in different 
ways depending on the axis a load is applied to. Cortical bone is stronger in compression than 
tension, under higher strain rates and with longitudinal loads [28]. Trabecular bone transfers 
mechanical loads from articular surface to the cortical bone. Generally, this bone is also less 
mineralized, and forms an interconnected network within the bone marrow [29]. 
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Bone Material Properties Assessment in a Mouse Model: 
 Fourier transform infrared spectroscopy (FTIR), Raman Spectroscopy and 
nanoindentation are three techniques used to characterize bone quality.  FTIR illuminates a 
sample with infrared radiation and measures the vibrational dipole moment changes 
representative of the overall configuration of atoms and functional groups. The result is an 
absorption spectra that can be used to determine characteristic components of bone (Figure 1.4) 
[30]. Raman spectroscopy uses a laser to excite molecules. The vibrational motion can cause 
light to lose energy and scatter at longer wavelengths. These shifts in frequency are used to 
identify composition of the tissue (Figure 1.5) [10]. Nanoindentation measures Young’s modulus 
by applying a force to a material using a well-defined instrument tip and measuring displacement 
(or vice versa) [31].   
Both FTIR and Raman are used to quantify major bone material parameters including 
mineral to matrix ratio, carbonate to phosphate ratio and crystallinity/mineral maturity [30]. 
Mineral matrix ratio represents the amount of mineral normalized to the amount of collagen 
Figure 1.4: Example FTIR spectrum of bone. Reproduced 
from Kobrina et al. 2010 [2] 
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present. Similarly, carbonate to phosphate ratio represents the amount of carbonate substitution 
in the crystal lattice and has been shown to correlate with fracture risk [32]. Crystallinity 
measures the maturity of the mineral and correlates with yield stress and hardness [32]. 
 For FTIR images, mineral to matrix ratio is calculated as the ratio of the integrated 
phosphate band (900-1200 cm-1) to any of the amide bands, but usually the Amide 1 band (1585-
1725 cm-1). Carbonate to phosphate ratio is found by taking the integrated area of the carbonate 
band (850-900 cm-1) divided by the phosphate band (900-1200 cm-1). Crystallinity is found by 
taking the 1030 cm-1 peak divided by the 1020 cm-1 peak [30]. 
 For Raman spectroscopy, the mineral to matrix ratio is calculated based off a several 
different measures for matrix bands, including amide I, amide III, proline, hydroxyproline and 
phenylalanine. In this discussion, mineral to matrix ratio is calculated as the ratio between the 
primary phosphate peak (959 cm-1) and the proline peak (855 cm-1), due to the fact that the 
proline peak is less influenced by laser polarization [10]. Raman measures for carbonate to 
phosphate ratio are found by taking the carbonate intensity (1070 cm-1) divided by the phosphate 
Figure 1.5: Example Raman spectrum of bone. Reproduced from 
Morris and Mandair 2011 [10] 
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peak intensity (959 cm-1). Crystallinity is quantified by taking the full-width half-maximum for 
the phosphate band at 959 cm-1 [10]. 
Raman spectroscopy offers the advantages of not requiring specimen preparation 
(embedding/maximum thickness etc.) and greater spatial resolution [33]. On the other hand, 
Raman spectra can be influenced by laser polarization while this is not an issue with FTIR. 
Certain vibrations in Raman peaks are known to be weaker than in FTIR and vice versa. 
Therefore, these techniques are often used together [34]. Each of the parameters assessed using 
FTIR and Raman Spectroscopy have been correlated to bone strength. Increases in mineral to 
matrix ratio correlate with increased stiffness and brittleness, while decreased carbonate to 
phosphate ratio correlates with higher strain, greater maximum load and greater post-yield 
toughness [35]. Crystallinity is correlated with tissue-level strength and is inversely correlated to 
yield strain, ductility and fatigue-life [36, 37].Since the publication of the Oliver and Pharr 
method, nanoindentation has emerged as a relevant test for determining the Young’s modulus of 
Figure 1.6: Example load vs. displacement plot with 
parameters used for Oliver-Pharr method calculation of 
Young's Modulus. Reproduced from Oliver and Pharr 1992 [7] 
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bone tissue [7]. The Oliver Pharr method allows for calculation of Young’s modulus from the 
slope of the unloading curve based on the assumption that the unloading response is purely 
elastic.  
The reduced modulus is calculated directly from the unloading curve by the equation 
𝐸𝑟 √
√
 where S is the slope of the upper portion of the unloading data and A is the projected 
area of the elastic contact [7]. The contact area is specific to tip geometry. In this case, a 
Berkovich tip, a three-sided pyramid, is used for indentation. The area function for a perfect 
Berkovich indenter is 𝐴 ℎ 24.5ℎ  where ℎ  is the contact depth. Prior to gathering data, 
the Berkovich tip area function is generally calibrated using fused silica. The Young’s Modulus 
can be calculated from the reduced modulus (Er) based on the equation  where 
E and v are the Young’s modulus and Poisson’s ratio for the specimen and Ei and vi are the same 
parameters for the indenter (see Figure 1.6). The reduced modulus is often reported instead of 
Young’s modulus. It is important to keep in mind that sample preparation, hydration state, tip 
geometry, gender, age and loading conditions can all have an effect on collected data [31].  
 Studies have shown a decrease in Young’s modulus in osteoporotic bone compared to 
healthy controls [38]. However, the relationship between Young’s modulus and mechanical 
behavior is not straightforward. By taking into account bone composition through Raman 
spectroscopy and FTIR in combination with nanoindentation, the relationship between material 
quality, modulus and strength can be more accurately assessed. For example, an increased 
mineral to matrix ratio has been correlated with an increase in bone strength [39]. However, if 
additional mineral is not formed in a connected network that can transmit strain, there will not be 
a corresponding increase in Young’s modulus. An increase in both mineralization and modulus 
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would suggest an increase in strength. A schematic of parameters that contribute to bone strength 
can be found in Figure 1.7.   
 
Postmenopausal Osteoporosis 
 Osteoporosis is defined clinically as a bone mineral density is 2.5 standard deviations or 
more below the mean for young normal people as measured by DEXA [40]. Each year in the 
United States of America, osteoporosis is responsible for 1.5 million fractures [41]. A majority 
of these fractures occur in postmenopausal women due to a decline in estrogen [42]. Estrogen 
inhibits RANKL-stimulated osteoclast differentiation and can induce osteoclast apoptosis [43]. 
Estrogen has also been shown to indirectly affect osteoclasts through suppressed RANKL 
production by osteoblastic, T and B-cells [44]. This results in accelerated bone resorption 
following a loss of estrogen [45]. 
Figure 1.7: Factors that contribute to bone strength and fracture risk. 
Reproduced from Torres-del-Pliego et al. 2013 [8] 
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In addition to increased resorption, there is also an increase in bone formation at the 
tissue level [45]. Estrogen inhibits osteoblast apoptosis and can increase osteoblast lifespan. 
However, the rate of formation is slower than the rate of bone resorption, leading to a net bone 
loss at each BMU [40].  
Postmenopausal osteoporosis is studied in a mouse model through ovariectomy (OVX), 
or removal of the ovaries [46]. A longitudinal study in C57BL/6 mice 14 weeks of age at 
ovariectomy reports a 7% decline in BV/TV after two weeks and a 38% decline after eight weeks 
post-surgery [47]. 
Bisphosphonates 
 Bisphosphonates are a class of drugs that prevent bone loss by inhibiting bone resorption 
[48]. A bisphosphonate tightly adheres to the surface of the bone and inhibits the farnesyl 
pyrophosphate synthase enzyme necessary for cytoskeleton formation in osteoclasts [48]. The 
current bisphosphonates approved to treat postmenopausal osteoporosis include alendronate, 
ibandronate, risedronate and zoledronate. Of the bisphosphonates, zoledronate has the highest 
affinity and longest half-life in bone [49]. However, there are some concerns regarding their side 
effects and potential problems with long-term use [48]. Atypical femoral fracture and 
osteonecrosis of the jaw have recently been linked to long-term use, although these risks are 
estimated to occur in less than 0.00002% of the population [48].  
Radiation Therapy and Bone 
 Radiation therapy for cancer treatment has been shown to increase fracture risk [3, 50-
52].  A retrospective cohort study including 6428 women aged 65 years and older showed that 
women who underwent radiation therapy were more likely to have a pelvic fracture than women 
who did not undergo radiation therapy [3]. Additionally, 90% of those fractures were hip 
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fractures [3]. Pelvic fractures are particularly concerning due to the high mortality rate associated 
with their occurrence [53]. The one year mortality rate following hip fracture in patients 65 years 
of older is 24% for females and 48% for males [53]. In addition to local bone loss, radiation 
therapy also induces systemic declines in bone mineral density [54-57]. 
 There is clinical evidence that premenopausal women with gynecological tumors may 
experience a premature and permanent menopause as a result of damage to the ovaries from 
radiation therapy [58]. The effects of an early onset estrogen deficiency may have a more severe 
impact on bone density due to the fact that these patients likely have not reached peak bone 
mass.  
Ionizing radiation has enough energy to remove electrons from atoms and break 
molecular bonds [59]. This can cause damage to DNA, RNA, cell organelles and more. There are 
also indirect effects from ionizing radiation including the generation of reactive oxygen species 
created from ionization of water molecules. These reactive oxygen species can further damage 
DNA and destroy cell structures leading to cell death [60]. Radiation quickly diminishes vascular 
supply to bone through perivascular edema, small vessel hemorrhage and decreased perfusion 
[60]. Additionally, marrow fibrosis can develop and decrease hematopoiesis long term [60]. Both 
osteoblasts and osteoclasts are affected by radiation. Almost immediately following radiation, 
there is a decline in osteoblast number [61]. Initially, there is an increase in osteoclast number 
that leads to an increase in bone resorption after radiation exposure [62]. In the long term, there 
is a loss of osteoclasts due to damage of osteoclast progenitor cells [63].  
Structural and material changes in bone resulting from ionizing radiation are dose 
dependent [55, 62-64]. The Fowler equation is used to calculate biologically effective dosing for 
mouse studies [65]. Biologically effective dose (BED) is the total dose required to give the same 
16 
 
log cell kill as the schedule being studied, at an infinitely low dose-rate or with infinitely small 
fractions spaced over time [65]. The relationship can be described through the Fowler 
equation 𝐵𝐸𝐷 𝑇 1  where Td is the total physical dose, d is the dose-per-fraction and 
α/β depends on the tissue of interest and whether it is an early or late responding tissue. The α/β 
ratio can be calculated from cell survival curves by finding the dose where cell killing due to the 
linear and quadratic components are equal [65]. The number of fractions administered can also 
influence bone response. As radiation-induced cell damage occurs, other cells are recruited to 
clean up the damage, potentially leading to increased cell death upon further exposure [66].  
Even radiation doses as low as 1 Gray (Gy) can significantly affect bone growth [64]. 
Experiments in mice have shown a single 2 Gy dose of X-rays leads to a 32% decrease in 
trabecular bone density after just one week in the proximal tibia [67]. Another mouse study 
showed a single 5 Gy dose of Cs-137 radiation led to a 40% decline in trabecular bone volume 
after 10 days and reached more than 45% decline by 56 days in the tibia [68]. While changes in 
material properties are not fully understood, a study by Gong et al. demonstrated that 20 Gy 
localized radiation in a mouse altered collagen crosslinking and mineralized matrix by one week 
following exposure [69]. FTIR studies have shown a decrease in mineral composition by 2 days 
following 5 Gy radiation exposure and persisting through at least 10 days [70]. Full 
characterization of the structural and material changes of bone following radiation therapy and 
long-term effects can lead to improved screening for potential therapeutics. 
Hemophilia A and Bone 
 Hemophilia A is an X-linked disorder caused by an absent, deficient or defective plasma 
coagulation factor VIII [71]. Factor VIII is responsible for accelerating the rate of cleavage of 
factor X by activated factor IX during coagulation. In fact, factor VIII increases the rate of the 
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reaction several thousandfold. A diagram describing the coagulation pathways and where Factor 
VIII is required can be found in Figure 1.8. The disease can present in mild, moderate or severe 
forms depending on the level of factor VIII present in the plasma [71]. One of the hallmark 
symptoms of severe hemophilia patients is unprovoked bleeding into the joints (hemarthrosis) 
[71].   
Over time, repeated micro-hemorrhages into the joint will lead to joint arthropathy, 
characterized by synovial inflammation, osteophyte formation and cartilage degeneration [6]. In 
both adults and children with hemophilia, low bone density has been reported [72-76]. There are 
a number of factors contributing to the decline in bone mass including joint bleeding, lack of 
activity, low vitamin D and other infections, such as HIV [77]. A recent study showed that low 
Figure 1.8: Overview of coagulation pathways. Reproduced 
from Goswami et al. 2014 [5] 
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bone density in hemophilia patients also exists independently of joint bleeds and other factors 
[78].  
Knee joint hemarthrosis is often modeled in factor VIII gene knockout mice by 
puncturing the knee joint capsule with a 30.5 gauge needle, followed by injection of 5 microliters 
of saline [79]. Recent investigations have shown a significant decrease of trabecular bone two 
weeks following knee hemarthrosis, but rapid calcification of joint soft tissues and cortical bone 
[79]. A timeline of the mineralization as well as identifying changes in structural and material 
properties could help elucidate targets for treatment. 
Research Objectives 
 When it comes to determining fracture risk, both bone structure and material properties 
are essential for consideration. Structural parameters, such as bone volume and trabecular 
thickness, are often studied more frequently due to ease of access to imaging modalities and the 
ability to image in vivo. Finite element analysis can be used for simulated mechanical testing and 
Figure 1.9: Comparison of hemophilic arthropathy to a normal 
joint. Reproduced from Pulles et al. 2017 [6] 
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bone strength estimation based on these determined structural parameters. However, changes in 
bone composition and material properties resulting from disease states or treatment methods are 
just as critical in predicting bone function, but are more difficult to assess and interpret. 
 In Chapter 2, fractionated radiation therapy in a mouse model will be characterized by 
administering a biologically effective dose for cervical cancer treatment in humans. The added 
effect of induced menopause from radiation therapy on bone will also be explored through an 
ovariectomized mouse model. By quantifying the structural changes resulting from radiation 
therapy in a mouse model, potential therapeutics can then be evaluated. 
 In Chapter 3, the short and long term effects of zoledronate and concurrent fractionated 
radiation on bone morphology, compressive stiffness, composition and elastic modulus will be 
quantified. Bone health will be assessed through microCT, finite element analysis (FEA), 
fluorescent imaging, FTIR, Raman spectroscopy and nanoindentation. The results from this 
chapter can be used to inform clinical assessment of bisphosphonates for use during cancer 
treatment. 
 In Chapter 4, the structural and material properties of the femur and tibia will be assessed 
following knee joint hemarthrosis in both male and female mouse models. Three time points will 
be evaluated to understand the timeline of joint injury. The techniques developed for assessment 
of bone material properties from Chapter 2 will be used to inform experiment design. The results 
from this study can help elucidate the timeline of disrupted bone formation following knee 
hemarthrosis in male and female hemophilic mice and suggest potential mechanisms for 





CHAPTER 2: A MOUSE MODEL FOR SKELETAL STRUCTURE AND FUNCTION 
CHANGES CAUSED BY RADIATION THERAPY AND ESTROGEN DEFICIENCY 
Introduction  
More than 110,000 women are diagnosed with a gynecological cancer each year in the 
United States [80]. As diagnosis and treatment of gynecological tumors have improved, so has the 
number of survivors. External beam radiation therapy is a common procedure used to treat 
gynecological tumors [81]. This treatment method typically requires the transmission of high 
energy, fractionated doses of x-rays to the pelvic region in an attempt to kill the cancer cells [81]. 
The dose targeted at the tumor can be as much as 50 to 55 Gray (Gy) x-rays throughout the course 
of treatment [82]. Healthy normal tissue, such as bone in the pelvic region and proximal femur, is 
exposed to x-rays as well, though at lower doses [51]. 
There is now a large population of patients who exhibit decreased bone density and 
increased fracture risk following external beam radiation therapy for cancer treatment. A 2005 
study by Baxter et al. showed that postmenopausal women who received radiation therapy were 
more likely to experience a pelvic fracture, with the 5-year cumulative chance of fracture as high 
as 14% for anal cancer patients [3]. Additionally, 90% of these fractures were hip fractures [3]. A 
2017 study determined that the rate of pelvic insufficiency fracture following radiation therapy for 
cervical cancer was 15.8% [52]. Of the patients who fracture, the fractures occur early: 38% of the 
women fracture within one year and 83% fracture within two years [83]. The one year mortality 
rate following hip fracture in patients 65 years or older is 24% for females and 38% for males [53]. 
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Previous experiments in mice have shown that even a single dose of 2 Gy x-rays can lead 
to a 32% decrease in trabecular bone density after just one week in the proximal tibia [67]. Willey 
et al. showed that this loss is attributed to an early increase in osteoclast number evident at three 
days following a single 2 Gy x-ray exposure [62]. Similarly, three weeks following a single 1 Gy 
dose of x-rays resulted in a 21% decrease in bone volume fraction (BV/TV) in the mouse distal 
femur [84]. Decreases in bone density and strength correspond to an increased risk of fracture. 
There are other confounding factors that may influence bone fragility following cancer 
treatment. Postmenopausal osteoporosis is a well-documented condition that leads to a decline in 
bone density due to a decrease in estrogen [85]. During the menopausal transition phase, an 
estimated 10% areal bone mineral density (aBMD) is lost in women [86]. Areal BMD is measured 
using Dual-energy X-ray absorptiometry (DEXA) and provides a two dimensional measure for 
bone mass in a projected area [87]. Elderly women lose approximately 1.2% areal BMD per year 
and elderly men lose about 0.8% areal BMD [88]. While areal BMD provides valuable information 
on bone strength, this measure is limited in describing specific changes to trabecular architecture 
and is influenced by bone size. On the other hand, quantitative computed tomography (qCT) 
provides measures for volumetric (3D) bone density (vBMD), as well as separate data for cortical 
and trabecular bone compartments [89]. Volumetric measures for cortical and trabecular bone 
mineral density are two-fold higher in elderly women than men [88].  
There is clinical evidence that pre-menopausal women with gynecological tumors may 
experience a premature and permanent menopause as a result of damage to the ovaries caused by 
radiation therapy [11]. The effects of this early-onset estrogen deficiency on bone health may be 
more severe due to the fact that these patients likely have not reached peak bone mass. In order to 
simulate radiation-induced estrogen deficiency in a mouse model, an ovariectomy procedure is 
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performed two days prior to the first dose of radiation. Due to anatomical differences in mouse 
and human ovaries, mouse hindlimb radiation would not result in a loss of mouse ovarian function, 
as the ovaries are positioned outside the radiation field. In contrast, human ovaries are often located 
within the pelvic radiation field [58].  
Menopause is commonly modeled in mice using the ovariectomy procedure. Just as occurs 
with menopause in women, ovariectomy in mice causes bone loss by increasing osteoclast number 
and lifespan [90-92]. Eight weeks following ovariectomy, female C57BL/6 mice lose up to 35% 
of their trabecular volumetric bone mineral density in the distal femur compared to Sham-operated 
controls. Just two weeks following the ovariectomy procedure, female C57BL/6J wild-type mice 
have been shown to lose 18% bone volume fraction (BV/TV) [90].  
Previous studies have investigated the effect of induced ovariectomy performed two 
months prior to a single radiation dose on bone remodeling and distal femur bone volume fraction 
[93]. This model simulates the intentional disruption of ovarian function in order to induce 
estrogen deficiency in women undergoing treatment for estrogen-sensitive cancers. A key 
difference between this Hui et al. model and our study is the timeline between ovariectomy and 
radiation. In the Hui et al. study, mouse ovaries were removed fifty-seven days prior to radiation 
therapy [93]. There are several ways estrogen deficiency can occur during cancer treatment that 
may have a similar impact on bone, including chemotherapy, estrogen blockers or hysterectomy.  
The overall goal of this study is to quantify bone architectural and functional changes in a 
mouse model simulating a clinically relevant, radiation-induced estrogen deficiency in pre-
menopausal women receiving treatment for gynecological tumors.  Specifically, we aim to 
characterize bone density, morphometric alterations and functional changes in order to establish a 
model to test potential bone therapeutics. This paper reports results of ovariectomy combined with 
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modeled radiation therapy on mouse bone structure and function using DEXA, micro-computed 
tomography (microCT) and computational mechanical testing via finite element analysis (FEA). 
We hypothesize that bone loss resulting from concurrent ovariectomy and fractionated radiation 
therapy will result in more drastic trabecular bone degradation than ovariectomy completed 
months prior to radiation. The implications of this study provide insight into the clinical condition 
of women undergoing radiation therapy for gynecological tumors.  
Materials and Methods 
X-ray Dose Validation 
In order to determine whether radiation should be given in fractions or a single biologically 
effective dose, a preliminary dosing study was performed. Thirty-six female C57BL/6N mice were 
purchased from Charles River (Charles River Laboratories, Morrisville, NC). All mice were 
fourteen weeks of age at the start of the study with food and water available ad libitum throughout 
the study. All investigations were approved by the University of North Carolina, Chapel Hill 
Institutional Animal Care and Use Committee. 
The mice were divided into three groups with twelve mice in each group (n=12). The first 
group received a single 18 Gray dose of X-rays to the hindlimbs on Day 0 and the second group 
received a 6 Gray dose of X-rays to the hindlimbs on Days 0, 3 and 7 (3x6 Gy). The final group 
served as a control and did not undergo irradiation. Mice were irradiated while under anesthesia 
(1.5% isoflurane) with a single field of 320 kV(p) x-rays at a dose rate of 0.5 Gy/min to the 
hindlimbs only (X-RAD 320, Precision X-Ray, North Branford, CT). All mice were humanely 
euthanized on Day 14 and the left hindlimb was collected at dissection for Microcomputed 
Tomography (MicroCT) analysis.  The left tibiae were cleaned of soft tissue, fixed in 10% formalin 
for 48 hours and then placed into 70% ethanol for storage. 
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Proximal Tibia MicroCT for Dose Validation 
MicroCT scans of the left tibiae were taken at 10-micron isotropic voxel size (µCT80; 
Scanco Medical AG, Brüttisellen, Switzerland). The scans were acquired using a 70-kVp peak X-
ray tube potential, a 0.5 mm Al filter, and an integration time of 800 ms to reduce beam hardening 
effects and improve the signal-to-noise ratio. Scanco software was used to analyze and quantify 
bone microarchitectural parameters from contoured regions. All contouring was performed semi-
automatically to separate trabecular and cortical compartments. For the proximal tibia, a 1 mm 
section of the metaphysis just below the growth plate was chosen as the contour region. Trabecular 
bone volume fraction (BV/TV) was quantified for comparison between mouse groups.  
OVX and Radiation Study 
Animals and Study Design 
Thirty-two female C57BL/6N mice were purchased from Charles River (Charles River 
Laboratories, Morrisville, NC). All mice were thirteen weeks of age at the start of the study with 
food and water available ad libitum throughout the study. All investigations were approved by the 
University of North Carolina, Chapel Hill Institutional Animal Care and Use Committee. 
Sixteen mice had their ovaries surgically removed (OVX) and the other sixteen mice 
received a sham operation (Sham). The OVX and Sham surgeries were performed by Charles River 
Laboratories two days prior to the first irradiation procedure. Within each operation group, eight 
mice (n=8) were irradiated (IRR) and the other eight were not (NR). The ovariectomy procedure 
served as the start of the experiment (Day 0). The irradiated mice received a 6 Gy dose of X-rays 
to the hindlimbs at Day 2, Day 4 and Day 7 (18 Gy total). Mice were irradiated while under 
anesthesia (1.5% isoflurane) with a single field of 320 kV(p) x-rays at a dose rate of 0.5 Gy/min 
to the hindlimbs only (X-RAD 320, Precision X-Ray, North Branford, CT). The mouse radiation 
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dose was calculated based on the Fowler equation (biologically effective dose or BED) for the 
estimated 27 Gy total dose to each hip throughout radiation therapy (30 fractions of 0.9 Gy X-
rays) for cervical cancer in women [65]. For the human BED calculation, the total dose was 27 
Gy, the fraction dose was 0.9 Gy and the alpha to beta ratio was estimated to be 8, for a BED of 
30.4 Gy. The alpha to beta ratio estimate was based on multiple studies indicating that bone is a 
very acute responding tissue, in terms of rapid bone loss and increased osteoclast activity [94-96]. 
For the animal calculation, the total dose was 18 Gy, the fraction dose was 6 Gy and the alpha to 
beta ratio was also 8, for a BED of 31.5 Gy. 
Tissue Collection 
Each mouse was weighed, then humanely euthanized on Day 35 (28 days following the 
final dose of radiation). The vertebral column, left hindlimb and right hindlimb were collected at 
dissection for further analysis. Tibiae, femora and vertebrae were cleaned of soft tissue and fixed 
in a solution of 10% formalin. After 48 hours, the bones were placed in 70% ethanol for storage. 
Dual-energy X-ray absorptiometry (DEXA) 
DEXA images (Lunar PIXImus, GE Lunar Corp.) were acquired at Day 2, Day 21 and Day 
35 while mice were sedated using isoflurane. This scanner uses a cone beam X-ray source 
generating energies of 35 and 80 keV and a flat 100 × 80 mm detector having individual pixel 
dimensions of 0.18 × 0.18 mm. Each mouse was placed in the prone position with legs moved 
away from the body for scanning. Lunar PIXImus software was used to determine bone density 




Microcomputed Tomography (MicroCT) 
The right tibiae, right femora and vertebral column were removed from ethanol and cleaned 
of nonosseous tissue for further analysis. MicroCT scans of the right tibia, right femora and L1 
vertebrae were taken at 10-micron isotropic voxel size (µCT80; Scanco Medical AG, Brüttisellen, 
Switzerland). The scans were acquired using a 70-kVp peak X-ray tube potential, a 0.5 mm Al 
filter, and an integration time of 800 ms to reduce beam hardening effects and improve the signal-
to-noise ratio. Scanco software was used to analyze and quantify bone microarchitectural 
parameters from contoured regions. All contouring was performed semi-automatically to separate 
trabecular and cortical compartments. For the proximal tibia, a 1 mm section of the metaphysis 
just below the growth plate was chosen as the contour region. For the femur, contouring was 
performed at a 0.5 mm section at the femoral midshaft. The entire vertebral body between the two 
endplates was contoured for the L1 vertebra. Trabecular bone parameters including bone volume 
fraction (BV/TV), connectivity density (Conn.D), trabecular number (Tb.N), trabecular thickness 
(Tb.Th), trabecular separation (Tb.Sp), structure model index (SMI), volumetric bone mineral 
density (vBMD),  cortical porosity (Ct. Po), cortical area (Ct. Ar), marrow area (M. Ar) and total 
area (T. Ar) were quantified. 
Finite Element Analysis 
Example visual representations of each bone segment mesh used for finite element analysis 








Figure 2.1: Example finite element analysis meshes for whole proximal tibia 
segment (a), loaded whole tibia (b), cortical proximal tibia segment (c), loaded 
cortical tibia (d), proximal femur mesh with nodes selected in red to be displaced 




The same 1 mm region of each proximal tibia used for microCT analysis was exported 
from the scanner and imported as a tetrahedral mesh into Abaqus software (Abaqus/CAE 6.9-EF1, 
Dassault Systems Simulia Corp, Providence, RI) for finite element analysis. For each individual 
bone section, homogenous material properties were applied to the tibia by assigning a Young’s 
Modulus of 10 GPa and Poisson’s Ratio of 0.3. Then, two nodes sets were created: one containing 
all nodes on the proximal end of the tibia segment and the other comprised of all distal nodes of 
the tibia segment. For the loading step, boundary conditions were applied to secure the distal end 
of the tibia while displacing the proximal end 50 microns (~5% strain) downward in the z-
direction. The resultant force was measured and used to calculate compressive stiffness 
(force/displacement). 
Proximal Femur 
A 3.25 mm region of each right femur starting at the proximal end of the femoral head and 
continuing 3.25 mm (325 slices) distally was imported from the scanner into Abaqus as a 
tetrahedral mesh.  Choosing a consistent place to measure the stress output is essential in ensuring 
that length will not play a role in the calculated bone stiffness. All nodes within the femoral head 
were selected manually and saved as a node set. The distal end nodes were also saved as a set. For 
the initial step, the boundary condition for these nodes were set to constrain both translation and 
rotation in all three directions, essentially holding the model fixed. For the loading step, the femoral 
head displacement was set to 50 microns in the downward z direction. The resultant force on the 






Significance was determined using SigmaPlot 12.0 (Systat Software Inc., San Jose, CA). 
The threshold for significance for all tests was set at a 5% probability of a type I error (p=0.05). 
All statistical comparisons were made using a two-way ANOVA. A Tukey post-hoc test was run 
to explore potential interactions and to maintain a Type 1 error of 0.05 across multiple comparisons 
(NR, IRR, OVX and Sham). This method was used to determine differences in final body mass, 
DEXA aBMD, DEXA BMC, microCT morphometric parameters and finite element analysis 
stiffness data.  
Results 
X-ray Dose Validation Study 
Proximal Tibia MicroCT 
At the proximal tibia, there was a 24% decline in BV/TV in the single 18 Gy dose mice 
compared to the non-irradiated control mice. For the 3x6 Gy dose mice, there was a 32% decrease 
in BV/TV compared to the non-irradiated control mice. 
OVX and Radiation Study 
Body Mass  
At the start of the study (Day 0), there were no statistically significant differences in body 
mass between study groups. By Day 35, the OVX groups had gained more weight than Sham 
groups. The OVX+NR group body mass was 14% greater than the Sham+NR group and the 
OVX+IRR body mass was 7% greater than the Sham+IRR group body mass at sacrifice. More 




By the end of the study, there was a significant decrease in whole body and hindlimb aBMD 
resulting from ovariectomy in both irradiated (IRR) and non-irradiated (NR) mice, with no 
significant changes seen from irradiation. Hindlimb and whole body DEXA data can also be found 
in Table 2.1.  
 SHAM-NR SHAM-IRR OVX-NR OVX-IRR 
Body Mass 
(grams)  
Day 2 20.9 ± 0.7 20.8 ± 1.0 20.8 ± 1.4 20.7 ± 1.0
Day 35 22.5 ± 0.8 23.0 ± 1.0 25.7 ± 1.5# 24.7 ± 1.8# 
Increase in 
body mass 
from start to 
end 





Day 2 52.4 ± 2.5 52.2 ± 1.7 53.1 ± 1.4 52.2 ± 2.5 
Day 21 56.6 ± 1.9 55.6 ± 2.0 54.4 ± 1.1# 54.8 ± 1.7 




Day 2 0.043 ± 0.003 0.042 ± 0.003 0.043 ± 0.003 0.041 ± 0.003 
Day 21 0.046 ± 0.003 0.045 ± 0.003 0.047 ± 0.002 0.046 ± 0.002 





Day 2 47.7 ± 1.2 47.8 ± 1.7 46.8 ± 0.9 45.9 ± 2.7# 
Day 21 50.0 ± 1.7 49.0 ± 0.9 47.2 ± 1.0# 47.3 ± 1.3# 




Day 2 0.41 ± 0.02 0.41 ± 0.03 0.41 ± 0.02 0.39 ± 0.04 
Day 21 0.40 ± 0.02 0.39 ± 0.02 0.38 ± 0.01 0.38 ± 0.02 
Day 35 0.43 ± 0.03 0.41 ± 0.01 0.39 ± 0.02# 0.37 ± 0.03# 
Whole body aBMD  
At Day 21, OVX+NR whole body aBMD was 6% lower than Sham+NR and OVX+IRR 
whole body aBMD was 3% less than Sham + IRR. At Day 35, OVX+NR whole body aBMD was 
5% less than Sham+NR aBMD and OVX+IRR whole body aBMD was 6% less than Sham+IRR. 
There was a 9% decrease in bone mineral content (BMC) in the OVX+NR group compared to the 
Table 2.1: Body mass summary and DEXA aBMD results from right hindlimb and whole body. 
All data presented as mean ± standard deviation. *= significant effect of irradiation within Sham 
or OVX groups; #=significant effect of OVX within NR or IRR groups (p<0.05) 
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Sham+NR group and a 9% decrease in BMC in the OVX+IRR group compared to the Sham+IRR 
group on Day 35. 
Right Hindlimb aBMD  
On Day 21, there was a significant decrease (4%) in hindlimb aBMD for OVX+NR 
compared to Sham+NR. On Day 35, both OVX groups had a 5% decrease in hindlimb aBMD 
compared to Sham groups. There were no significant changes in right hindlimb BMC.  
MicroCT Proximal Tibia 
All microCT morphometry data can be found in Table 2.2 for the purpose of running 
statistics. Selected bone morphometric data for the proximal tibia have also been presented in 





















BV/TV 0.090 ± 0.017 0.049 ± 0.007* 0.058 ± 0.012# 0.034 ± 0.011*# 
vBMD 
(mgHA/cm3) 
78.1 ± 16.3 28.2 ± 9.24* 41.4 ± 11.6# 6.67 ± 10.8*# 
TMD 808 ± 17.0 794 ± 15.6 797 ± 23.9 794 ± 10.1 
Conn. Dens. 
(mm-3) 








0.046 ± 0.002 0.050 ± 0.005* 0.041 ± 0.004# 0.051 ± 0.003* 
Trab. 
Spacing (mm) 





BV/TV 0.926 ± 0.015 0.951 ± 0.006* 0.906 ± 0.033 0.931 ± 0.020* 
vBMD 
(mgHA/cm3) 
718.9 ± 31.7 777.4 ± 15.6* 677.1 ± 43.5# 739.4 ± 29.9*# 
TMD 847 ± 25.8 879 ± 15.3* 822 ± 30.7# 863 ± 18.8* 
Cortical 
Porosity 









BV/TV 0.904 ± 0.020 0.898 ± 0.014 0.900 ± 0.014 0.886 ± 0.022 
vBMD 
(mgHA/cm3) 
1007.9 ± 28.5 1001.8 ± 26.4 994.6 ± 21.7 984.9 ± 21.9 
Cortical 
Porosity 




0.181 ± 0.011 0.174 ± 0.007 0.170 ± 0.004# 0.170 ± 0.004 
Marrow 
Area (mm2) 
0.781 ± 0.055 0.806 ± 0.033 0.854 ± 0.059# 0.852 ± 0.049 
Total Area 
(mm2) 
1.48 ± 0.081 1.48 ± 0.046 1.53 ± 0.064 1.53 ± 0.057 
BA/TA 0.473 ± 0.018 0.456 ± 0.014* 0.443 ± 0.016# 0.442 ± 0.014 
Cortical 
Area (mm2) 





BV/TV 0.240 ± 0.027 0.219 ± 0.033 0.170 ± 0.014# 0.162 ± 0.022# 
vBMD 
(mgHA/cm3) 
201.8 ± 20.8 182.3 ± 29.4 141.2 ± 12.7# 135.4 ± 21.7# 
TMD 781 ± 15.7 764 ± 23.8 744 ±18.0# 745 ± 29.5 
Conn. Dens. 
(mm-3) 








0.048 ± 0.001 0.046 ± 0.002* 0.041 ± 0.001# 0.041 ± 0.002# 
Trab. 
Spacing (mm) 
0.204 ± 0.020 0.209 ± 0.016 0.234 ± 0.016# 0.238 ± 0.017# 
Table 2.2: MicroCT bone morphometry data for proximal tibia, midshaft femur and L1 vertebra. All data presented 
as mean ± standard deviation. *= significant effect of irradiation within Sham or OVX groups; #=significant effect 
of OVX within NR or IRR groups (p<0.05) 
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Figure 2.2: Example MicroCT scans of proximal tibia segment showing trabecular bone in pink 
and cortical bone in gray for Sham-NR mouse (a), Sham-IRR mouse (b), OVX-NR mouse (c) 
and OVX-IRR mouse (d) 
 
Proximal Tibia Trabecular Morphometry (Figure 2.3a-2.3d)  
In the proximal tibia region, both radiation and ovariectomy had an adverse effect on 
trabecular microarchitecture. BV/TV in the Sham+IRR group was 46% less than the Sham+NR 
group and OVX+IRR group BV/TV was 41% less than the OVX+NR group. There was a 36% 
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decline in BV/TV in the OVX+NR group compared to the Sham+NR group and a 30% decrease 
in BV/TV for the OVX+IRR group versus the Sham+IRR group. 
Volumetric bone mineral density (vBMD) decreased 64% in Sham+IRR mice compared to 
Sham+NR mice and 84% in OVX+IRR mice compared to OVX+NR mice. Similarly, there was a 
47% decline in vBMD for OVX+NR mice compared to Sham+NR mice and a 76% decrease in 
vBMD from OVX+IRR mice relative to Sham+IRR mice. 
Connectivity density decreased 69% in the Sham+IRR group compared to the Sham+NR 
group and 77% in OVX+IRR group versus OVX+NR group. Within NR mice only, there was a 
41% decrease in connectivity density from OVX compared to the Sham group.  
There was a 10% increase in trabecular thickness in Sham+IRR mice compared to 
Sham+NR mice and a 24% increase in trabecular thickness from OVX+IRR mice compared to 
OVX+NR mice. On the other hand, the OVX+NR group had a 10% decline in trabecular thickness 
compared to the Sham+NR group.  
Trabecular number decreased 30% in the Sham+IRR group versus the Sham+NR group 
and decreased 35% in the OVX+IRR group versus the OVX+NR group. The OVX+NR group 
resulted in a 13% decline in trabecular number compared to the Sham+NR group and a 19% 
decline in OVX+IRR compared to the Sham+IRR group.  
Proximal Tibia Cortical Morphometry (Figure 2.3e-2.3h)  
Cortical porosity decreased 33% in Sham+IRR mice compared to Sham+NR mice and 
decreased 26% in OVX+IRR group versus OVX+NR group. Changes in cortical porosity from 
both OVX groups compared to Sham groups were not statistically significant.  
There was an 8% increase in vBMD in Sham+IRR mice compared to Sham+NR mice and 
a 9% increase in vBMD in the OVX+IRR mice compared to the OVX+NR mice. On the other 
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hand, vBMD in the OVX+NR group decreased 6% versus the Sham+NR group and decreased 5% 
in the OVX+IRR group compared to the Sham+IRR group.  
Tissue Mineral Density (TMD) increased 4% in Sham+IRR mice compared to Sham+NR 
mice and increased 5% in the OVX+IRR mice versus OVX+NR mice. There was a 3% decrease 
in TMD in OVX+NR group compared to the Sham+NR group, but no significant change in the 
IRR mice. 
Sham+IRR mice had a cortical thickness 36% greater than Sham+NR mice and OVX+IRR 
mice had a cortical thickness 33% greater than OVX+NR mice. Conversely, cortical thickness 
decreased 12% in OVX+NR mice compared to Sham+NR mice and decreased 14% in OVX+IRR 




Figure 2.3: Graphs for MicroCT morphometry data for the proximal tibia segment 
including trabecular BV/TV (a), trabecular connectivity density (b), trabecular thickness 
(c), trabecular number (d), cortical porosity (e), cortical vBMD (f), cortical tissue mineral 
density (g) and cortical thickness (h). Error bars indicate standard error of the mean. 
*=significant effect of irradiation within Sham or OVX groups; #=significant effect of 
OVX within NR or IRR groups (p<0.05) 
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Proximal Tibia Finite Element Analysis  
Simulated compression testing using finite element analysis was performed on the isolated 
cortical compartment, trabecular compartment and whole bone (trabecular+cortical) segment. 
Proximal tibia FEA results are also presented in Figure 2.4. 
Proximal Tibia Trabecular Bone Stiffness  
Trabecular bone stiffness declined 47% in Sham+IRR mice compared to Sham+NR mice 
and declined 40% in OVX+IRR mice compared to OVX+NR mice. OVX+IRR trabecular bone 
stiffness was 21% less than Sham+IRR stiffness.  
Proximal Tibia Cortical Bone Stiffness  
In the isolated cortical bone segment, cortical stiffness increased 29% in Sham+IRR mice 
compared to Sham+NR mice and increased 32% in OVX+IRR mice compared to OVX+NR mice. 
Cortical stiffness declined 17% in OVX+NR group versus Sham+NR group and declined 15% in 
the OVX+IRR group relative to the Sham+IRR group.  
Proximal Tibia Whole Bone Stiffness (Trabecular and Cortical Combined)  
For the whole proximal tibia segment, there was a 10% increase in stiffness in the 
Sham+IRR mice relative to the Sham+NR mice and a 15% increase in stiffness in the OVX+IRR 
mice compared to the OVX+NR mice. Whole bone stiffness in OVX+NR mice was 18% less than 








MicroCT Midshaft Femur  
Midshaft Femur Cortical Morphometry  
At the midshaft of the femur, there were no statistically significant changes in cortical 
porosity for any groups. The only significant change in cortical thickness was a 6% decline in 
thickness in OVX+NR mice versus Sham+NR mice. The marrow area at the midshaft of the femur 
increased 9% in the OVX+NR group compared to the Sham+NR group. However, there were no 
statistically significant changes seen in cortical area or total area. Selected morphometry data for 









Figure 2.4: Graphs for proximal tibia finite element analysis data including proximal tibia 
cortical stiffness (a), proximal tibia trabecular stiffness (b) and whole proximal tibia segment 
stiffness (c). Error bars indicate standard error of the mean. *= significant effect of irradiation 
within Sham or OVX groups; #=significant effect of OVX within NR or IRR groups (p<0.05) 
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Proximal Femur Finite Element Analysis  
Proximal Femur Stiffness  
At the femoral neck, the only significant change in stiffness was a 9% decline in stiffness 
in OVX+NR mice compared to Sham+NR mice. A graphical representation of this data is provided 
in Figure 2.6.  
Figure 2.5: Graphs for MicroCT cortical morphometry data for the midshaft femur segment 
including cortical area (a), marrow area (b), BA/TA (c), cortical porosity (d) and cortical 
thickness (e). Error bars indicate standard error of the mean. *=significant effect of irradiation 
within Sham or OVX groups; #=significant effect of OVX within NR or IRR groups (p<0.05) 
Figure 2.6: Graph for femoral neck stiffness determined 
using finite element compression simulation. Error bars 
indicate standard error of the mean. #=significant effect of 
OVX within NR or IRR groups (p<0.05) 
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MicroCT L1 Vertebra 
Selected morphometry data for the L1 Vertebra can be found in Figure 2.7 (a-c). 
L1 Vertebra Trabecular Morphometry  
BV/TV declined 29% in OVX+NR mice relative to Sham+NR mice and declined 26% in 
OVX+IRR mice compared to Sham+IRR mice. Similarly, there was a 30% decrease in vBMD in 
OVX+NR mice versus Sham+NR mice and a 26% decrease in OVX+IRR mice compared to 
Sham+IRR mice.  
Figure 2.7: Graphs for MicroCT trabecular morphometry data for the L1 vertebra including 
BV/TV (a), vBMD (b), trabecular thickness (c) and stiffness determined through finite element 
compression simulation (d). Error bars indicate standard error of the mean. *= significant effect 




Trabecular thickness in Sham+IRR mice was 4% less than in Sham+NR mice. The 
OVX+NR group had a 14% decrease in trabecular thickness compared to the Sham+NR group and 
the OVX+IRR group had an 11% decrease in trabecular thickness relative to the Sham+IRR group.   
L1 Vertebra Finite Element Analysis 
L1 Vertebra Stiffness  
Based on the finite element model, the OVX+NR group stiffness was 14% less than the 
Sham+NR group and the OVX+IRR group stiffness was 11% less than the Sham+IRR group. 
These results are also presented as a graph in Figure 2.7 (d).  
Discussion 
In 2017, gynecological cancers constituted approximately 13% of all new cancer diagnoses 
for women in the United States [42]. Improved screening guidelines and advances in treatment 
have led to an increase in the number of survivors who may experience various long-term adverse 
side effects of radiation therapy. The results from this study characterize the structural and 
functional changes in bone resulting from fractionated irradiation in a mouse model for treatment 
of both pre- and post-menopausal women with gynecological tumors. In addition to gynecological 
cancers, radiation therapy is used to treat many other cancers where bone loss has been similarly 
reported. There are currently several ongoing clinical trials to look at the efficacy of larger dose 
fractions of stereotactic body radiotherapy (SBRT) given in a smaller number of fractions to treat 
oligometastatic cancers, such as breast cancer. Two examples of this treatment protocol use three 
fractions of 10 Gy X-rays within three weeks to treat breast metastases in the bone [97, 98]. This 
is becoming a new standard of treatment and the dosing protocol is similar to the one used in our 
mouse model.  The results from this study may be extrapolated to understand bone structural and 
functional changes resulting from radiation therapy for prostate, anorectal, lung or breast cancers 
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as well. In 2017, prostate, anorectal, lung and breast cancers accounted for a combined 40% of 
cancer diagnoses for men and women in the United States [42]. 
There are two distinct mouse models utilized and compared in this study: fractionated 
radiation therapy for treatment of gynecological tumors in women and the ovariectomy mouse 
model for the onset of menopause in women. Both models provide quantitative information on 
bone mechanisms, structure and function altered through radiation and menopause in women. 
However, it is important to note that mice lack the Haversian systems for vasculature seen within 
human bone [99]. Vasculature-related damage may therefore affect mouse and human bone 
differently. In contrast to humans, the mouse femoral neck has minimal trabecular bone due to the 
small size. Therefore, the proximal tibia region just distal to the epiphyseal plate is a common 
skeletal site for microCT analysis in a mouse to quantify changes in trabecular microarchitecture 
[100]. The ovariectomized mouse model has been shown to closely model changes in cancellous 
bone seen in postmenopausal women, but not cortical bone [24]. However, the mechanisms 
involved in estrogen deficiency are consistent with those seen in women, including increased bone 
resorption. There is also an increase in bone formation (bone surface) that cannot compensate for 
the increase in resorption, leading to a net imbalance in bone remodeling.  
The fractionated radiation protocol used for this study was developed based on the data 
gathered from the X-ray dose validation preliminary data, BED calculations and anesthesia 
considerations. In the X-ray dose validation preliminary data, mice that received three fractions of 
6 Gy x-rays saw a greater decline in proximal tibia BV/TV than mice that received one single 18 
Gy dose. Hong et al. demonstrated that inflammatory genes are rapidly induced (within one to six 
hours) in the lung following irradiation and that fractionated radiation maintains an up-regulation 
of cytokine gene expression for a longer period than single dose [66]. These results suggest 
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differences in tissue response to fractionated vs. single doses of radiation. In response to the cell 
damage within bone, macrophages are recruited and osteoclast numbers increase. We posit that 
this additional recruitment of cells to the field of radiation between fractions increases the overall 
damage to the bone. Therefore, fractionated radiation therapy in the mouse model should more 
closely mimic clinical treatment in humans. 
Ideally, radiation in a mouse study would be given in the same number (~30) of fractions 
as in women with gynecological tumors. However, the mouse must be anesthetized each time a 
radiation fraction is given. If more fractions were given, the anesthesia would have too large of an 
effect in the mice, including loss of body mass, lethargy and lack of eating. Female mice have been 
shown to experience greater side effects than males, including a higher stress level [101]. 
With DEXA, there were both whole body and hindlimb declines in aBMD detected from 
OVX compared to Sham groups. This is not due a loss of body mass, as the OVX mice gained 
weight throughout the study. 
Both ovariectomy and fractionated irradiation in this mouse model caused significant loss 
of trabecular bone in the proximal tibia. Additionally, the combination of irradiation and 
ovariectomy had an apparent additive effect in the proximal tibia, with greater trabecular bone loss 
than either procedure alone. These data suggest that there are different mechanisms being activated 
in each case. The decrease of estrogen during menopause in women results in an increase in the 
number and lifespan of osteoclasts, leading to an imbalance in resorption and formation [91, 92, 
102]. Ovariectomy models the acute effects of menopause including bone loss driven by stimulated 
bone marrow macrophages.  
With radiation, there is a rapid early increase in osteoclasts, although a depletion of 
osteoclast progenitor cells, leading to long-term osteoclast decline [63]. Previous studies have 
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shown increased osteoclast numbers persist for only two weeks [67]. Ionizing radiation causes cell 
damage in several ways, such as DNA interactions with reactive oxygen species resulting in cell 
death [59]. The cell death seen in the bone marrow triggers the infiltration and activation of 
macrophages and neutrophils. Lymphocytes are particularly sensitive to radiation, whereas 
monocyte-lineage leukocytes are significantly less affected [103]. The suppression of estrogen 
from ovariectomy in combination with radiation therapy may increase the inflammatory response 
to radiation through greater infiltration of radiation resistant phagocytes. Bone formation is also 
impaired following radiation therapy due to a reduction in the number of osteoblasts and osteoblast 
precursors [59]. 
Clinical data provides evidence for the decline in trabecular bone density within the 
radiation field for women with gynecological tumors [104], but cortical bone data is not well-
documented in women. Rapid, longitudinal cortical bone loss in the ribs of patients treated with 
radiosurgical protocols for lung cancer was identified by only 3 months after starting stereotactic 
body radiation therapy, at all sites absorbing greater than 10 Gy [105]. Moreover, rapid loss of 
trabecular and cortical bone were observed from the proximal femur was observed from the 
proximal femur of anal cancer patients within two months of completing intensity modulated 
radiation therapy [106]. From non-human primate models, a single 10 Gy fraction delivered to the 
chest of rhesus macaques simulated radiosurgical protocols caused cortical thinning within the 
exposed vertebrae [107]. In our mouse model, there is an increase in cortical thickness and 
decrease in cortical porosity seen at the proximal tibia 28 days following the final radiation dose, 
despite major loss of trabeculae. In a study by Turner et al., C57Bl/6 mice saw an increase in bone 
formation as a result of activation of bone lining cells within one day of 6 Gy gamma-irradiation 
[108]. Additionally, there was a strong correlation between marrow cell death resulting from 
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irradiation and activation of bone lining cells to express osteoblast phenotype, which could offer 
insight into cortical thickening [108]. Our animal model might provide an understanding of what 
happens in the cortical bone, although it is important to recognize the absence of a tumor in the 
model. The 2014 study by Oest et al. provides insight as to the potential mechanism leading to 
compartmental differences in the bone response [63]. There is an early increase (2 days) of 
osteoclasts following irradiation, but a long term depletion of osteoclasts. This accounts for a rapid 
early decrease in trabecular bone, followed by long term matrix deposition without bone turnover. 
While the thickness of the cortical bone has increased, the bone is likely becoming brittle with 
time [63].  
There is also evidence that adoptive transfer of hematopoietic stem cells (HSCs) and 
unpurified bone marrow are successful in repopulating bone marrow in irradiated mice, but those 
cells are unable to prevent trabecular bone loss or reduce the bone loss after two months [109]. We 
hypothesize that macrophages are rapidly activated following radiation damage in response to the 
dead and dying marrow cells. Since osteoclasts are closely related to macrophages, they are also 
activated in a way that causes a rapid and profound bone loss. Osteoclast activation has been 
demonstrated within three days of irradiation and most bone loss is evident seven to ten days 
following irradiation [62]. Once trabecular connections are lost, they can no longer transmit 
mechanical loads that may be necessary for communicating bone repair.  
Since radiation rapidly activates osteoclasts, it makes sense to use bisphosphonates early 
on to prevent the initial activation of osteoclasts. Bisphosphonates are already commonly used 
clinically to prevent further bone loss resulting from post-menopausal osteoporosis [110]. 
Risedronate has been tested in a mouse model and demonstrated the ability to mitigate bone loss 
resulting from 2 Gy x-rays, though not for a dose modeling the BED for fractionated radiation 
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therapy [67]. One study found a rapid decrease in fecal calcium excretion in both OVX and Sham 
mice after a zoledronate injection following a 16 Gy single dose of irradiation, suggesting a rapid 
increase in bone remodeling [111]. Another mouse study showed zoledronate given out to 3 weeks 
following radiation effectively prevented bone loss, but did not significantly improve bone 
compressive strength following irradiation [112]. These results suggest the need to further examine 
material properties altered through concurrent bisphosphonate and radiation treatment. It is also 
important to consider the side effects of bisphosphonate treatment, including immune suppression. 
Alendronate and zoledronic acid directly decrease macrophage survival and impair monocyte 
differentiation into macrophages [113]. Many cancer patients may already be immunosuppressed 
and therefore, further studies need to be done to assess the risk to the patient.   
Loss of bone density and structural stiffness following ovariectomy occurred at all skeletal 
sites analyzed in this study: tibia, femur and L1 vertebra. Since the L1 vertebra is located outside 
of the radiation field, there was no significant change in trabecular bone resulting from the 
radiation treatment. As expected, the suppression of estrogen via ovariectomy had a systemic effect 
while radiation was largely specific to the X-ray field.  
In the proximal tibia, the cortical porosity decreases while cortical thickness increases 
following radiation. This decrease in porosity could indicate lamellar bone rather than woven bone 
at one month following the final radiation dose.  
In summation, an animal model for women receiving radiation therapy for gynecological 
tumors was studied. To accomplish this, the standard, well-characterized ovariectomized mouse 
model was combined with fractionated radiation to the lower limbs. There was a loss of bone 
structure and function, which is consistent with clinical study results. During the acute phase of 
bone loss, it makes sense to test bisphosphonate therapies to reduce osteoclast proliferation. 
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Further studies can be used to expand this model to other cancers, such as prostate cancer. The 
addition of a tumor to the mouse model prior to radiation therapy could also be employed to further 





































CHAPTER 3: EFFECTS OF RADIATION AND HIGH-DOSE ZOLEDRONATE 
TREATMENT ON THE STRUCTURAL AND MATERIAL PROPERTIES OF BONE IN 
A MOUSE MODEL 
Introduction 
From 2016 to 2018, the number of cancer survivors in the United States grew from 15.5 
to 16.9 million [114, 115]. This number is expected to continue to increase as treatment options 
and diagnostic screenings improve [115]. Radiation therapy is commonly used in the oncological 
setting to kill cancer cells and reduce tumor size. By 2020, the number of cancer survivors who 
have been treated with radiation is projected to reach 3.38 million [114]. However, this treatment 
method has damaging side effects including altered bone morphology and increased fracture risk 
[60, 116]. Several studies have shown that women receiving therapeutic pelvic radiation are 
more likely to experience a pelvic fracture [3, 83]. The median time from the final radiation dose 
to fracture is 14.1 months, with 83% of fractures happening within two years of treatment 
completion [83].  
Both bone structure and material properties contribute to overall bone function and 
fracture risk. In the clinical setting, bone structure is the main parameter for assessing bone 
health [22]. Imaging modalities, including DEXA and pQCT, allow for visualization of bone 
structure and quantification of bone morphometric parameters. These techniques also offer the 
advantage of being minimally invasive and easy to administer [22]. Bone quality and material 
properties, on the other hand, are more difficult to assess, but just as important in contributing to 
clinical bone strength [117]. Developments in spectroscopy have allowed for spatial mapping of 
bone composition using Fourier Transform Infrared Imaging (FTIR) and Raman Spectroscopy. 
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Generally, studies are performed in animal models so that samples can be embedded or a laser 
can be focused directly to the bone. In a mouse study, Gong et al. found changes in 
mineralization resulting from four fractions of 5 Gy x-ray irradiation using Raman to assess 
mineral to matrix ratio [69]. The study suggests time-dependence of bone quality changes with 
increase in mineralization seen at 4 weeks, but decreased mineralization at 12 weeks following 
irradiation [69]. A complete analysis and timeline for changes in bone material quality resulting 
from radiation and bisphosphonate treatment can provide information on overall changes in bone 
function. 
During treatment of cervical cancer, the total radiation dose targeted at the tumor can be 
up to 55 Gy given in smaller daily fractions for several weeks [82]. In mice, a single dose of 2 
Gy X-rays causes a 32% decrease in trabecular bone density at the proximal tibia after just one 
week [67]. Willey et al. demonstrated an early increase in osteoclast number evident at three 
days following a single 2 Gy X-ray exposure [62]. This initial increase is followed by a long-
term depletion of osteoclasts [63]. Oest et al. showed that elevated levels of osteoclasts persist 
for approximately two weeks following either a single 5 Gy X-ray dose or four fractions of 5 Gy 
X-ray dose and then drop in number significantly [63]. Since trabecular bone resorption 
correlates temporally with elevated osteoclast levels, bisphosphonates could be used in the short 
term to prevent trabecular bone loss during radiation therapy.  
Bisphosphonates are a class of drugs that inhibit osteoclasts in order to prevent bone loss 
[118]. Compared to the other bisphosphonates, zoledronate has the highest potency and affinity 
for bone and is commonly used for other reasons in the oncological setting [119, 120]. Since 
bisphosphonates are already FDA-approved and in use for osteoporosis treatment, the 
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demonstration of their efficacy in mitigating radiation-induced bone loss can have a rapid 
clinical impact.  
Currently, risedronate and zoledronate have been tested within different mouse models 
for radiation therapy. In a risedronate study, mice received 2 Gy x-rays to their whole body and 
treated with 30 µg/kg every other day for one, two or three weeks [67]. Risedronate prevented 
trabecular bone loss and reduced osteoclast number following radiation therapy [67]. In another 
study, mice received a single hindlimb exposure of 20 Gy and were given 100 µg/kg zoledronate 
injections four days prior to irradiation and once a week for up to three weeks following 
radiation treatment depending on the group time point [112].  Zoledronate improved bone 
morphology in irradiated mice, but did not increase compressive strength through mechanical 
testing [112]. While the therapeutic potential of bisphosphonates during radiation therapy has 
been shown, there is limited data for use with radiation fractionation, long-term bone 
morphology and characterization of material properties. 
The goal of this study is to characterize the short and long term effects of zoledronate and 
concurrent fractionated radiation on bone morphology, compressive stiffness, composition and 
elastic modulus. We hypothesize that zoledronate will improve bone morphology, increase 
mineralization and overall compressive stiffness of bone following irradiation. In order to assess 
the therapeutic efficacy of zoledronate for radiation therapy, micro-computed tomography 
(microCT), finite element analysis (FEA), Fourier Transform Infrared Spectroscopy (FTIR), 
Raman spectroscopy and nanoindentation will be employed. The results from the study can be 




Animals and Study Design  
One hundred and twenty female C57BL/6 mice were purchased from Charles River 
(Charles River Laboratories, Morrisville, NC). All mice were 14 weeks of age at the start of the 
study with food and water available ad libitum throughout the study. All investigations were 
approved by the University of North Carolina, Chapel Hill Institutional Animal Care and Use 
Committee.  
The mice were divided into 3 groups of 40 mice per group based on time points for 
sacrifice: 3 days, 14 days and 6 months. Within each group, half of the mice were irradiated 
(IRR) and half were not (NR). The IRR mice received three fractions of 6 Gy X-rays per fraction 
to the hindlimbs given on days 0, 2 and 4 (18 Gy total). Within NR and IRR mice, half of the 
mice received a 50 µg/kg injection of zoledronate (ZOL) every other day for two weeks starting 
Day 0, while the other half received placebo (PLAC) saline injections (n=10). For all mice, a 
calcein fluorescent label (10 mg/kg) was injected subcutaneously on Day 0 prior to irradiation. A 
tetracycline fluorescent label (20 mg/kg) was given two days prior to sacrifice. Following 
dissections, the left hindlimb was wrapped in PBS soaked gauze and frozen at -20C and the right 
hindlimb was stored in 70% ethanol. All mice were weighed at the start of the study and at 
dissection. 
Microcomputed Tomography  
MicroCT scans of the right tibia were taken at 10-micron isotropic voxel size (µCT80; 
Scanco Medical AG, Brüttisellen, Switzerland). The scans were acquired using a 70-kVp peak 
X-ray tube potential, a 0.5-mm Al filter and an integration time of 800 ms to reduce beam-
hardening effects and improve the signal-to-noise ratio. Scanco software was used to analyze and 
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quantify bone microarchitectural parameters from contoured regions. All contouring was 
performed semi-automatically to separate trabecular and cortical compartments. For the proximal 
tibia, a 1 mm section of the metaphysis just below the growth plate was chosen as the contour 
region. Structural parameters including bone volume fraction (BV/TV), connectivity density 
(Conn.D), trabecular number (Tb.N), trabecular thickness (Tb.Th), trabecular separation (Tb.Sp), 
structure model index (SMI), volumetric bone mineral density (vBMD), cortical porosity, 
cortical area, marrow area and total area were quantified. 
Finite Element Analysis  
The same 1-mm region of each proximal tibia used for microCT analysis was exported 
from the scanner and imported as a tetrahedral mesh into Abaqus software (Abaqus/CAE 6.9-
EF1, Dassault Systems Simulia Corp, Providence, RI) for finite element analysis. For each 
individual bone section, homogenous material properties were applied to the tibia by assigning a 
Young’s Modulus of 10 GPa and Poisson’s Ratio of 0.3. Then, two node sets were created: one 
containing all nodes on the proximal end of the tibia segment and the other comprised of all 
distal nodes of the tibia segment. For the loading step, boundary conditions were applied to 
secure the distal end of the tibia while displacing the proximal end 5 µm (~ 0.5% strain) 
downward in the z-direction. The resultant force was measured and used to calculate 
compressive stiffness (force/displacement).  
Statistical Analysis 
Significance was determined using SigmaPlot 12.0 (Systat Software Inc., San Jose, CA). 
The threshold for significance for all tests was set at a 5% probability of a type I error (p = 0.05). 
All statistical comparisons for MicroCT and Finite Element Analysis data were made using a 
two-way ANOVA within each time point (3 day, 14 day and 6 month). A Tukey post hoc test 
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was run to explore potential interactions and to maintain a Type 1 error of 0.05 across multiple 
comparisons (NR, IRR, ZOL and PLAC). 
Nanoindentation 
In order to characterize changes to the average elastic modulus of bone resulting from 
radiation and zoledronate, nanoindentation was performed on tibiae from the 14 day and 6 month 
time points. Each tibia was embedded in Clarocit resin and then sectioned using a low-speed 
diamond saw approximately 2 mm from the proximal end (about 0.5 mm from the distal border 
of the growth plate). The end of the tibia distal to the cut was ground using wet silicon carbide 
paper (600, 800, 1200 and 2400 grit) and then polished using 0.1 micron aluminum oxide paste 
and rayon cloth. The same region was used for testing in each bone (Figure 3.1) with the area for 
the indentation array shown in red rectangle. Starting from the endosteal surface, six rows of four 
indents were made with a maximum load of 5 mN/indent. Between all neighboring indents in an 
array, there was a separation distance of 20 microns. A Berkovich tip and a ramp and hold 
profile with a one minute hold at the maximum load was used for every indent. Twenty four 
tibiae total were tested, with n=3 per treatment group. 
Figure 3.1: Optical microscope proximal tibia image with 
region for nanoindentation array in a red rectangle. Six rows 
of four indents per row were performed starting close to the 
endosteal surface and ending close to the periosteal surface 
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Upon testing completion, the force-displacement curves were analyzed to determine 
whether the tip used for indenting had hit a pore in the bone and should be eliminated from the 
data set (outlier). From the remaining curves, the Hysitron software was used to calculate the 
reduced modulus based on the Oliver-Pharr method [7]. Histograms for all reduced modulus data 
were created to look for skew. In order to determine statistical significance, two different 
approaches were used. First, a Two-Way ANOVA was run within each time point (14 day and 6 
month) to compare average reduced modulus between groups (NR-PLAC, NR-ZOL, IRR-PLAC, 
IRR-ZOL) using SigmaPlot 12.0 (Systat Software Inc., San Jose, CA). Specifically, an average 
reduced modulus value from all 24 indents within each bone was calculated and used as one data 
point within a test group (i.e. NR-PLAC) resulting in n=3 per test group. The threshold for 
significance for all tests was set at a 5% probability of a type I error (p = 0.05). A Tukey post hoc 
test was run to explore potential interactions and to maintain a Type 1 error of 0.05 across 
multiple comparisons (NR, IRR, ZOL and PLAC). 
In order to look for changes from endosteal to periosteal surface of the cortical thickness, 
a mixed model approach was used for the 14 day and 6 month time points with JMP Software 
from SAS (SAS Institute, Cary, NC). Tibia sample number was added as a random effect, nested 
within radiation and zoledronate. The fixed effects were radiation group, zoledronate group and 
percentage of cortical thickness from endosteal surface. A full factorial of the three fixed effects 
was used to look both at independent effects and interaction effects. The reduced modulus was 
chosen for the outcome or dependent variable. The threshold for significance for all tests was set 




Fourier Transform Infrared Spectroscopy Imaging 
In order to investigate bone composition, the proximal tibiae were evaluated using FTIR 
imaging. The embedded tibiae used for nanoindentation were cut down to 4 mm thickness by 
removing material from the distal tibia end and leaving the proximal surface intact. Spectral 
images were collected using the Perkin Elmer Spotlight FT-IR Imaging system (Perkin Elmer, 
Seer Green, UK) at a spectral resolution of 4 cm-1 and spatial resolution of 1.56 microns in  
Attenuated Total Reflection Imaging mode. Background and Clarocit resin spectra were also 
collected for each sample to allow for correction. A 50 by 500 micron region was imaged for 
each tibia as shown in Figure 3.2 to ensure a full cross-section of the cortical bone was captured. 
Using Spectrum Image Software, all spectra were atmosphere corrected, baseline corrected and 
Clarocit contributions were subtracted. Images of three tibiae for each treatment group (NR-
PLAC, NR-ZOL, IRR-PLAC, IRR-ZOL) within the 14 day and 6 month time points were taken 
and evaluated. Each pixel in an image represents the absorbance spectra of infrared light at that 
location in the bone. Based on this spectra, significant ratios relating to bone quality and 
composition can be calculated [121]. Mineral to matrix ratio was calculated by taking the 
Figure 3.2: Example image of proximal tibia set up 
for FTIR imaging. The blue rectangle represents the 
area for FTIR assessment. 
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integrated area of the phosphate band (900-1200 cm-1) and dividing by the amide I band (1585-
1725 cm-1). Carbonate to phosphate ratio was calculated as the integrated area of the carbonate 
band (850-900 cm-1) divided by the phosphate band (900-1200 cm-1). Crystallinity, which is a 
measure of crystal size/strain and maturation, is determined by taking the 1030 cm-1 absorbance 
peak divided by the 1020 cm-1 peak [121]. Average ratios were calculated for each bone and 
used as one data point for n=3 per group. A Two-Way ANOVA was run within each time point 
(14 day and 6 month) to compare average reduced modulus between groups (NR-PLAC, NR-
ZOL, IRR-PLAC, IRR-ZOL). The threshold for significance for all tests was set at a 5% 
probability of a type I error (p = 0.05). A Tukey post hoc test was run to explore potential 
interactions and to maintain a Type 1 error of 0.05 across multiple comparisons (NR, IRR, ZOL 
and PLAC). 
Raman Spectroscopy 
Raman spectroscopy mapping of the proximal tibia was performed in order to evaluate 
bone composition from endosteal to periosteal surface. A Renishaw inVia confocal microscopy 
system (Renishaw, Wotton-under-Edge, Gloucestershire, UK) using 785 nm wavelength laser 
light routed through fiberoptic cables to a 50× objective (NA 0.75) and mounted on a 
nanoindenter z-stage (TI 950, Hysitron, Minneapolis, MN) was used [122]. The laser power was 
set to 100 and 6 accumulations of 10 seconds exposure were collected from each location in the 
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array. Spectra were taken in three rows spaced 15 microns between each acquisition in either 
direction and extending the full thickness of the cortical bone (Figure 3.3).  
The baseline was subtracted and cosmic rays were removed using the Renishaw WIRE software. 
Custom MATLAB code developed in Dr. Virginia Ferguson’s lab by Dr. Chelsea Heveran was 
used to subtract a reference PMMA spectrum from each point and calculate all ratios. Mineral to 
matrix ratio was calculated by taking the area of the phosphate (961 cm-1) peak divided by the 
area of the proline peak (855 cm-1). Carbonate to phosphate ratios were evaluated by taking the 
area ratios of carbonate (1071 cm-1) to phosphate (961 cm-1). Lastly, crystallinity was determined 
by taking the inverse of the half-width at the full maximum height of the v1 phosphate peak. 
In order to determine statistical significance, two different approaches were used. First, a Two-
Way ANOVA was run within each time point (14 day and 6 month) to compare average 
parameter values (mineral to matrix ratio, carbonate to phosphate ratio, crystallinity) between 
groups (NR-PLAC, NR-ZOL, IRR-PLAC, IRR-ZOL). Specifically, an average parameter value 
from all three rows of spectra taken across the cortical thickness within each bone was calculated 
Figure 3.3: (a) Proximal tibia cross section with area for Raman array in a red rectangle. Three 
indents per row were spaced 15 microns apart from periosteal to endosteal surface. (b) Example 




and used as one data point within a test group (i.e. NR-PLAC) resulting in n=5 per test group at 
the 6 month time point and n=3 at the 14 day time point.  
A mixed methods approach was used to look for changes from endosteal to periosteal 
surface of the cortical thickness with JMP software from SAS. Tibia sample number was added 
as a random effect, nested within radiation and zoledronate. The fixed effects were radiation 
group, zoledronate group and percentage of cortical thickness from endosteal surface. A full 
factorial of the three fixed effects was used to look both at independent effects and interaction 
effects. The mineral to matrix ratio, carbonate to phosphate ratio and crystallinity were assigned 
dependent variables. The threshold for significance for all tests was set at a 5% probability of a 
type I error (p = 0.05). 
Results 
Body Mass (Table 3.1) 
At the start of the study (Day 0), there were no statistically significant differences in body 
mass between study groups. At the 3 day time point and 14 day time point, there were no 
differences in body mass between study groups as well. For the 6 month time point, there was a 










 NR-PLAC NR-ZOL IRR-PLAC IRR-ZOL 
3 day initial 
body mass 
21.4 ± 1.1 21.5 ± 1.2 21.5 ± 0.7 21.4 ± 1.2 
3 day final body 
mass 
21.8 ± 1.2 22.3 ± 1.4 21.7 ± 0.5  21.6 ± 1.1 
3 day average 
change in body 
mass 
0.39 ± 0.64 0.84 ± 0.49 0.18 ± 0.79 0.15 ± 0.50 
14 day initial 
body mass 
21.4 ± 1.3 21.4 ± 1.0 21.3 ± 1.3 21.6 ± 1.4 
14 day final 
body mass 
22.0 ± 1.1 22.5 ± 1.2 21.9 ± 1.6 22.3 ± 1.3 
14 day average 
change in body 
mass 
0.62 ± 0.76 1.11 ± 0.60 0.54 ± 1.01 0.72 ± 0.67 
6 month initial 
body mass 
22.0 ± 1.1 21.2 ± 1.0 21.6 ± 0.9 21.5 ± 0.8 
6 month final 
body mass 
28.7 ± 3.6 29.9 ± 3.6 32.0 ± 5.2 34.9 ± 5.2* 
6 month 
average change 
in body mass 
11.1 ± 7.8 8.7 ± 3.1 10.5 ± 4.5 13.5 ± 5.0* 
Table 3.1: Initial body mass, final body mass and average change in body mass for each 
treatment group and time point. *=statistically significant effect of irradiation (p<0.05) 
Proximal Tibia MicroCT  
All microCT proximal tibia data can be found in Table 3.2. Example microCT images of 
a 6 month NR-ZOL proximal tibia can be found in Figure 3.4. Graphs for proximal tibia bone 
volume fraction at each time can be found in Figure 3.5 below.  
3 Day Time Point 
There were no significant changes in bone volume fraction (BV/TV), volumetric bone 
mineral density (vBMD) or connectivity density at Day 3. Trabecular number increased 10% 
from NR-PLAC to NR-ZOL. Trabecular thickness declined 9% from NR-PLAC to NR-ZOL and 
increased 12% from NR-ZOL to IRR-ZOL. There was a 10% decrease in trabecular spacing 
from NR-PLAC to NR-ZOL.  
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14 Day Time Point 
Overall, radiation damaged trabecular architecture and zoledronate improved trabecular 
morphometric parameters. Bone volume fraction (BV/TV) decreased 31% from NR-PLAC to 
IRR-PLAC, but increased 38% from NR-PLAC to NR-ZOL and increased 117% from IRR-
PLAC to IRR-ZOL. Similarly, vBMD decreased 43% from NR-PLAC to IRR-PLAC, but 
increased 33% from NR-PLAC to NR-ZOL and increased 120% from IRR-PLAC to IRR-ZOL. 
Connectivity density decreased 61% from NR-PLAC to IRR-PLAC. There was an increase in 
connectivity density from NR-PLAC to NR-ZOL (+41%) and from IRR-PLAC to IRR-ZOL 
(+222%). Trabecular number decreased 21% from NR-PLAC to IRR-PLAC, increased 20% 
from NR-PLAC to NR-ZOL and increased 40% from IRR-PLAC to IRR-ZOL. There was a 10% 
increase in trabecular thickness from IRR-PLAC to IRR-ZOL and an 11% increase in trabecular 
thickness from NR-ZOL to IRR-ZOL. Trabecular spacing increased 30% from NR-PLAC to 
IRR-PLAC, but decreased 17% from NR-PLAC to NR-ZOL and decreased 30% from IRR-
PLAC to IRR-ZOL. 
6 Month Time Point 
There was a 1292% increase in BV/TV from NR-PLAC to NR-ZOL and an 1139% 
increase from IRR-PLAC to IRR-ZOL, with no changes resulting from irradiation after six 
months. The high-dose zoledronate treatment had similarly dramatic effects on other trabecular 
microarchitecture parameters after 6 months, including large increases in vBMD, trabecular 
number and thickness. Figure 3.4 shows an example NR-ZOL image for the 6 month time point, 














Figure 3.4: MicroCT example images of NR-ZOL bone at 6 month 
time point. The trabecular compartment (show in pink) is almost 
entirely filled in with bone.  
Figure 3.5: Proximal tibia trabecular bone volume fraction at 3 day, 14 day and 6 month time 
points. *=significant effect of irradiation with PLAC or ZOL groups, #=significant effect of 
ZOL within NR or IRR groups (p<0.05) 
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BV/TV 0.079 ± 0.018 0.081 ± 0.012 0.086 ± 0.013 0.084 ± 0.014 
vBMD 
(mgHA/cm3) 88.2 ± 15.3 86.3 ± 11.9 91.1 ± 10.6 87.4 ± 14.4 
Conn. Dens. 








0.050 ± 0.004 0.046 ± 0.003# 0.052 ± 0.006 0.051 ± 0.005* 
Trab. 
Spacing (mm) 






BV/TV 0.079 ± 0.011 0.103 ± 0.021# 0.049 ± 0.007*  0.107 ± 0.027# 
vBMD 
(mgHA/cm3) 88.4 ± 10.6 117.6 ± 20.1
# 50.6 ± 8.4*  111.4 ± 25.4# 
Conn. Dens. 
(mm-3) 43.1 ± 13.1 60.6 ± 20.8








0.050 ± 0.004 0.049 ± 0.002 0.050 ± 0.005 0.055 ± 0.004*# 
Trab. 






BV/TV 0.031 ± 0.013 0.429 ± 0.052# 0.034 ± 0.011 0.427 ± 0.051# 
vBMD 
(mgHA/cm3) 36.2 ± 7.3 412.0 ± 47.4
# 35. 5 ± 14.8 424.2 ± 49.4# 
Conn. Dens. 
(mm-3) 7.9 ± 14.3 121.3 ± 21.1








0.058 ± 0.007 0.081 ± 0.005# 0.070 ± 0.007* 0.084 ± 0.010# 
Trab. 
Spacing (mm) 0.566 ± 0.071 0.223 ± 0.021# 0.529 ± 0.107 0.227 ± 0.030# 
Table 3.2: Mean and standard deviation for 3 day, 14 day and 6 month proximal tibia trabecular 
analysis. *=significant effect of irradiation with PLAC or ZOL groups, #=significant effect of 




Proximal Tibia Finite Element Analysis 
At three days, there were no changes in stiffness in the whole proximal tibia segment or 
isolated trabecular compartment. However, there was an 11% increase in stiffness in the isolated 
cortical bone from NR-PLAC to IRR-PLAC.  
In the 14 Day groups, zoledronate increased whole bone stiffness in both NR mice 
(+15%) and IRR mice (+17%). There was also a 9% increase in whole bone stiffness from NR-
ZOL to IRR-ZOL In the isolated trabecular compartment, there was an increase in stiffness 
resulting from zoledronate in both NR (+18%) and IRR (+74%) mice. Trabecular stiffness 
declined 37% from NR-PLAC to IRR-PLAC. Cortical stiffness, however, increased 19% from 
NR-PLAC to IRR-PLAC and increased due to zoledronate within both NR (+14%) and IRR 
(+14%) mice.  
   At 6 months, zoledronate increased whole bone stiffness within NR (+90%) and IRR 
(+116%) mice. Most of this increase in stiffness came from the trabecular compartment, with a 
108% and 867% increase in isolated trabecular bone stiffness from zoledronate within NR mice 
and IRR mice, respectively. Cortical stiffness also increased with zoledronate treatment in both 
NR (+23%) and IRR (+26%). There were no changes between NR and IRR mice in whole bone, 
trabecular bone or cortical bone stiffness. Graphs for proximal tibia FEA stiffness can be found 





Based on the two-way ANOVA using single value modulus averages for each bone, there 
were no significant changes in reduced modulus between any groups in the study (NR-PLAC, 
NR-ZOL, IRR-PLAC, IRR-ZOL) resulting from radiation or zoledronate treatment at the 14 day 
or 6 month time points (Figure 3.7).  
Mixed Effects Model 
6 Month Analysis 
The mixed effects model including all indents across the cortical thickness of each bone 
revealed modulus changes within the bone from endosteal to periosteal surface. There was a 
Figure 3.6: FEA proximal tibia stiffness comparison for treatment groups at 3 day, 14 day and 
6 month time points. *=significant effect of irradiation with PLAC or ZOL groups, 
#=significant effect of ZOL within NR or IRR groups (p<0.05) 
Figure 3.7: Mean and standard deviation bar graphs of 
nanoindentation data for 14 days and 6 month time points by using 
average modulus for each bone as single data point (n=3).  
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significant effect (p=0.0001) of percentage of cortical thickness from endosteal surface within 
both 6 month and 14 day time points (Table 3.3 and 3.4). The effects of radiation and 
zoledronate from endosteal to periosteal surfaces within 6 month and 14 day time points are 













Effect of Radiation Group on Reduced Modulus 
along Cortical Thickness at 6 months 
Effect of Zoledronate Group on Reduced Modulus 
along Cortical Thickness at 6 months 
Figure 3.8: Reduced modulus least square means for 6 month time point along 
cortical thickness from endosteal to periosteal surface from the mixed model analysis. 
Left graph compares irradiated mice (red) to non-irradiated mice (blue) and right 
graph compared zoledronate treated mice (blue) with placebo treated mice (red). 
Table 3.3: 6 month nanoindentation fixed effect results from full-factorial 
mixed model analysis and significance (p<0.05) shown by p-value in Prob>F 
column on the far right. 
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Table 3.4: 14 day nanoindentation fixed effect results from full-factorial 
mixed model analysis and significance (p<0.05) shown by p-value in 
Prob>F column on the far right. 
Effect of Radiation Group on Reduced Modulus 
along Cortical Thickness at 14 days 
Effect of Zoledronate Group on Reduced Modulus 
along Cortical Thickness at 14 days 
Figure 3.9: Reduced modulus least square means for 14 day time point along cortical 
thickness from endosteal to periosteal surface using the mixed model analysis. Left 
graph compares irradiated mice (red) to non-irradiated mice (blue) and right graph 
compared zoledronate treated mice (blue) with placebo treated mice (red). 
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Fourier Transform Infrared Spectroscopy 
There were no significant differences between groups (NR-PLAC, NR-ZOL, IRR-PLAC, 
IRR-ZOL) within the 14 day or 6 month time point for mineral to matrix ratio, carbonate to 
phosphate ratio or crystallinity. The data for mineral to matrix ratio, carbonate to phosphate ratio 









Figure 3.10: FTIR graphs for relevant bone material ratios at the cortical 
tibia. (a) 14 day mineral to matrix ratio (b) 6 month mineral to matrix 
ratio (c) 14 day carbonate to phosphate ratio (d) 6 month carbonate to 
phosphate ratio (e) 14 day crystallinity (f) 6 month crystallinity 
a b c 




Two-Way ANOVA  
Based on the two-way ANOVA using single value parameter averages for each bone, 
there were no significant changes in mineral to matrix ratio, carbonate to phosphate ratio or 
crystallinity between any groups in the study (NR-PLAC, NR-ZOL, IRR-PLAC, IRR-ZOL) 
resulting from radiation or zoledronate treatment at the 14 day or 6 month time points (Figure 




Figure 3.11: Raman spectroscopy graphs for relevant bone material ratios at 
the cortical tibia using a single average value per bone sample within a 
treatment group. (a) 14 day mineral to matrix ratio (b) 6 month mineral to 
matrix ratio (c) 14 day carbonate to phosphate ratio (d) 6 month carbonate to 




Mixed Model Statistical Analysis 
6 month analysis  
Mineral to Matrix Ratio at 6 month time point (Figure 3.13): There was a significant 
effect of percentage of cortical thickness from endosteal surface for mineral to matrix ratio 
(Table 3.6). There was also a significant interaction (p=0.0095) between radiation and 




Figure 3.12: Heat maps for Raman Mineral to Matrix Ratio from each bone 
(white/yellow=high mineral to matrix ratio, red/black=low mineral to matrix ratio). 





Carbonate to Phosphate Ratio at 6 month time point (Figure 3.14): There was a 
significant effect of percentage of cortical thickness from endosteal surface for carbonate to 
phosphate ratio (Table 3.7). In addition, there was a significant interaction between zoledronate 
and percentage of cortical thickness (p=0.0324), as well as radiation, zoledronate and percentage 
of cortical thickness (p=0.0013). 
 
 
Table 3.5: 6 month mineral to matrix ratio fixed effect results from 
full-factorial mixed model analysis and significance (p<0.05) shown 
by p-value in Prob>F column on the far right. 
Effect of Radiation Group on Mineral to Matrix 
Ratio along Cortical Thickness at 6 months 
Effect of Zoledronate Group on Mineral to Matrix 
Ratio along Cortical Thickness at 6 months 
Figure 3.13: Mineral to matrix ratio least square means for 6 month time point along 
cortical thickness of the proximal tibia from endosteal to periosteal surface using the mixed 
model analysis. Left graph compares irradiated mice (red) to non-irradiated mice (blue) and 




















Table 3.6: 6 month carbonate to phosphate ratio fixed effect test 
results from full-factorial mixed model analysis and significance 
(p<0.05) shown by p-value in Prob>F column on the far right 
Effect of Radiation Group on Carbonate to Phosphate 
Ratio along Cortical Thickness at 6 months 
Effect of Zoledronate Group on Carbonate to Phosphate 
Ratio along Cortical Thickness at 6 months 
Figure 3.14: Carbonate to phosphate ratio least square means for 6 month time point along 
cortical thickness of the proximal tibia from endosteal to periosteal surface using the mixed 
model analysis. Left graph compares irradiated mice (red) to non-irradiated mice (blue) and 
right graph compared zoledronate treated mice (blue) with placebo treated mice (red). 
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Crystallinity at 6 month time point (Figure 3.15): There was a significant effect of 







Table 3.7: 6 month crystallinity fixed effect test results from full-
factorial mixed model analysis and significance (p<0.05) shown by p-
value in Prob>F column on the far right 
Effect of Radiation Group on Crystallinity along Effect of Zoledronate Group on Crystallinity along 
Figure 3.15: Crystallinity least square means for 6 month time point along cortical thickness 
of the proximal tibia from endosteal to periosteal surface using the mixed model analysis. 
Left graph compares irradiated mice (red) to non-irradiated mice (blue) and right graph 
compared zoledronate treated mice (blue) with placebo treated mice (red). 
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14 day analysis 
Mineral to Matrix Ratio at 14 day time point (Figure 3.16): There was a significant effect 
of percentage of cortical thickness from endosteal surface for mineral to matrix ratio (Table 3.9). 
Additionally, there was a significant interaction between radiation group and percentage of 
cortical thickness from endosteal surface as well as between radiation, zoledronate and 
percentage of cortical thickness. 
 
 
Table 3.8: 14 day mineral to matrix ratio fixed effect test results from full-
factorial mixed model analysis and significance (p<0.05) shown by p-value in 
Prob>F column on the far right 
Effect of Radiation Group on Mineral to Matrix 
Ratio along Cortical Thickness at 14 Days 
Effect of Zoledronate Group on Mineral to Matrix 
Ratio along Cortical Thickness at 14 Days 
Figure 3.16: Mineral to matrix ratio least square means for 14 day time point along cortical 
thickness of the proximal tibia from endosteal to periosteal surface using the mixed model 
analysis. Left graph compares irradiated mice (red) to non-irradiated mice (blue) and right 
graph compared zoledronate treated mice (blue) with placebo treated mice (red). 
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Carbonate to Phosphate Ratio at 14 day time point (Figure 3.17): There was a significant 
effect of percentage of cortical thickness from endosteal surface for carbonate to phosphate ratio 





Table 3.9: 14 day carbonate to phosphate ratio fixed effect test results from full-factorial mixed 
model analysis and significance (p<0.05) shown by p-value in Prob>F column on the far right 
Effect of Radiation Group on Carbonate to Phosphate 
Ratio along Cortical Thickness at 14 Days 
Effect of Zoledronate Group on Carbonate to Phosphate 
Ratio along Cortical Thickness at 14 Days 
Figure 3.17: Carbonate to phosphate ratio least square means for 14 day time point along cortical 
thickness of the proximal tibia from endosteal to periosteal surface using the mixed model 
analysis. Left graph compares irradiated mice (red) to non-irradiated mice (blue) and right graph 
compared zoledronate treated mice (blue) with placebo treated mice (red). 
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Crystallinity at 14 day time point (Figure 3.18): There was a significant effect of 
percentage of cortical thickness from endosteal surface for crystallinity (Table 3.11). Also, there 






Table 3.10: 14 day crystallinity fixed effect test results from full-factorial mixed model analysis 
and significance (p<0.05) shown by p-value in Prob>F column on the far right 
Effect of Radiation Group on Crystallinity along 
Cortical Thickness at 14 Days 
Effect of Zoledronate Group on Crystallinity along 
Cortical Thickness at 14 Days 
Figure 3.18: Crystallinity least square means for 14 day time point along cortical 
thickness of the proximal tibia from endosteal to periosteal surface using the mixed model 
analysis. Left graph compares irradiated mice (red) to non-irradiated mice (blue) and right 




The main goal of this study was to look at the effects of high-dose zoledronate treatment 
combined with fractionated irradiation on the material properties of bone in a mouse model. 
Radiation therapy for treatment of gynecological tumors has been shown to increase fracture risk 
[3, 83]. Bisphosphonates, such as zoledronate, offer the potential to prevent bone loss seen from 
radiation therapy, but their effect on material properties and bone quality is not fully understood 
[123]. Alterations in material properties of bone influence fracture risk and bone strength. Each 
of the parameters assessed using FTIR and Raman Spectroscopy have been correlated to bone 
strength. Increases in mineral to matrix ratio correlate with increased stiffness and brittleness, 
while decreased carbonate to phosphate ratio correlates with higher strain, greater maximum load 
and greater post-yield toughness [35]. Crystallinity is correlated with tissue-level strength and is 
inversely correlated to yield strain, ductility and fatigue-life [36, 37]. Also, by definition, the 
elastic modulus determined by nanoindentation measures bone’s resistance to deformation when 
a stress is applied. 
However, one of the challenges in comparing tissue level properties is that bone is a 
heterogeneous and dynamic tissue. Both aging and bone turnover result in changes in 
compositional markers, such as mineral to matrix ratio. Recently, heterogeneity has emerged as 
another predictor of bone strength. The literature suggests more heterogeneous bone, as 
measured as the full-width half maximum of target spectral markers, prevents crack propagation 
[36]. Therefore, it is important to keep in mind while interpreting results that a direct relationship 
between changes in bone quality and fracture risk is not clearly defined.  
We observed a significant effect of the percentage of the cortical thickness from 
endosteal surface for all nanoindentation and Raman spectroscopy data collected. This result 
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highlights the complex relationship between material properties and overall bone strength [124]. 
New bone formation in a mouse takes place primarily on the endosteal and periosteal surfaces, as 
evidenced by fluorescent labeling in our study. Since mineral to matrix ratio and crystallinity are 
shown to increase with aging/time, it makes sense that the newer surface bone has different 
material properties than bone in the middle of the cortical segment [39]. By plotting least square 
mean values from a mixed model analysis of data by location in the cortical bone, important 
trends in material properties emerge. For example, at 14 days, irradiated bone modulus is lower 
than that of non-irradiated bone. By six months, the exact opposite is true. Chauhan et al. showed 
these changes also exist in human bone. Specifically, a single large dose (50 Gy) of radiation 
decreased mineral content and elastic modulus after 6 weeks [125]. Another study looked at four 
different time points following fractionated radiation and finds transient changes in material 
properties. Mineral to matrix ratio increases at 4 weeks compared to control, decreases compared 
to control at 12 weeks and is equivalent to control at 26 weeks [69]. Most post-radiation therapy 
fractures occur within two years of treatment [83]. These results emphasize the importance of 
establishing relevant time points for comparison between specimens. Osteoclast levels are 
elevated until fourteen days following irradiation, but then there is a long term loss of osteoclasts 
[63]. Without osteoclastic bone remodeling, the modulus increases, but the bone may become 
more brittle over time. 
Zoledronate binds to hydroxyapatite and reduces bone turnover. Time plays a major role 
in the bone material changes affected by zoledronate, with long-term use (3+ years) shown to 
increase incidence of osteonecrosis of the jaw [126]. It is clear from the literature that there is an 
association between long-term bisphosphonate use and atypical femoral fractures (AFF) [127, 
128]. Other studies have demonstrated that no changes in mean elastic modulus occur six-week 
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post single injection zoledronate treatment [129]. It is also important to characterize the rodent 
model to see how well the results mirror changes seen clinically. Our zoledronate dosing was 
intentionally large in order to determine potential changes before assessing a clinically relevant 
dose. Looking only at bone in the first 20% of the cortical thickness from endosteal surface, 
zoledronate-treated bone crystallinity is decreased compared to the placebo groups. At 6 months, 
the first 20% of the cortical thickness is equal to that of placebo groups. Additionally, the 20%-
40% region zoledronate-treated bone is increased compared to placebo.  
In the short term, treatment with zoledronate seems highly advantageous: preventing 
trabecular bone loss related to elevated osteoclast levels and potential increases in mineral to 
matrix ratio and elastic modulus. However, the long term effects on bone health are less clear. 
Radiation leads to a long term loss of osteoclasts, so the increased osteoclast suppression through 
zoledronate treatment could lead to decreased heterogeneity. The potential increases in 
crystallinity and modulus at the 6 month time point are not necessarily beneficial if the bone is 
becoming more homogenous and brittle. These compositional changes suggest the predominant 
mechanism for atypical fractures from zoledronate use is increased microcrack progression due 
to suppressed bone turnover [128].    
Since certain vibrations in Raman peaks are known to be weaker than in FTIR and vice 
versa, these techniques are often used together [34]. If zoledronate treatment were to alter 
cortical bone material properties in a mouse model, we would expect those changes to be 
amplified with such high dosing. There is conflicting literature on the effect of zoledronate 
therapy on bone material properties and many of the discrepancies can be explained by the 
testing location within the bone or bisphosphonate dosing. For example, Little et al. found that a 
single dose (0.1 mg/kg) of zoledronate does not alter material properties of fracture healing in a 
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rat model [129]. In a study looking at callus formation, there were no tissue compositional 
changes evident with treatment of zoledronate detected by Raman spectroscopy, but there were 
differences between existing tibia and newly forming callus mineralization [130]. Increases in 
mineral to matrix ratio as well as increased tissue modulus resulting from zoledronate were 
found in another study looking at the treatment of osteoporotic sheep, though only at the 
trabecular surface [131]. Changes may be more apparent at the trabecular surface than the 
cortical bone and differences in material properties are site specific. Additionally, dosing plays a 
major role in detection of material changes. A study by Olejnik et al. revealed no changes in 
bone material properties with single low dose or fractionated low dose treatment compared to 
control animals [132]. However, with large, fractionated dosing, there was a significant decrease 
in crystallinity and hydroxyproline-to-proline ratio [132]. 
Another important consideration when looking at Raman, FTIR and nanoindentation data 
is the animal model, length scale and overall size of the areas of interest. Many of the studies that 
see changes in the material properties of bone are performed in larger animal models, such as 
ewes [131, 133]. Since bone is a heterogeneous tissue and there is generally a relatively large 
variance when working with biological tissues, techniques for assessment of nanoscale properties 
require a greater number of data points within each specimen to make comparisons. If interested 
in assessing actively forming bone compared to existing bone properties, the testable area in 
mice is much smaller than in large animals or humans, making it harder to confirm such changes. 
We chose to perform 24 indents per bone in order to account for spatial variability. However, the 




Loss of trabecular bone mass following radiation therapy for cancer treatment is well-
documented [57, 59, 134, 135]. As expected, a significant decrease in trabecular BV/TV is 
evident at 14 days in the IRR-PLAC mice compared to the NR-PLAC mice. By 6 months, the 
effects of aging have resulted in diminished BV/TV in the NR-PLAC equal to that of IRR-PLAC 
mice. Temporal studies of trabecular microarchitecture in C57BL/6 mice over mouse lifespan 
have been performed in both male and female mice. In female C57BL/6 mice, the distal femur 
trabecular BV/TV peaks by 6 weeks and then begins to decline [136]. Female C57BL/6 mice 
also experience a more severe trabecular bone decline than males in adolescence, but then 
maintain a similar steady decline to male mice during adulthood [136]. It is important to note 
that fractures resulting from radiation therapy typically happen soon after treatment, with 83% of 
fractures occurring within two years of treatment completion [83]. 
Following the initial large dosing, zoledronate was incorporated into the bone and 
continued to increase bone density through a slow release mechanism. Bisphosphonates adhere 
to the bone matrix and will persist in bone for a long time, as demonstrated by the trabecular 
compartment of the proximal tibia continuing to increase bone volume up to the 6 month time 
point despite administration within a two week window [137]. While we only looked at the 
proximal tibia region near the growth plate, other studies have shown that this bone formation 
from zoledronate is mainly seen in the area of the growth plate of long bones [138]. 
At the 14 day time point, trabecular BV/TV declined significantly compared to controls, 
yet finite element modeling to simulate compression of the proximal tibia revealed an overall 
increase in bone stiffness. Since homogenous material properties were applied to the model, this 
confirms there was an increase in cortical BV/TV at the proximal tibia as seen in previous 
studies [139].  
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In order to expand upon this model, future studies to look at trabecular material property 
changes as well as solely newly formed bone would help confirm changes resulting from 
radiation and zoledronate treatment. This study also suggests the importance of long-term 
characterization to see whether bone material and structural changes continue to progress or 
whether recovery and function are maintained.  
This first assessment of material properties across three different testing techniques 
suggests changes are not as large in material as structure. However, small changes in material 
properties would result in large changes in function in the three dimensional environment and 
should be incorporated into functional assessment. Overall, the changes in structure caused by 
zoledronate treatment and radiation therapy are much more significant than the material changes 








CHAPTER 4: CHARACTERIZATION OF STRUCTURAL AND MATERIAL 
CHANGES IN BONE FOLLOWING KNEE JOINT BLEEDING IN MALE AND 
FEMALE FACTOR VIII DEFICIENT MICE 
Introduction 
Hemophilia refers to a class of bleeding disorders resulting from gene mutations in 
coagulation proteins located on the X chromosome [140]. Hemophilia A, caused by a Factor VIII 
deficiency, is the most common form of the disease worldwide [141]. While the disease affects 
mostly males, females can also have hemophilia or experience bleeding abnormalities as a carrier 
[142]. In both males and females, recurrent joint bleeding often leads to hemophilic arthropathy, 
characterized by reduced joint space and limited joint motion [143]. Additionally, reduced bone 
density has been observed in patients with hemophilia [72-76, 144].  
In order to better understand the effects of hemarthrosis on joint health, a hemophilic 
mouse model for knee joint hemorrhage has been commonly used [79, 145-153]. Lau et al. 
demonstrated that joint hemorrhage in hemophilic mice causes an acute loss of trabecular bone in 
the injured joint as early as two weeks following knee injury [79]. The effects of rapid bone loss 
following hemarthrosis can greatly increase fracture risk, especially since research studies have 
shown FVIII deficiency independently leads to decreased bone mineral density [78, 154, 155]. 
The FVIII/von Willebrand Factor complex inhibits Receptor activator of nuclear factor kappa-Β 
ligand (RANKL)-induced osteoclastogenesis [154]. Therefore, Factor VIII deficiency increases 
bone resorption through an increase in osteoclasts. Further research needs to be done to look at 
long-term effects of acute hemarthrosis on trabecular bone density.  
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 In addition to trabecular bone loss, Lau et al. showed acute mineralization of the femur, 
tibia, fibula tendon insertion points, patella, patellar tendon, menisci, ligaments and cartilage 
following knee injury [79]. Evidence of increased osteoblast number and decreased IL-6 number 
at one day post-injury and roughening cortical bone surface by three days post-injury may 
explain this heterotopic mineralization [153]. By one week following injury, IL-6 levels increase 
and osteoclast number increases, resulting in bone resorption [153].  Calcifications of the knee 
joint may lead to osteoarthritis and further joint degradation through altered knee function [156]. 
The material properties and timeline of this calcification are not well understood.  
The main goal of this study is to characterize the structure and material properties of both 
the femur and tibia following joint bleeding in both hemophilic male and female mouse models. 
Three time points were examined for changes in bone density using micro-computed tomography 
and fluorescent imaging. At twenty-eight days following knee injury, material properties of the 
distal femur were also examined using nanoindentation and Raman spectroscopy. The results 
from this study can help elucidate the timeline of disrupted bone formation following knee 
hemarthrosis in male and female hemophilic mice and suggest potential mechanisms for 











Animals and Study Design  
All investigations were approved by the University of North Carolina-Chapel Hill 
Institutional Animal Care and Use Committee and were performed in accordance with relevant 
guidelines and regulations. FVIII−/−  male and female mice were originally supplied by Dr. H. H. 
Kazazian Jr [157] and then bred in house and back-crossed 12 generations with C57Bl/6J mice. 
At 18-19 weeks of age, the FVIII−/− mice were subjected to knee joint hemorrhage induced by 
puncture of the joint capsule using a Hamilton syringe with a 30.5-G needle via a small (∼0.5 
mm) incision of the skin overlying the patella. Following injury, all of the mice had access to 
Tylenol gel for pain relief.  
 




The mice were divided into four groups based on the number of days following injury for 
euthanization. There were 16 mice (9 Male, 7 Female) in the 28 day group, 16 mice (8 Male, 8 
Female) in the 14 day group and 15 mice (10 Male, 5 Female) in the 7 day group.  All mice 
received a calcein fluorescent label (10 mg/kg) injected subcutaneously on Day 0 and 3 days 
prior to euthanization as shown in Figure 4.1. The hindlimbs were removed at dissection and 
stored in ethanol at 4 degrees C. The three time points allow for characterization of the 
progression of the mineralization. All mice were weighed at euthanization. 
Microcomputed Tomography  
MicroCT scans of the whole knee joint, including proximal tibia and full femur, were 
taken at 10-micron isotropic voxel size (µCT80; Scanco Medical AG, Brüttisellen, Switzerland). 
Both injured and contralateral limbs were scanned per mouse. The scans were acquired using a 
70-kVp peak X-ray tube potential, a 0.5-mm Al filter and an integration time of 800 ms to reduce 
beam-hardening effects and improve the signal-to-noise ratio. Scanco software was used to 
analyze and quantify bone microarchitectural parameters from contoured regions. All contouring 
was performed semi-automatically to separate trabecular and cortical compartments. For the 
proximal tibia, a 1 mm section of the metaphysis just below the growth plate was chosen as the 
contour region. For the distal femur, a 1 mm section starting 0.5 mm proximal to the most 
proximal point of the continuous epiphyseal line is used as the contour region. Trabecular bone 
parameters including bone volume fraction (BV/TV), connectivity density (Conn.D), trabecular 
number (Tb.N), trabecular thickness (Tb.Th), trabecular separation (Tb.Sp), structure model 
index (SMI), volumetric bone mineral density (vBMD) were quantified for the proximal tibia 
and distal femur. For both the proximal tibia and distal femur, the cortical smoothness ratio was 
calculated by taking the smoothed cortical surface volume divided by the unsmoothed cortical 
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surface volume, to quantify the post-injury surface mineralization [153]. For the midshaft of the 
femur, BV/TV, periosteal volume, endosteal volume, cortical porosity, cortical thickness, bone 
area fraction (BA/TA), cortical vBMD and cortical tissue mineral density (Ct. TMD) were 
quantified.  
Finite Element Analysis 
 The same 1 mm region of each male distal femur (injured and contralateral, all time 
points) used for microCT analysis was converted to a tetrahedral mesh for finite element analysis 
using Scanco software (SCANCO Medical FE-software, SCANCO Medical AG, Bassersdorf, 
Switzerland). Both whole bone and cortical bone stiffness were determined. For each bone 
section, homogenous material properties were applied to the distal femur by assigning a Young’s 
Modulus of 10 GPa and Poisson’s Ratio of 0.3. The distal surface was fixed and the proximal 
surface was displaced 0.02 mm longitudinally (2% strain) to simulate axial compression. The 
stiffness of each section was calculated by taking the resultant force on the distal surface divided 
by the displacement (0.02 mm). Trabecular bone stiffness was determined by subtracting the 
cortical bone stiffness from the corresponding whole segment stiffness. 
Sample Preparation and Keyence Profilometry 
Following microCT analysis, 8 male injured femurs and the 8 contralateral femurs were 
dehydrated in increasing concentrations of ethanol followed by one day in xylene. Then, each 
femur was embedded in poly(methyl)methacrylate (PMMA). Embedded bones were sectioned at 
2 mm proximal to the distal end of the femur using a low speed diamond saw (Isomet, Buehler, 
Lake Bluff, IL). The embedded bones were then ground using wet silicon carbide paper (600, 
800, 1200, 2400) and then polished using wet diamond lapping films (3 µm, 1 µm and 0.5 µm, 
Allied Tech). Samples were sonicated between each polishing step and at the end.  
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In order to ensure minimal surface roughness for nanoindentation testing, all embedded 
femurs were imaged using a Keyence Confocal Laser Scanning Microscope (Keyence VKx1100, 
Osaka, Japan). Through a combination of optical microscopy and laser profilometry, this 
microscope can obtain high resolution images and measure surface roughness.  
Nanoindentation 
Nanoindentation was performed for five randomly selected male mice, both injured and 
contralateral femurs, within the 28 day time point (n= 5 injured, n=5 uninjured). A Hysitron Ubi-
1 Nanoindenter (Hysitron Inc., Minneapolis, MN) was used to perform all indents. Indents were 
performed with a Berkovich tip and a ramp and hold profile with a one minute hold at the 
maximum load. For uninjured femurs, two rows of ten indents per row spaced 20 µm between 
each indent were performed from endosteal to periosteal surface, spanning the cortical bone. The 
first row had a maximum load of 5 mN and the second row had a maximum load of 10 mN to 
make sure data is independent of load. To account for increased cortical thickness and increased 
porosity in the injured femurs, each of the two rows were split in half, with five indents starting 
from the endosteal surface spaced 10 µm apart and five indents starting from the periosteal 
surface spaced 10 µm apart. The maximum loads per row remained the same as the uninjured 
femurs (5mN and 10 mN). The test area within injured and uninjured femurs is shown in red 






Raman spectroscopy mapping of the distal femur was performed in order to evaluate 
bone composition from endosteal to periosteal surface. A Horiba XploRA PLUS Confocal 
Raman Microscope (HORIBA Scientific, Kyoto, Japan) with 785 nm wavelength laser and 1200 
gr/mm grating was used to collect all spectra. The laser power was set to 100 and 3 
accumulations of 10 seconds exposure were collected from each location in the array. Spectra 
were taken in three rows spaced 36.5 microns between rows (same region as nanoindentation 
from Figure 4.2). Within each row, seven spectra were taken evenly spaced throughout the 
cortical thickness from endosteal to periosteal surface (21 total spectra per bone). The baseline 
was subtracted using Horiba software and spectra were exported as .txt files for further analysis. 
Custom MATLAB code developed in Dr. Virginia Ferguson’s lab by Dr. Chelsea Heveran was 
used to subtract a reference PMMA spectrum from each point and calculate all ratios. Mineral to 
matrix ratio was calculated by taking the area of the phosphate (961 cm-1) peak divided by the 
area of the proline peak (855 cm-1). Carbonate to phosphate ratios were evaluated by taking the 
area ratios of carbonate (1071 cm-1) to phosphate (961 cm-1). Lastly, crystallinity was 
determined by taking the inverse of the half-width at the full maximum height of the v1 
phosphate peak. 
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Figure 4.2: Fluorescent image of cross-section of 28 day distal 
femurs for (a) non-injured limb and (b) injured limb with red 
rectangles marking the area for nanoindentation. Fluorescent 




Significance was determined using SigmaPlot 12.0 (Systat Software Inc., San Jose, CA). 
The difference between the injured and uninjured limb (within each time point) was evaluated by 
a paired t-test at a level of significance of p<0.05. If the differences were non-normally 
distributed, a Wilcoxon Signed Rank test was used to determine significance (p<0.05). For 
nanoindentation and Raman spectroscopy data, measurements were averaged within each bone 
and the average value was used for the paired t-test. 
Results 
Final mouse weights within male and female groups were consistent at all three time 
points, showing mice did not gain weight following injury. Male weights were higher than 
female weights at all time points.  
 Male Female 
7 day final body 
mass (g) 
24.8 ± 1.0 20.3 ± 2.7 
14 day final 
body mass (g) 
23.3 ± 1.4 20.7 ± 1.5 
28 day final 
body mass (g) 
24 ± 1.3 19.6 ± 1.3 
Table 4.1: Mean mouse body mass at dissection for each time point. 
MicroCT 
All microCT data for each time point can be found in Tables 4.2-4.4. Selected microCT 
parameter graphs can also be found in Figures 4.3 and 4.4. Example knee joint microCT images 
for an injured limb at 7 days, 14 days and 28 days can be found in Figure 4.5. Example 
fluorescent calcein images of the distal femur in male and female injured limbs can be found in 
Figure 4.6. Within male mice, there was a decrease in trabecular bone volume fraction (BV/TV) 
seven days following injury in both the proximal tibia (-15%) and distal femur (-29%) compared 
to the contralateral limb. At 14 days, the trabecular BV/TV continued to decline at the proximal 
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tibia (-26%) and distal femur (-44%) compared to the contralateral limb. By day 28, there was a 
29% decline in the injured distal femur BV/TV, but no statistically significant differences 
between injured and contralateral proximal tibiae.  
At the midshaft of the femur within male mice, there were no significant changes in 
cortical area or cortical porosity at day 7.  Cortical area increased 19% at 14 days and 16% at 28 
days following injury compared to the contralateral limb. Cortical porosity increased 2220% at 
14 days and 97% at 28 days compared to the contralateral limb.  
Smoothness ratio is a measure of surface roughness for quantification of post-injury 
surface mineralization. At day 7, smoothness had decreased 2% at the proximal tibia and 6% at 
the distal femur from injury compared to the contralateral limb. Smoothness following injury 
decreased 5% compared to the contralateral limb at day 14 and 4% at day 28 in both the 
proximal tibia and the distal femur.  
Within female mice, there were no differences in trabecular BV/TV at the proximal tibia 
between injured and contralateral limbs at day 7, 14 or 28. At the distal femur, there was a 28% 
in trabecular BV/TV at day 14 from injury compared to the contralateral limb, but no changes 
seen at day 7 or day 28.  
At the midshaft of the femur, there were no changes in the cortical area observed at day 
7. There was a 21% and 37% increase in midshaft femur cortical area from injury compared to 
contralateral limb at day 14 and day 28, respectively. Cortical porosity increased 88% by day 7 
in the injured femur and continued to increase 1076% at day 14 compared to contralateral limb. 
By day 28, there was a 570% increase in cortical porosity resulting from injury.  
At day 7, there was a 4% decrease in smoothness ratio at the proximal tibia, but no 
statistically significant changes at the distal femur. At day 14, there was a 6% decline in 
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smoothness at the proximal tibia and a 5% decline at the distal femur compared to the 
contralateral limb. Smoothness decreased 5% and 6% at the proximal tibia and distal femur, 









Figure 4.3: Selected microCT data comparing injured limb to contralateral limb in male mice. 
(a) Proximal tibia BV/TV (b) Distal femur BV/TV (c) Midshaft femur cortical area (d) Midshaft 







Figure 4.4: Selected microCT data comparing injured limb to contralateral limb in female 
mice. (a) Proximal tibia BV/TV (b) Distal femur BV/TV (c) Midshaft femur cortical area (d) 


















BV/TV 0.075 ± 0.01 0.063 ± 0.01* 0.132 ± 0.04 0.110 ± 0.03 
vBMD 
(mgHA/cm3) 85.16 ± 11.7 75.43 ± 12.7 154.63 ± 41.1 134.03 ± 33.2 
Conn. Dens. 








0.042 ± 0.002 0.038 ± 0.002* 0.047 ± 0.003 0.046 ± 0.004 
Trab. 
Spacing (mm) 






BV/TV 0.05 ± 0.01 0.04 ± 0.01* 0.08 ± 0.02 0.06 ± 0.02 
vBMD 
(mgHA/cm3) 53.06 ± 8.06 38.16 ± 7.35* 88.08 ± 21.31 70.00 ± 15.47 
Conn. Dens. 








0.034 ± 0.001 0.032 ± 0.001* 0.037 ± 0.003 0.036 ± 0.004 
Trab. 
Spacing (mm) 















0.24 ± 0.02 0.24 ± 0.03 0.25 ± 0.03 0.24 ± 0.02 
Cortical 
Porosity 




0.20 ± 0.01 0.20 ± 0.01 0.21 ± 0.02 0.22 ± 0.03 
Marrow 
Area (mm2) 
0.48 ± 0.04 0.49 ± 0.05 0.50 ± 0.05 0.47 ± 0.03 
Total Area 
(mm2) 1.15 ± 0.05 1.17 ± 0.08 1.21 ± 0.16 1.20 ± 0.15 
BA/TA 0.583 ± 0.02 0.585 ± 0.02 0.584 ± 0.03 0.605 ± 0.04 
Cortical 
Area (mm2) 











0.909 ± 0.01 0.856 ± 0.02* 0.912 ± 0.03 0.880 ± 0.02 
Table 4.2: Mean and standard deviation for 7 day microCT data (*=significant p<0.05) 
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BV/TV 0.08 ± 0.01 0.06 ± 0.02* 0.14 ± 0.02 0.12 ± 0.03 
vBMD 
(mgHA/cm3) 92.8 ± 16.4 71.1 ± 25.3 157.5 ± 21.0 141.1 ± 34.2 
Conn. Dens. 








0.042 ± 0.002 0.036 ± 0.005* 0.048 ± 0.003 0.045 ± 0.004 
Trab. 
Spacing (mm) 






BV/TV 0.06 ± 0.01 0.03 ± 0.02* 0.08 ± 0.02 0.06 ± 0.02* 
vBMD 
(mgHA/cm3) 61.9 ± 14.6 36.2 ± 20.1* 81.3 ± 21.4 65.3 ± 18.3 
Conn. Dens. 








0.038 ± 0.002 0.032 ± 0.004* 0.038 ± 0.002 0.036 ± 0.003 
Trab. 
Spacing (mm) 















0.25 ± 0.02 0.25 ± 0.01 0.24 ± 0.02 0.25 ± 0.01 
Cortical 
Porosity 




0.200 ± 0.004 0.20 ± 0.01 0.21 ± 0.01 0.21 ± 0.01 
Marrow 
Area (mm2) 
0.50 ± 0.04 0.49 ± 0.03 0.48 ± 0.04 0.51 ± 0.02 
Total Area 
(mm2) 1.16 ± 0.06 1.28 ± 0.07* 1.19 ± 0.05 1.36 ± 0.11* 
BA/TA 0.57 ± 0.02 0.62 ± 0.03* 0.59 ± 0.03 0.63 ± 0.02* 
Cortical 
Area (mm2) 











0.918 ± 0.01 0.869 ± 0.03* 0.929 ± 0.01 0.881 ± 0.02* 
Table 4.3: Mean and standard deviation for 14 day microCT data (*=significant p<0.05) 
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BV/TV 0.06 ± 0.01 0.05 ± 0.01 0.07 ± 0.02 0.07 ± 0.02 
vBMD 
(mgHA/cm3) 71.6 ± 13.7 52.6 ± 11.0 89.7 ± 26.2 78.6 ± 25.4 
Conn. Dens. 








0.044 ± 0.002 0.044 ± 0.005 0.044 ± 0.003 0.043 ± 0.004 
Trab. 
Spacing (mm) 






BV/TV 0.05 ± 0.01 0.03 ± 0.01* 0.06 ± 0.02 0.06 ± 0.02 
vBMD 
(mgHA/cm3) 47.07 ± 16.7 30.72 ± 15.8* 61.00 ± 16.23 62.67 ± 18.6 
Conn. Dens. 








0.042 ± 0.005  0.040 ± 0.005* 0.040 ± 0.004  0.041 ± 0.004 
Trab. 
Spacing (mm) 















0.24 ± 0.03 0.27 ±0.02* 0.24 ± 0.02 0.28 ± 0.03* 
Cortical 
Porosity 




0.20 ± 0.01 0.20 ± 0.01 0.21 ± 0.01 0.20 ± 0.03 
Marrow 
Area (mm2) 
0.48 ± 0.05 0.55 ± 0.04* 0.48 ± 0.04 0.56 ± 0.05* 
Total Area 
(mm2) 1.13 ± 0.07 1.29 ± 0.10* 1.15 ± 0.07 1.46 ± 0.21* 
BA/TA 0.58 ± 0.02 0.58 ± 0.02 0.58 ± 0.03 0.62 ± 0.03 
Cortical 
Area (mm2) 











0.905 ± 0.02 0.870 ± 0.03* 0.924 ± 0.02 0.870 ± 0.02* 






Finite Element Analysis 
At 7 days following injury, cortical bone stiffness declined 16%, trabecular stiffness 
declined 31% and whole bone (trabecular+cortical) stiffness declined 31%.  At 14 days 
following injury, cortical bone stiffness increased 66%, trabecular bone stiffness increased 48% 
and whole bone stiffness increased 59%. There were no changes in trabecular bone stiffness at 
28 days. Cortical bone stiffness increased 30% and whole bone stiffness increased 29% at day 
28. All comparisons are made with respect to uninjured contralateral limbs and corresponding 
graphs are found in Figure 4.7.  
 
 
a b c 
Figure 4.5: MicroCT images of injured knee joint at (a) 7 days (b) 14 days and (c) 28 days 
following injury 
a b 
Figure 4.6: Fluorescent imaging of calcein label of injured distal 
femur at 28 days following injury. (a) Female injured limb (b) 





An example laser+optical image with area of interest highlighted as well as a surface 
roughness profile is shown in Figure 4.8 below. All samples were polished until the entire 
surface roughness for nanoindentation testing was less than 5 µm. For the example shown, the 





Figure 4.7: Male distal femur finite element analysis for (a) cortical bone only (b) trabecular 
bone only and (c) trabecular and cortical bone combined stiffness 
a b
Figure 4.8: Example Keyence profilometry assessment (a) selected region for quantified 
surface roughness and (b) heat map image of bone section for surface roughness with 




At 28 days, there was a 23% decrease in mean reduced modulus at the distal femur 
cortical bone in the injured group compared to the contralateral group (Figure 4.9). The variance 
of the data also decreased in the injured group.  
 
Raman Spectroscopy 
At 28 days, there was a 27% decrease in mineral to matrix ratio in the injured distal 
femur cortical bone compared to contralateral limbs (Figure 4.11). There were no statistically 
significant changes between injured and contralateral limbs for carbonate to phosphate ratio or 
crystallinity (4.10).  
Figure 4.9: Box and whisker plot comparison of 
reduced modulus for uninjured and injured male 










Figure 4.11: Box and whisker plots for comparison of (a) carbonate to 
phosphate ratio and (b) crystallinity for uninjured and injured male 
distal femurs at 28 days 
Figure 4.10: Box and whisker plot comparison of 
mineral to matrix ratio for uninjured and injured 




 In recent years, there have been many advancements made in therapies to treat 
hemophilia, including gene therapy and monoclonal antibodies [158]. These breakthroughs have 
increased life expectancy in the hemophilia population, but also highlight the importance of fully 
characterizing the potential short and long-term effects of a joint bleed in order to improve 
quality of life. In this study, structural and material alterations to the tibia and femur following 
knee hemarthrosis are quantified in both male and female Factor VIII deficient mice.  
 In the male mice, a decline in trabecular BV/TV in both proximal tibia and distal femur is 
evident by seven days and continues to decrease further at day 14. At day 28, there is a smaller 
difference in contralateral and injured trabecular BV/TV in the tibia and femur than day 14. 
However, this seems to be due to the contralateral limb losing BV/TV, rather than a recovery in 
trabecular bone volume. A comparison with uninjured mice would be necessary to determine 
whether this is a systemic effect of injury on the contralateral limb or an effect of aging. In 
general, female trabecular bone seems to be less affected by joint injury than males. There were 
no significant changes in BV/TV between injured and contralateral limbs in the female proximal 
tibia at any time point. There was a significant decrease in female distal femur BV/TV at day 14, 
though less than the change seen in males. Female mice also had higher starting values for 
BV/TV at both the proximal tibia and distal femur than male mice.  
 In the cortical compartment, as evaluated in the midshaft region of the femur, female 
mice experienced more dramatic increases in cortical area and porosity than male mice. This 
elevated response to joint injury could potentially be due to an increased immune response. 
Women have a higher incidence of autoimmune disease and estrogen is known to have an 
immune-enhancing effect on bone [159, 160].  
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 In addition to differences in trabecular and cortical responses, male and female mice have 
a different timeline for bone formation following injury. At the 28 day time point, the cortical 
thickening is evident in both male and female femurs, though only the formation in the male 
mice is fluorescent. Calcein labels were given at injury and three days prior to euthanization.  
In the cortical region of the male distal femur, both mean reduced modulus and mineral to 
matrix ratio decreased in the injured limb. Interestingly, the variance of mineral to matrix ratio 
and reduced modulus also decreased in the injured limb. Heterogeneity in nanoscale material 
properties and mineralization has emerged as a contributor to bone fracture toughness and energy 
dissipation [161]. Increased heterogeneity should prevent crack initiation and propagation within 
bone [162]. A decrease in variance suggests more homogenous bone and therefore, cracks are 
more likely to propagate along the bone.  
Clinically, low bone density has been recognized in both adults and children with 
hemophilia [72-75]. There are a variety of factors that contribute to this problem, including 
limited physical activity, joint bleeding and the effects of HIV or other infections [73]. The 
results from this study confirm that joint injury can further exacerbate decreased trabecular bone 
density and also alter morphology of the cortical bone. Previous reports using ultrasound have 
described the bone to have osteophytes and surface erosion following hemarthrosis [163]. The 
smoothness ratio described in this study offers a way to quantify the phenotypic response to 
hemophilic injury.  
Overall, the identification of cortical mineralization (also described as heterotopic 
ossification [79, 153]) following hemarthrosis is fairly new and this is the first time a time course 
has been described. Based on this study, most cortical formation happens within 7-14 days 
following hemarthrosis. The porosity continues to fill in up to the 28 day timepoint and the new 
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formation begins to look more like normal bone. Including the female mice in this study provides 
suggestions about mechanisms that could be contributing to bone alterations, including hormones 
and inflammatory immune response. In future studies, we would like to look at long-term effects 
of knee hemarthrosis to see if the cortical mineralization is resorbed with time or if cortical 






















CHAPTER 5: CONCLUSION AND FUTURE WORK 
Summary of Findings 
 The goal of this work was to characterize structural and material changes of bone in a 
mouse model for radiation therapy induced estrogen deficiency and hemophilic joint bleeding. 
Both disease states are associated with altered bone phenotype, but lack full understanding of the 
factors contributing to bone fragility or optimal targets for therapeutic development. Through 
microCT, DEXA, finite element analysis, fluorescent imaging, FTIR, Raman spectroscopy and 
nanoindentation assessment, bone alterations were quantified at multiple length scales to provide 
a more complete evaluation of bone strength. Additionally, multiple time points were 
characterized to determine whether bone changes were transient or persisted long-term.  
 In Chapter 2, bone morphological parameters and structural stiffness in the trabecular and 
cortical compartments were quantified at three skeletal sites following concurrent fractionated 
radiation and estrogen deficiency. A biologically effective dose (BED) was used to simulate 
cervical cancer treatment. First, a validation experiment demonstrated greater loss in trabecular 
bone density from multiple fractions of radiation compared to a single large dose. Following 
dose validation, fractionated irradiation using a BED led to significant decline in trabecular bone 
volume and stiffness. Interestingly, radiation caused an increase in cortical thickness and 
stiffness at the proximal tibia. The combination of irradiation with ovariectomy had an additive 
effect at the proximal tibia, with greater trabecular bone loss seen than in either procedure alone. 
Ovariectomy had a systemic effect, while skeletal radiation damage was largely specific to 
trabecular bone within the X-ray field.  
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 The mouse model characterization from Chapter 2 allowed for assessment of the ability 
of high-dose zoledronate treatment to prevent bone loss from radiation therapy in Chapter 3. 
Zoledronate prevented loss of trabecular bone volume fraction at the 3 and 14 day time points. 
At six months, there were extreme structural changes (+1140% BV/TV), with the trabecular 
compartment almost completing filling in with bone. Average changes in material properties 
were less apparent. However, location within cortical thickness from endosteal to periosteal 
surface proved to have a significant effect in the mixed model analysis for both nanoindentation 
and Raman spectroscopy. Newer bone formed close to the endosteal surface showed trends of 
increased modulus, mineral to matrix ratio and crystallinity at 6 months, though not statistically 
significant (p<0.05). At 14 days, newer bone following irradiation has a trending lower modulus 
compared to controls, while the exact opposite is true at six months. Interestingly, heterogeneity 
of tissue is also used to quantify bone health, with increases in heterogeneity considered 
beneficial [36]. The mixed model results highlight the complexity of the relationship between 
material properties and overall bone strength as well as the importance of using multiple 
modalities (nanoindentation, FTIR, Raman spectroscopy) to define material alterations.  
 In Chapter 4, insights from material characterization in Chapter 3 led to the 
characterization of rapid mineralization and cortical thickening at the knee joint following joint 
injury in a male and female Hemophilia A mouse model. Fluorescent images and microCT 
morphometric analysis revealed large areas of new cortical bone formation at the distal femur 
within the 7 day time point and persisting through the 28 day time point. Most cortical bone 
formation happened within 7-14 days following hemarthrosis. The cortical porosity continued to 
fill in up to the 28 day time point. Additionally, significant loss of trabecular bone was evident at 
all time points in the male distal femur. Female mice saw fewer changes in trabecular 
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microarchitecture, but large changes in cortical thickness and porosity. Male and female 
differences following joint injury may be related to immune response [159, 160]. In addition to 
structural changes, there were large changes in material properties at the 28 day time point. 
Distal femur cortical reduced modulus and mineral to matrix ratio decreased significantly. 
Reduced modulus and mineral to matrix variability also decreased.  
Beyond the quantitative data gathered, considerations for experiment design, sample 
preparation assessment and data interpretation were highlighted through this work. First, length 
scale is critical in the discussion of relating structural and material properties to strength.  
Whether or not material changes have “positive” or “negative” impacts on bone health must be 
discerned at each hierarchical level. For example, from the literature, an increase in mineral to 
matrix ratio correlates with an increase in bone strength [39]. However, mineral to matrix ratio 
alone does not provide that information. Assessment at the micrometer level would be necessary 
to validate the functional contribution of that material change. Addition of mineral alone may not 
influence nanoindentation modulus if the mineral is not added in a way that can transmit strain. 
In other words, the increase in mineral is only useful if it is organized in a way that also increases 
tissue modulus. Similar thought processes apply to interpretation of all material parameters.  
Variability is just as important as material parameters of interest. Drugs such as 
zoledronate offer huge benefits for preserving bone structure, but ultimately halt bone 
remodeling. Evidence for decreased remodeling can be seen through increases in crystallinity 
with decreases in crystallinity variability. Though the bone structure may remain intact, this 
homogenization of mature mineral in a localized region may cause the bone to become brittle 
and allow microcracks to propagate.  For this reason, the crystallinity increase is only beneficial 
to bone health if there is still tissue heterogeneity.   
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For future studies, I would take a more targeted approach in locations for material testing. 
Since we know bone mineralizes over time, new and old bone properties are expected to be 
different. For this reason, I would focus on the new or old regions and gather more data within 
each region, rather than equally spaced through the cortical thickness. A fluorescent label would 
be valuable in defining new and old bone.  
The development of the Oliver-Pharr equation led to a significant increase in use of 
nanoindentation in the literature. However, numerous factors other than load and displacement 
go into the measured values. Surface roughness, tip geometry, maximum depth, distance from 
bone surface (must assume continuum for Oliver-Pharr method), thermal drift, embedding 
medium, hydration state, hold time at maximum load and loading profile are just a few factors 
worth mentioning that influence the modulus value obtained [164]. Ideally, to compare values, 
all of the testing factors should be the same. One small step towards understanding values 
reported would be the addition of surface profilometry data following sample preparation. The 
maximum surface roughness measurement in combination with depth information would ensure 
the indenting protocol was actually probing the bone and following the well-defined contact 
geometry necessary to use Oliver-Pharr calculations [165]. 
 The mixed model analysis provides a more thorough understanding of the material 
properties data and informs future studies. In gathering data in bone, often times there will be 
outliers representative of pores in the bone. This leads to unequal number of data points per row 
or sample, invalidating the assumptions required to run an ANOVA. Therefore, values are often 
averaged across a sample, reducing each bone to one data point within a treatment group. As a 
heterogeneous, biological sample, one data point does not well represent overall bone material or 
variability. For this reason, a mixed model can account for both random effects (such as sample 
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number) as well as all potential fixed effects. All post-hoc analyses can still be run with a mixed 
model to understand local changes taking place and inform further studies to focus on those 
specific locations.  
Overall, this work demonstrates the importance of characterization of bone health at 
multiple length scales and time points. Though zoledronate offers the potential to decrease bone 
loss seen following radiation therapy and estrogen deficiency, concerns about long-term effects 
on bone mineralization and variability require further investigation with dosing or a less potent 
bisphosphonate. In the hemarthrosis model, the timeline of cortical mineralization and trabecular 
bone decline has been characterized in a male and female model to help elucidate mechanisms 
for therapeutic targets.    
Limitations 
 One of the limitations of mouse studies is that mice lack Haversian systems and do not 
undergo osteonal remodeling. The mouse cortical bone is a mixture of woven bone and 
circumferential lamellar bone. Typically, circumferential lamellar bone is laid down on the 
periosteal surface and resorption occurs on the endosteal surface, though formation can also 
occur at the endosteal surface [166]. Therefore, changes in osteonal bone remodeling in humans 
will not be represented in the mouse model. 
 For changes in trabecular architecture, the proximal tibia and distal femur regions are 
analyzed instead of the femoral neck. Most pelvic fractures resulting from pelvic radiation 
therapy occur at the femoral neck [167]. However, in a mouse, there is very little trabecular bone 
present due to the small size. Therefore, changes are more evident in trabecular-rich areas, such 
as the proximal tibia and distal femur.  
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 Additionally, material properties characterization in Chapter 3 had a small sample size 
(n=3). In order to account for variability in bone tissue, many data points are gathered per bone. 
However, in order to increase the power in future studies, I would incorporate a larger number of 
samples. More specific study limitations can be found in the discussions of Chapters 2-4. 
Future Work 
Clinical dose bisphosphonate treatment 
Now that the long-term structural and material changes resulting from high-dose 
zoledronate have been characterized, further analysis of a single injection at a clinically relevant 
dose would provide meaningful information for the utility in radiation therapy. Due to the 
extreme structural changes at six months following zoledronate administration, a less potent 
bisphosphonate such as alendronate could be used. A calcein label injected at the first radiation 
dose would provide the boundaries for localized material properties testing in new and extant 
bone for assessment.  
Include OVX model into material characterization for drug efficacy 
 In addition to testing clinical bisphosphonate dosing, an OVX model should be 
incorporated to determine if there are additional alterations in material or structural properties 
that suggest a better option for a therapeutic. Chapter 2 revealed an additive effect from OVX 
and radiation therapy on bone loss, which could influence the clinical dose required to prevent 
osteoclast activation.  
Validation of heterotopic ossification in hemarthrosis model 
 Based on microCT imaging, soft-tissues surrounding the knee joint appear to be 
mineralizing. Peterson et al. developed a method to verify the existence of heterotopic 
ossification versus cortical bone [168]. Specifically, using microCT images to guide locations for 
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testing, high resolution Raman spectroscopy and histologic sections in combination can be used 
to identify soft tissue mineralization. With heterotopic ossification, the phosphate vibrational 
region shifts to the right and crystallinity/mineral to matrix ratio are significantly decreased. 
Picrosirius red and pentachrome staining to view collagen structure can be used to confirm 
results. 
Improve finite element model to include modulus estimates as well 
 Functional evaluation in this dissertation utilized finite element models from microCT 
images with homogeneous material properties applied for the assessment of stiffness. In order to 
improve upon this estimate, modulus values obtained from nanoindentation or microindentation 
could be applied to areas within the bone. Further assessment of material properties at multiple 
length scales should be performed prior to assigning modulus values. This is not a trivial task, 
considering the heterogeneity to be represented in bone tissue. Another option for an improved 
finite element model would be to scale material properties by grayscale values obtained from 


































Figure 5.1: Right hindlimb DEXA data for OVX+Radiation study 






















Figure 5.2: Whole body DEXA data for OVX+Radiation study with 











Mouse Group Rad VOX‐TV VOX‐BV VOX‐BV/TV Conn‐Dens. TRI‐SMI DT‐Tb.N DT‐Tb.Th DT‐Tb.Sp vBMD vBMD2 TMD
1192 sham NR 1.9121 0.1368 0.0715 47.3292 2.564 3.3742 0.0448 0.2963 62.0599 56.46527 789.724
1242 sham NR 1.928 0.2104 0.1091 80.6553 2.2461 4.0992 0.049 0.2435 98.9122 90.59446 830.38
1291 sham NR 2.0333 0.2126 0.1045 75.9831 1.95 4.1233 0.0437 0.2415 82.092 83.31221 797.246
1357 sham NR 1.7505 0.2015 0.1151 85.4062 2.1525 3.4515 0.0489 0.2903 102.6312 91.72411 796.908
1689 sham NR 1.9503 0.1661 0.0852 62.0433 2.3232 3.4876 0.0449 0.2862 73.6396 69.8122 819.392
1880 sham NR 2.1782 0.1735 0.0797 50.5014 2.3802 3.6883 0.0441 0.2698 69.667 66.15435 830.042
6‐R1 sham NR 1.7678 0.1603 0.0907 55.1526 2.0518 3.2329 0.0469 0.3095 79.4717 73.22256 807.305
7‐R1 sham NR 1.8218 0.1272 0.0698 42.2647 2.4424 3.603 0.0435 0.2756 56.4813 55.10501 789.47
MEAN 1.91775 0.17355 0.0907 62.416975 2.263775 3.6325 0.045725 0.276588 78.11936 73.29877 807.5584
ST DEV 0.142451 0.032501 0.017242224 16.361224 0.205361 0.325759 0.002249 0.024276 16.33754 14.22517 17.03555
1024 sham IRR 1.6317 0.0828 0.0508 13.4833 3.1368 2.8653 0.0498 0.3513 28.673 39.78732 783.215
1170 sham IRR 1.5747 0.071 0.0451 15.2411 3.2435 2.214 0.0574 0.4391 18.5302 35.73471 792.344
1196 sham IRR 1.289 0.0749 0.0581 18.619 3.0262 2.6372 0.0537 0.3786 44.1408 47.29729 814.067
1427 sham IRR 1.5864 0.0639 0.0403 16.7048 3.5461 2.681 0.0486 0.3739 19.3754 32.57183 808.234
1492 sham IRR 1.4772 0.0613 0.0415 11.8471 3.2242 2.5405 0.0442 0.3922 22.0802 31.82295 766.818
1704 sham IRR 1.6422 0.0799 0.0486 15.8321 2.8887 2.5219 0.0548 0.3991 24.1933 38.82421 798.852
1774 sham IRR 1.5168 0.0717 0.0473 30.656 3.0589 2.3481 0.0469 0.4193 29.8563 38.0336 804.093
1902 sham IRR 1.6497 0.0978 0.0593 34.2492 2.7104 2.4422 0.0463 0.4151 38.9849 46.46475 783.554
MEAN 1.545963 0.075413 0.048875 19.579075 3.10435 2.531275 0.050213 0.396075 28.22926 38.81708 793.8971
ST DEV 0.120382 0.011595 0.006991985 8.25394966 0.250656 0.202673 0.00463 0.02823 9.244825 5.724361 15.57313
1151 ovx NR 2.2652 0.1324 0.0584 47.8976 2.5855 3.1681 0.0394 0.3125 32.4766 44.51067 762.169
1218 ovx NR 2.248 0.1584 0.0705 46.2627 2.4929 3.1786 0.0465 0.3126 54.1992 54.31687 770.452
1517 ovx NR 2.4959 0.1341 0.0537 30.4505 2.7788 3.3976 0.0391 0.2936 40.2527 43.17072 803.924
1707 ovx NR 2.2694 0.177 0.078 50.8956 2.415 3.5436 0.0456 0.2815 60.7075 65.02018 833.592
1729 ovx NR 2.3278 0.1087 0.0467 27.2795 2.8208 3.2053 0.0372 0.3118 32.6456 37.50379 803.079
1856 ovx NR 1.8214 0.0892 0.049 29.9219 2.4604 2.2931 0.0421 0.4372 31.7159 39.22244 800.458
2‐R2 ovx NR 2.4342 0.1257 0.0516 25.6754 2.7891 3.2612 0.0389 0.3053 37.8016 41.5784 805.783
2035 (femur only) ovx NR
MEAN 2.265986 0.132214 0.058271429 36.9118857 2.620357 3.149643 0.041257 0.322071 41.39987 46.47472 797.0653
ST DEV 0.217167 0.029271 0.011719174 10.9035069 0.172711 0.401471 0.003586 0.052089 11.55359 9.80862 23.91281
1055 ovx IRR 1.6741 0.0479 0.0286 5.0775 2.8711 2.58 0.0505 0.4222 ‐0.5722 22.6973 793.612
1069 ovx IRR 1.7034 0.0557 0.0327 5.8706 3.0055 1.9488 0.0496 0.5305 4.3302 25.66917 784.99
1394 ovx IRR 1.9143 0.1069 0.0558 23.5068 2.8932 2.2283 0.0555 0.4618 28.2504 43.45816 778.82
1535 ovx IRR 1.8937 0.0815 0.043 12.6739 2.5807 2.1907 0.0527 0.4591 16.079 34.62326 805.192
1594 ovx IRR 1.8273 0.0652 0.0357 4.6517 2.7395 2.16 0.0535 0.4591 8.7254 28.88416 809.08
1748 ovx IRR 1.5211 0.0444 0.0292 8.5462 2.9646 1.5747 0.0516 0.6409 0.0195 23.09203 790.823
1809 ovx IRR 1.5471 0.0395 0.0255 3.8783 3.6293 2.0227 0.0498 0.5056 ‐4.5448 20.3923 799.698
2‐R1 ovx IRR 1.5503 0.0371 0.0239 4.5153 3.0552 1.7606 0.045 0.5611 1.1183 18.94713 792.767
MEAN 1.703913 0.059775 0.0343 8.5900375 2.967388 2.058225 0.051025 0.505038 6.675725 27.22044 794.3728
ST DEV 0.159465 0.024028 0.01060027 6.68940929 0.307881 0.30815 0.003149 0.070915 10.80485 8.248057 10.05272
Proximal Tibia Trabecular Analysis










Mouse Group Rad VOX‐TV VOX‐BV VOX‐BV/TCt. Po DT‐Ct.Th vBMD TMD
1192 sham NR 0.9332 0.8661 0.9281 0.0719 0.1149 718.2172 846.8622
1242 sham NR 1.0851 1.017 0.9373 0.0627 0.1318 753.041 871.7122
1291 sham NR 0.793 0.7062 0.8905 0.1095 0.0915 649.584 798.6838
1357 sham NR 1.0615 0.985 0.9279 0.0721 0.1248 723.1196 847.0313
1689 sham NR 0.9832 0.9164 0.932 0.068 0.1204 738.5029 864.6122
1880 sham NR 0.9779 0.9064 0.9269 0.0731 0.11 737.9113 873.2337
6‐R1 sham NR 1.0197 0.9466 0.9283 0.0717 0.1228 727.5994 850.8349
7‐R1 sham NR 0.9248 0.8662 0.9367 0.0633 0.116 703.172 820.2373
0.9723 0.901238 0.925963 0.074038 0.116525 718.8934 846.651
0.091816 0.095044 0.014893 0.014893 0.012118 31.75203 25.83889
1024 sham IRR 1.1416 1.0724 0.9393 0.0607 0.1579 760.6481 870.0218
1170 sham IRR 1.1372 1.0863 0.9552 0.0448 0.1671 791.1611 890.3919
1196 sham IRR 1.0163 0.9668 0.9513 0.0487 0.1584 770.8755 867.8242
1427 sham IRR 1.11 1.0469 0.9431 0.0569 0.1502 760.31 866.6408
1492 sham IRR 1.1568 1.1069 0.9569 0.0431 0.1664 791.4147 887.6872
1704 sham IRR 1.1012 1.0532 0.9564 0.0436 0.1545 781.2719 879.5729
1774 sham IRR 1.09 1.036 0.9504 0.0496 0.1699 802.6564 906.7896
1902 sham IRR 1.0387 0.9884 0.9516 0.0484 0.1436 760.6481 861.8229
1.098975 1.044613 0.950525 0.049475 0.1585 777.3732 878.8439
0.046499 0.044381 0.005915 0.005915 0.008468 15.55049 14.27825
1151 ovx NR 0.9145 0.7981 0.8727 0.1273 0.0987 617.465 768.5933
1218 ovx NR 0.9115 0.7978 0.8753 0.1247 0.0969 627.6923 790.3159
1517 ovx NR 0.9191 0.8481 0.9227 0.0773 0.1026 700.9744 838.8325
1707 ovx NR 0.9272 0.8043 0.8675 0.1325 0.0966 651.7816 827.4218
1729 ovx NR 0.9027 0.8449 0.936 0.064 0.1091 719.0624 849.9051
1856 ovx NR 0.8525 0.8005 0.939 0.061 0.1066 710.6946 833.9301
2‐R2 ovx NR 0.9053 0.8428 0.931 0.069 0.1056 712.3005 845.5944
2035 (femur only) ovx NR
0.904686 0.8195 0.906314 0.093686 0.1023 677.1387 822.0847
0.024444 0.024245 0.032726 0.032726 0.005005 43.46832 30.67723
1055 ovx IRR 0.9651 0.9027 0.9354 0.0646 0.1348 740.8696 861.4848
1069 ovx IRR 1.004 0.9251 0.9214 0.0786 0.1342 716.9493 841.6218
1394 ovx IRR 1.0692 0.9459 0.8846 0.1154 0.124 675.8708 829.1968
1535 ovx IRR 1.0299 0.9709 0.9427 0.0573 0.1324 756.2529 876.6146
1594 ovx IRR 1.0174 0.9604 0.944 0.056 0.1364 760.9862 881.348
1748 ovx IRR 1.0309 0.9781 0.9488 0.0512 0.1503 764.8743 867.6551
1809 ovx IRR 0.9675 0.9023 0.9326 0.0674 0.1402 742.9827 862.5837
2‐R1 ovx IRR 0.9394 0.8794 0.936 0.064 0.1343 756.4219 881.1789
1.002925 0.9331 0.930688 0.069313 0.135825 739.401 862.7105
0.042819 0.03622 0.020403 0.020403 0.007431 29.86555 18.80589
Proximal Tibia Cortical Analysis
Table 5.2: OVX+Radiation study proximal tibia cortical microCT raw data.











Mouse Group Rad VOX‐TV VOX‐BV VOX‐BV/TV Ct. Po DT‐Cort.Th Vbmd TMD M.Ar T.Ar BA/TA Cort. Ar
1192 sham NR 0.3478 0.3112 0.8947 10.53 0.1695 991.4822 1037.2097 0.856 1.5438 0.445524 0.6878
1242 sham NR 0.3792 0.3425 0.9033 9.67 0.1992 994.5251 1036.5334 0.7392 1.4884 0.503359 0.7492
1291 sham NR 0.3134 0.2693 0.8591 14.09 0.1656 949.7276 995.9621 0.726 1.346 0.460624 0.62
1357 sham NR 0.3687 0.3342 0.9066 9.34 0.1875 1012.1906 1058.3406 0.7826 1.5112 0.482133 0.7286
1689 sham NR 0.3686 0.3377 0.9162 8.38 0.1785 1028.4192 1074.4846 0.8616 1.5902 0.458181 0.7286
1880 sham NR 0.3645 0.3312 0.9087 9.13 0.1836 1027.1514 1076.006 0.8042 1.5244 0.472448 0.7202
6‐R1 sham NR 0.357 0.3294 0.9228 7.72 0.1839 1036.618 1081.5846 0.7594 1.4648 0.481567 0.7054
7‐R1 sham NR 0.3383 0.3102 0.917 8.3 0.1779 1023.1786 1067.2156 0.7218 1.3904 0.480869 0.6686
0.354688 0.320713 0.90355 9.645 0.1807125 1007.911588 1053.417075 0.78135 1.4824 0.473088 0.70105
0.021088 0.023829 0.020005356 2.000535643 0.010510327 28.53739781 28.81210469 0.055297404 0.080533 0.018001 0.041438
1024 sham IRR 0.3678 0.3375 0.9176 8.24 0.1878 1032.3073 1077.9501 0.785 1.512 0.48082 0.727
1170 sham IRR 0.3478 0.3123 0.898 10.2 0.1755 1002.5549 1052.3394 0.8244 1.512 0.454762 0.6876
1196 sham IRR 0.3229 0.2875 0.8904 10.96 0.1691 978.6347 1023.6013 0.7764 1.415 0.451307 0.6386
1427 sham IRR 0.3451 0.3023 0.876 12.4 0.1693 962.6597 1008.218 0.8726 1.555 0.438842 0.6824
1492 sham IRR 0.3388 0.2996 0.8843 11.57 0.1733 978.2121 1025.6299 0.7974 1.4668 0.456368 0.6694
1704 sham IRR 0.3503 0.3201 0.9137 8.63 0.1794 1026.3906 1072.9631 0.773 1.4654 0.472499 0.6924
1774 sham IRR 0.3461 0.3134 0.9054 9.46 0.1738 1027.9966 1080.4858 0.82 1.5042 0.45486 0.6842
1902 sham IRR 0.3219 0.2905 0.9024 9.76 0.1672 1005.8513 1054.0299 0.801 1.4376 0.442821 0.6366
0.342588 0.3079 0.898475 10.1525 0.174425 1001.8259 1049.402188 0.806225 1.4835 0.456535 0.677275
0.01498 0.016448 0.014304919 1.430491923 0.006689811 26.3591014 27.49877546 0.032677723 0.045624 0.014036 0.029506
1151 ovx NR 0.3433 0.2999 0.8736 12.64 0.1629 957.4193 1002.893 0.9784 1.6572 0.409607 0.6788
1218 ovx NR 0.3533 0.3223 0.9122 8.78 0.1712 1016.5859 1062.7358 0.89 1.5886 0.439758 0.6986
1517 ovx NR 0.3368 0.2999 0.8904 10.96 0.1719 997.0609 1047.7751 0.7886 1.4546 0.457858 0.666
1707 ovx NR 0.3532 0.3227 0.9137 8.63 0.1757 1015.8251 1060.7073 0.8414 1.5396 0.453494 0.6982
1729 ovx NR 0.3386 0.3067 0.9056 9.44 0.1701 1000.8644 1045.8311 0.8192 1.489 0.449832 0.6698
1856 ovx NR 0.3335 0.3001 0.8999 10.01 0.1649 989.3692 1034.843 0.8602 1.5196 0.43393 0.6594
2‐R2 ovx NR 0.3473 0.3163 0.9108 8.92 0.1718 1010.7537 1055.7203 0.839 1.5256 0.450052 0.6866
2035 (femur only) ovx NR 0.3406 0.3036 0.8913 10.87 0.1735 968.9145 1010.162 0.8158 1.4892 0.452189 0.6734
0.343325 0.308938 0.8996875 10.03125 0.17025 994.599125 1040.08345 0.854075 1.532925 0.44334 0.67885
0.007384 0.009979 0.013879938 1.387993799 0.004292186 21.74408312 22.61815088 0.0587257 0.064138 0.015669 0.014539
1055 ovx IRR 0.3399 0.3049 0.8969 10.31 0.1722 993.9335 1040.0835 0.8062 1.4782 0.454607 0.672
1069 ovx IRR 0.3386 0.2837 0.8378 16.22 0.1637 937.1336 987.9323 0.915 1.5848 0.42264 0.6698
1394 ovx IRR 0.3361 0.2913 0.8669 13.31 0.174 970.8585 1024.9537 0.7724 1.437 0.462491 0.6646
1535 ovx IRR 0.3455 0.3083 0.8924 10.76 0.1676 990.637 1039.0692 0.9026 1.5858 0.430824 0.6832
1594 ovx IRR 0.3528 0.3164 0.8971 10.29 0.1707 996.131 1045.0703 0.8896 1.5868 0.439375 0.6972
1748 ovx IRR 0.3544 0.3173 0.8953 10.47 0.1763 993.8489 1041.5204 0.8402 1.541 0.45477 0.7008
1809 ovx IRR 0.33 0.2986 0.905 9.5 0.1654 1008.4715 1055.2977 0.8472 1.4998 0.435125 0.6526
2‐R1 ovx IRR 0.3322 0.2976 0.8957 10.43 0.1681 988.1014 1035.0966 0.846 1.5028 0.437051 0.6568
0.341188 0.302263 0.8858875 11.41125 0.16975 984.889425 1033.627963 0.8524 1.527025 0.44211 0.674625
0.009009 0.011767 0.022400602 2.240060187 0.004321706 21.926474 20.352499 0.048659047 0.05654 0.013733 0.017735
Midshaft Femur Cortical Analysis
Table 5.3: OVX+Radiation study midshaft femur cortical microCT raw data. Mean and 











Mouse Group Rad Whole Bone Stiffness Whole Bone Cross‐Sectional Area Cortical Bone Stiffness Cortical Bone Cross‐Sectional Area Trabecular Bone Stiffness
1192 sham NR 6.72E+03 3.62E+00 5.23E+03 3.34E+00 1.50E+03
1242 sham NR 8.87E+03 3.75E+00 6.91E+03 3.21E+00 1.96E+03
1291 sham NR 6.44E+03 3.36E+00 4.13E+03 2.91E+00 2.31E+03
1357 sham NR 8.17E+03 3.73E+00 5.99E+03 3.33E+00 2.18E+03
1689 sham NR 7.69E+03 3.71E+00 6.07E+03 3.25E+00 1.62E+03
1880 sham NR 7.45E+03 3.74E+00 5.67E+03 3.30E+00 1.78E+03
6‐R1 sham NR 7.63E+03 3.65E+00 5.74E+03 3.32E+00 1.90E+03
7‐R1 sham NR 6.99E+03 3.39E+00 5.62E+03 3.06E+00 1.37E+03
7494.45 3.6185375 5668.35 3.216425 1826.1
791.7843447 0.157079552 790.9627804 0.154510561 325.4570325
1024 sham IRR 8.43E+03 3.37E+00 7.34E+03 3.16E+00 1.10E+03
1170 sham IRR 8.87E+03 3.14E+00 7.93E+03 2.97E+00 9.38E+02
1196 sham IRR 7.77E+03 2.93E+00 6.65E+03 2.72E+00 1.12E+03
1427 sham IRR 8.37E+03 3.02E+00 7.41E+03 2.89E+00 9.61E+02
1492 sham IRR 8.40E+03 3.31E+00 7.81E+03 3.16E+00 5.92E+02
1704 sham IRR 8.59E+03 3.17E+00 7.49E+03 3.06E+00 1.10E+03
1774 sham IRR 8.37E+03 3.12E+00 7.47E+03 2.95E+00 9.00E+02
1902 sham IRR 7.43E+03 3.38E+00 6.40E+03 3.15E+00 1.03E+03
8279.5 3.1798875 7313.2875 3.0069125 966.2125
459.7793819 0.162786525 530.7088694 0.157760392 171.2523988
1151 ovx NR 5.88E+03 3.62E+00 4.56E+03 3.29E+00 1.32E+03
1218 ovx NR 5.57E+03 3.83E+00 4.12E+03 3.50E+00 1.45E+03
1517 ovx NR 6.43E+03 3.95E+00 4.85E+03 3.54E+00 1.58E+03
1707 ovx NR 5.61E+03 4.06E+00 3.91E+03 3.71E+00 1.70E+03
1729 ovx NR 6.61E+03 3.68E+00 5.45E+03 3.19E+00 1.16E+03
1856 ovx NR 6.64E+03 3.19E+00 5.08E+03 3.05E+00 1.55E+03
2‐R2 ovx NR 6.49E+03 3.83E+00 5.15E+03 3.34E+00 1.34E+03
2035 (femur only) ovx NR
6174.542857 3.7353 4732.271429 3.373514286 1442.271429
472.6647891 0.28146895 563.9018523 0.223935098 185.1585511
1055 ovx IRR 6.96E+03 2.90E+00 6.19E+03 2.83E+00 7.64E+02
1069 ovx IRR 7.16E+03 3.02E+00 6.42E+03 2.85E+00 7.39E+02
1394 ovx IRR 6.57E+03 3.78E+00 5.02E+03 3.58E+00 1.55E+03
1535 ovx IRR 7.41E+03 3.30E+00 6.35E+03 3.14E+00 1.06E+03
1594 ovx IRR 7.55E+03 3.04E+00 6.73E+03 2.92E+00 8.21E+02
1748 ovx IRR 7.68E+03 2.94E+00 6.99E+03 2.86E+00 6.93E+02
1809 ovx IRR 6.77E+03 2.85E+00 6.07E+03 2.80E+00 7.02E+02
2‐R1 ovx IRR 6.87E+03 2.69E+00 6.26E+03 2.64E+00 6.08E+02
7120.0375 3.0664875 6252.7375 2.953275 867.3
396.5112967 0.338720822 581.9309236 0.290456959 307.2916344
Proximal Tibia Finite Element Analysis
Table 5.4: OVX+Radiation study proximal tibia finite element analysis raw data. Mean and 






Mouse Group Rad Stiffness (N/mm)
1192 sham NR 1233.628
1242 sham NR 1299.3
1291 sham NR 1106.582
1357 sham NR 1287.568
1689 sham NR 1406.25
1880 sham NR 1321.926
6‐R1 sham NR 1439.064
7‐R1 sham NR 1263.992
1294.78875
102.9276701
1024 sham IRR 1218.698
1170 sham IRR 1423.072
1196 sham IRR 1324.214
1427 sham IRR 1271.084
1492 sham IRR 1153.518
1704 sham IRR 1169.728
1774 sham IRR 1041.07
1902 sham IRR 1080.422
1210.22575
126.711636
1151 ovx NR 1096.432
1218 ovx NR 1173.608
1517 ovx NR 1253.492
1707 ovx NR 1257.446
1729 ovx NR 1389.626
1856 ovx NR 1098.82
2‐R2 ovx NR 1126.878
2035 (femur only) ovx NR 1019.486
1176.9735
118.0012657
1055 ovx IRR 1032.696
1069 ovx IRR 1192.654
1394 ovx IRR 1171.5
1535 ovx IRR 1274.566
1594 ovx IRR 1261.6
1748 ovx IRR 1396.244
1809 ovx IRR 1230.68
2‐R1 ovx IRR 1178.504
1217.3055
104.0128397
Table 5.5: OVX+Radiation study femoral 
neck finite element analysis raw data. 












Mouse Group Rad VOX‐TV VOX‐BV VOX‐BV/TV Conn‐Dens. DT‐Tb.N DT‐Tb.Th DT‐Tb.Sp vBMD Stiffness (N/mm)
1192 sham NR 1.5675 0.3738 0.2385 184.3726 4.6458 0.0467 0.2026 199.6788 2462.093333
1242 sham NR 1.8685 0.4803 0.257 237.3532 4.7968 0.0485 0.1976 214.3899 2872.133333
1291 sham NR 1.6329 0.4701 0.2879 227.1979 5.3789 0.0483 0.1695 236.639 2958.213333
1357 sham NR 1.4579 0.3827 0.2625 188.9743 4.9757 0.0501 0.1872 222.5763 2841.08
1689 sham NR 1.6612 0.3695 0.2224 171.8664 4.5709 0.0474 0.2044 190.8034 2774.186667
1880 sham NR 1.7331 0.3814 0.2201 201.9454 4.306 0.0465 0.2222 182.2523 2837.626667
6‐R1 sham NR 1.4541 0.3266 0.2246 167.4573 4.3543 0.0487 0.2202 190.4387 2686.106667
7‐R1 sham NR 1.5425 0.3189 0.2067 177.6362 4.1884 0.0455 0.2315 177.6323 2554.026667
1.6147125 0.3879125 0.2399625 194.6004125 4.6521 0.0477125 0.2044 201.8013375 2748.183333
0.1407864 0.0590641 0.02710751 25.69595729 0.393521 0.0014701 0.020228 20.78670684 169.1069354
1024 sham IRR 1.4617 0.3057 0.2091 172.3987 4.4524 0.0452 0.2163 178.3618 2513.92
1170 sham IRR 1.78 0.3363 0.189 163.2038 4.2203 0.0437 0.2249 156.9232 2545.346667
1196 sham IRR 1.6447 0.4467 0.2716 186.6553 4.9115 0.0499 0.1894 231.1679 3088.226667
1427 sham IRR 1.6241 0.3011 0.1854 171.4806 4.3133 0.043 0.2201 150.52 2458.666667
1492 sham IRR 1.2674 0.2765 0.2182 174.3763 4.4281 0.0471 0.2134 189.2634 2440.306667
1704 sham IRR 1.6945 0.3709 0.2189 190.6157 4.5724 0.0459 0.2079 177.4702 2468.72
1774 sham IRR 1.4544 0.2808 0.1931 164.6782 4.2991 0.044 0.2232 156.7206 2380.506667
1902 sham IRR 1.5738 0.4165 0.2646 214.7666 5.1878 0.047 0.1796 218.1184 2766.853333
1.562575 0.3418125 0.2187375 179.7719 4.548113 0.045725 0.20935 182.3181875 2582.818333
0.1622782 0.0637024 0.03304542 17.08860177 0.335944 0.0022601 0.016471 29.43906101 234.5601423
1151 ovx NR 1.6942 0.3166 0.1869 199.7956 4.509 0.0407 0.2145 156.4774 2502.853333
1218 ovx NR 1.7661 0.2723 0.1542 179.2046 3.7814 0.0394 0.2582 125.434 2266.96
1517 ovx NR 1.7151 0.3248 0.1894 183.0833 4.3793 0.0421 0.2204 159.5169 2405.706667
1707 ovx NR 1.6282 0.2843 0.1746 155.0833 4.2529 0.0418 0.2295 144.1978 2423.893333
1729 ovx NR 1.8794 0.3122 0.1661 179.5766 4.2772 0.0402 0.2239 134.7957 2385.546667
1856 ovx NR 1.7578 0.2889 0.1644 163.838 3.9078 0.0424 0.2505 133.4178 2220.786667
2‐R2 ovx NR 1.8386 0.2888 0.1571 116.6637 3.9457 0.0419 0.2432 134.593 2376.626667
2035 (femur only) ovx NR 1.6719 0.284 0.1699 177.6418 3.9911 0.0417 0.2432 143.671 2369.453333
1.7542 0.2982714 0.17038571 168.1778714 4.150471 0.0412143 0.234314 141.2046571 2368.978333
0.0855938 0.0194977 0.01381249 26.82469155 0.27218 0.0011246 0.016479 12.72590095 88.63156969
1055 ovx IRR 1.5918 0.2383 0.1497 136.949 4.0659 0.0385 0.2383 122.0703 2312.16
1069 ovx IRR 1.9804 0.2615 0.132 145.4215 3.7702 0.0382 0.2616 103.5091 2166.213333
1394 ovx IRR 1.7981 0.2503 0.1392 159.335 3.946 0.0382 0.2443 117.2071 2070.826667
1535 ovx IRR 1.7702 0.3247 0.1834 138.9707 4.266 0.0423 0.2247 157.2069 2510.733333
1594 ovx IRR 1.593 0.3162 0.1985 160.7024 4.5101 0.0442 0.2093 169.1622 2507.266667
1748 ovx IRR 1.7305 0.2738 0.1582 150.5346 3.9563 0.0412 0.2443 129.1219 2166.213333
1809 ovx IRR 1.6589 0.2717 0.1638 156.7304 3.8553 0.0412 0.2533 139.2941 2265.04
2‐R1 ovx IRR 1.6774 0.2932 0.1748 181.2352 4.3001 0.0409 0.2251 145.6163 2331.213333
1.7250375 0.2787125 0.16245 153.73485 4.083738 0.0405875 0.237613 135.3984875 2291.208333
0.1278656 0.0305662 0.02249203 14.26408716 0.252936 0.0021577 0.017056 21.71263744 159.1998574
L1 Vertebrae Trabecular Analysis
Table 5.6: OVX+Radiation study L1 Vertebra trabecular microCT analysis and finite element 






Bone Rad Treatment VOX‐TV VOX‐BV VOX‐BV/TV Conn‐Dens. TRI‐SMI DT‐Tb.N DT‐Tb.Th DT‐Tb.Sp vBMD
5145 NR PLAC 1.9321 0.1477 0.0765 45.2875 2.4317 3.194 0.0478 0.3106 83.0432
5146 NR PLAC 1.8704 0.1908 0.102 62.8212 2.2072 3.4542 0.0534 0.2885 105.576
5147 NR PLAC 1.727 0.1709 0.099 50.0861 2.4212 2.7904 0.056 0.3644 105.9002
5150 NR PLAC 1.8517 0.1129 0.061 27.8124 2.9027 3.0522 0.0472 0.3282 73.8436
5151 NR PLAC 2.2577 0.1391 0.0616 29.2335 2.6184 2.71 0.0536 0.3732 73.8031
5152 NR PLAC 1.6984 0.1435 0.0845 50.9298 2.4227 3.143 0.0473 0.3173 96.0522
5156 NR PLAC 2.1128 0.1769 0.0837 43.5433 2.2261 2.8133 0.0529 0.3605 89.568
5160 NR PLAC 2.0033 0.1888 0.0942 46.1728 2.19 3.485 0.0469 0.2881 105.4139
5164 NR PLAC 1.8189 0.1467 0.0806 39.8586 2.2507 3.078 0.0467 0.3312 87.1769
5166 NR PLAC 1.6568 0.078 0.0471 13.8825 3.4626 2.8724 0.0485 0.3533 61.8883
MEAN 0.07902 40.96277 2.51333 3.05925 0.05003 0.33153 88.22654
ST DEV 0.01784363 13.975943 0.39956 0.26925 0.003522 0.030767 15.30571
5148 NR ZOL 1.8366 0.1319 0.0718 42.1974 2.5483 3.3947 0.0465 0.2929 79.031
5149 NR ZOL 1.9864 0.141 0.071 31.4636 2.5537 3.0511 0.0471 0.3271 73.3573
5154 NR ZOL 1.8595 0.118 0.0635 33.0737 2.7553 2.96 0.0472 0.3365 68.0078
5158 NR ZOL 1.9097 0.1727 0.0904 43.7248 2.5965 3.4905 0.0482 0.2858 101.2802
5161 NR ZOL 1.6054 0.1402 0.0873 75.6822 2.2445 3.9038 0.0401 0.2554 96.5791
5163 NR ZOL 2.0528 0.1759 0.0857 51.6362 2.3286 3.3096 0.0496 0.3003 92.6885
5167 NR ZOL 1.7707 0.1199 0.0677 45.7455 2.8593 3.0787 0.0451 0.3194 79.9226
5170 NR ZOL 2.0258 0.1527 0.0754 33.8145 2.562 3.0653 0.045 0.3233 79.1931
5172 NR ZOL 2.0623 0.2083 0.101 94.7983 1.9555 4.0464 0.0401 0.2431 101.6044
5173 NR ZOL 2.0157 0.1855 0.092 52.3403 2.1302 3.3377 0.0471 0.2972 91.5943
MEAN 0.08058 50.44765 2.45339 3.36378 0.0456 0.2981 86.32583
ST DEV 0.01233115 20.2293543 0.28261 0.36657 0.003193 0.030617 11.92226
5142 IRR PLAC 2.1017 0.1886 0.0898 54.7166 2.4923 3.5681 0.0485 0.2779 94.958
5143 IRR PLAC 2.0666 0.1387 0.0671 28.549 2.585 2.6869 0.052 0.3726 76.0321
5144 IRR PLAC 1.7137 0.1521 0.0888 63.606 2.4278 3.2256 0.047 0.3108 96.8627
5153 IRR PLAC 1.8614 0.1443 0.0775 26.5935 2.7959 3.2958 0.0547 0.3004 90.0543
5157 IRR PLAC 1.8966 0.15 0.0791 37.436 2.6318 3.2394 0.0502 0.3067 82.4758
5165 IRR PLAC 1.817 0.1282 0.0705 25.317 2.8057 3.0699 0.0524 0.3234 77.5316
5169 IRR PLAC 1.9727 0.1675 0.0849 47.3965 2.3361 3.4478 0.0465 0.2868 88.19
5171 IRR PLAC 1.8123 0.1752 0.0967 30.6236 2.3252 2.8189 0.0656 0.3477 91.5132
5174 IRR PLAC 1.8341 0.1948 0.1062 31.3513 2.2661 2.7741 0.0587 0.3594 107.0755
5179 IRR PLAC 1.9807 0.2009 0.1014 55.0305 2.4166 3.9162 0.0492 0.2496 105.9812
MEAN 0.0862 40.062 2.50825 3.20427 0.05248 0.31353 91.06744
ST DEV 0.01291037 13.9449249 0.19128 0.38411 0.005903 0.038233 10.64582
5155 IRR ZOL 1.9089 0.18 0.0943 56.0541 2.2677 3.4976 0.0492 0.2821 96.417
5159 IRR ZOL 1.9694 0.1592 0.0809 31.7351 2.9535 3.1198 0.0584 0.3198 82.0705
5162 IRR ZOL 1.9745 0.1706 0.0864 26.8417 2.7923 3.0132 0.0603 0.3338 92.5669
5168 IRR ZOL 2.3978 0.1556 0.0649 23.7721 2.7168 3.1016 0.0494 0.3202 66.5083
5175 IRR ZOL 1.8422 0.1516 0.0823 41.5267 2.6742 3.471 0.051 0.2854 86.5285
5176 IRR ZOL 2.0204 0.1405 0.0695 29.6964 2.7121 3.337 0.0479 0.298 74.1678
5177 IRR ZOL 1.8393 0.2 0.1087 77.4768 2.0548 3.6059 0.0508 0.275 114.046
5178 IRR ZOL 2.0117 0.1644 0.0817 48.2184 2.363 3.5887 0.0457 0.2763 85.5964
5181 IRR ZOL 1.7164 0.1661 0.0968 60.884 2.4173 3.2887 0.0518 0.3008 102.2933
5180 IRR ZOL 1.8901 0.1325 0.0701 57.141 2.8167 3.1208 0.0471 0.332 74.1273
MEAN 0.08356 45.33463 2.57684 3.31443 0.05116 0.30234 87.4322
ST DEV 0.01362149 17.6019206 0.28528 0.21879 0.004719 0.022698 14.3757
Table 5.7: Radiation+Zoledronate study 3 day proximal tibia trabecular 





Bone Rad Treatment VOX‐TV VOX‐BV VOX‐BV/TV Conn‐Dens. TRI‐SMI DT‐Tb.N DT‐Tb.Th DT‐Tb.Sp vBMD
5233 NR PLAC 2.1794 0.185 0.0849 45.4244 2.5145 2.947 0.054 0.3407 95.5254
5234 NR PLAC 1.9925 0.1544 0.0775 39.6483 2.3588 2.9515 0.0466 0.3388 88.109
5235 NR PLAC 1.724 0.1591 0.0923 53.0737 2.4115 2.7741 0.0513 0.3622 103.8333
5236 NR PLAC 2.049 0.1466 0.0715 29.2822 2.4777 2.6431 0.0535 0.3782 79.7605
5237 NR PLAC 2.0043 0.1881 0.0939 49.1453 2.5153 3.3225 0.0527 0.3076 98.3622
5238 NR PLAC 2.295 0.1249 0.0544 13.9434 2.8352 2.7819 0.0558 0.3611 67.2378
5239 NR PLAC 2.1155 0.1706 0.0806 50.1058 2.1283 3.451 0.044 0.2876 88.5548
5240 NR PLAC 1.9976 0.1704 0.0853 55.8175 2.4548 3.3527 0.0495 0.296 94.877
5243 NR PLAC 1.9749 0.1576 0.0798 54.687 2.3353 3.2738 0.0484 0.3081 87.5011
5244 NR PLAC 2.3216 0.1683 0.0725 39.4124 2.3821 2.9478 0.0465 0.3382 80.5305
MEAN 2.06538 0.1625 0.07927 43.054 2.44135 3.04454 0.05023 0.33185 88.42916
ST DEV 0.17401 0.01853 0.01145901 13.1361595 0.17886 0.283 0.003844 0.030709 10.62216
5241 NR ZOL 2.076 0.1945 0.0937 55.1548 2.4108 3.469 0.0508 0.2816 104.9681
5242 NR ZOL 1.8884 0.1411 0.0747 27.8017 2.6117 3.0073 0.049 0.3313 86.8121
5245 NR ZOL 1.7602 0.1787 0.1015 62.4915 2.4727 3.7969 0.0483 0.2592 119.8008
5246 NR ZOL 2.0132 0.2317 0.1151 69.5421 2.4178 4.1226 0.0525 0.2352 132.0399
5247 NR ZOL 1.9295 0.1944 0.1007 58.3051 2.348 3.6577 0.0495 0.2706 113.8434
5248 NR ZOL 1.7526 0.2381 0.1358 99.28 1.867 4.1689 0.0457 0.2331 147.1158
5251 NR ZOL 1.846 0.2523 0.1367 63.6496 1.9123 3.8154 0.0537 0.2567 146.2242
5252 NR ZOL 2.2581 0.239 0.1059 77.4996 2.264 3.827 0.0482 0.2541 118.1392
5266 NR ZOL 2.08 0.1663 0.08 30.7697 2.4245 2.8442 0.0482 0.3535 93.0127
5267 NR ZOL 1.9247 0.1843 0.0958 61.4387 2.3372 3.7365 0.0475 0.2634 114.3297
MEAN 1.95287 0.20204 0.10399 60.59328 2.3066 3.64455 0.04934 0.27387 117.6286
ST DEV 0.15715 0.03657 0.02063522 20.7519019 0.23828 0.43144 0.002394 0.039268 20.11347
5249 IRR PLAC 2.1701 0.1187 0.0547 21.8886 2.9859 2.5731 0.0513 0.3864 56.2551
5250 IRR PLAC 1.9007 0.1098 0.0578 19.9923 3.1214 2.2448 0.058 0.4467 58.1598
5254 IRR PLAC 1.9452 0.1087 0.0559 25.4469 2.8782 2.8097 0.0452 0.3567 61.6857
5255 IRR PLAC 2.1934 0.104 0.0474 8.2064 3.0479 1.9703 0.053 0.5207 48.7982
5256 IRR PLAC 1.8661 0.1057 0.0567 29.4737 2.9227 2.3027 0.0533 0.4457 58.0383
5265 IRR PLAC 1.8977 0.0878 0.0462 13.7007 3.0439 2.1021 0.049 0.4793 44.1376
5269 IRR PLAC 1.9721 0.0801 0.0406 10.9022 2.9397 3.3748 0.043 0.2914 35.5865
5270 IRR PLAC 1.8939 0.0918 0.0485 14.52 2.9783 2.3342 0.0476 0.4385 52.4861
5271 IRR PLAC 1.7215 0.0609 0.0354 5.2281 2.9358 2.178 0.0451 0.4658 41.1387
5272 IRR PLAC 1.761 0.0877 0.0498 17.3193 2.878 2.1725 0.0523 0.4691 49.3656
MEAN 1.93217 0.09552 0.0493 16.66782 2.97318 2.40622 0.04978 0.43003 50.56516
ST DEV 0.15213 0.0172 0.00732378 7.66607297 0.0788 0.41633 0.004633 0.067122 8.382198
5253 IRR ZOL 1.671 0.1363 0.0816 38.0007 2.8723 3.0419 0.0514 0.326 93.418
5257 IRR ZOL 1.6073 0.2543 0.1582 78.3939 1.9898 3.6303 0.0586 0.273 154.0863
5258 IRR ZOL 1.8989 0.1351 0.0712 30.8069 3.2155 2.9614 0.0536 0.3319 74.1273
5259 IRR ZOL 1.8458 0.1424 0.0771 29.5261 2.9221 3.1211 0.0513 0.3212 80.4495
5260 IRR ZOL 2.0089 0.2092 0.1042 56.2506 2.6028 3.7271 0.0538 0.2615 102.2528
5261 IRR ZOL 1.4209 0.1426 0.1004 56.656 2.3794 2.8561 0.051 0.3493 110.3176
5262 IRR ZOL 1.6148 0.2106 0.1304 65.3343 2.1533 3.4217 0.0529 0.2924 138.2404
5263 IRR ZOL 1.6789 0.2123 0.1264 62.5392 2.4883 3.5552 0.0606 0.2765 131.8372
5264 IRR ZOL 1.8807 0.1983 0.1055 67.5272 2.5518 3.8235 0.0526 0.2525 109.2639
5268 IRR ZOL 1.6598 0.1869 0.1126 51.8122 2.7017 3.3103 0.0603 0.3055 120.4492
MEAN 1.7287 0.1828 0.10676 53.68471 2.5877 3.34486 0.05461 0.29898 111.4442
ST DEV 0.17553 0.04136 0.02677188 16.289782 0.36529 0.33925 0.003758 0.03278 25.39033
Table 5.8: Radiation+Zoledronate study 14 day proximal tibia trabecular 





BONE RAD Treatment VOX‐TV VOX‐BV VOX‐BV/TV Conn‐Dens. TRI‐SMI DT‐Tb.N DT‐Tb.Th DT‐Tb.Sp vBMD
6474 NR PLAC 2.0905 0.078 0.0373 3.8269 2.7955 2.3222 0.0556 0.4311 47.0258
6477 NR PLAC 2.0243 0.06 0.0296 1.482 3.205 1.8644 0.061 0.5349 42.8964
6479 NR PLAC 2.499 0.0674 0.027 3.2012 2.9139 1.7096 0.0533 0.5847 31.8015
6483 NR PLAC 2.3094 0.0656 0.0284 3.464 3.4287 1.9139 0.0732 0.5572 35.0549
6484 NR PLAC 2.2503 0.1373 0.061 45.7715 2.3681 2.0651 0.0601 0.4934 23.2925
6485 NR PLAC 2.4216 0.0688 0.0284 4.3361 2.1965 1.5737 0.0548 0.6376 40.7275
6494 NR PLAC 2.46 0.0676 0.0275 6.9106 3.051 1.7851 0.0528 0.5781 35.6388
6495 NR PLAC 2.1789 0.0265 0.0122 ‐0.2295 3.8843 1.5892 0.0512 0.6329 30.0079
6496 NR PLAC 2.2834 0.0595 0.0261 2.4086 2.8238 1.6396 0.0632 0.6467 39.7264
MEAN 2.279711 0.070078 0.030833333 7.907933333 2.962977778 1.8292 0.058355556 0.566288889 36.2413
ST DEV 0.163433 0.029002 0.013041376 14.33401623 0.515175957 0.245506701 0.006907625 0.071696782 7.253247
6491 NR ZOL 2.4695 0.8966 0.3631 96.9829 ‐1.7085 4.4382 0.0816 0.246 358.2274
6499 NR ZOL 2.4277 1.1445 0.4714 115.7468 ‐3.3499 5.7504 0.0874 0.1961 450.1989
6500 NR ZOL 2.6091 1.0311 0.3952 136.2523 ‐1.8221 4.9229 0.0813 0.2296 390.8033
6501 NR ZOL 2.5505 1.1933 0.4679 105.2753 ‐3.4431 5.6343 0.0816 0.2021 467.05
6502 NR ZOL 2.4842 0.8761 0.3527 169.0663 ‐1.5403 4.7696 0.071 0.2316 336.9134
6504 NR ZOL 2.3399 0.9832 0.4202 117.9558 ‐3.1285 5.0395 0.083 0.232 414.7033
6505 NR ZOL 2.6406 1.0211 0.3867 127.2448 ‐2.0295 5.3369 0.0765 0.2107 364.2337
6507 NR ZOL 2.5924 1.2988 0.501 97.5941 ‐5.6776 4.9676 0.0861 0.2615 471.221
6508 NR ZOL 2.8179 1.29 0.4578 124.9163 ‐3.0268 5.6306 0.087 0.1996 427.7588
6509 NR ZOL 2.5421 1.2104 0.4761 122.1449 ‐4.715 5.4909 0.0828 0.2225 438.9789
MEAN 2.54739 1.09451 0.42921 121.31795 ‐3.04413 5.19809 0.08183 0.22317 412.0089
ST DEV 0.131307 0.154312 0.052404462 21.09877131 1.356273706 0.434925124 0.004993117 0.021262907 47.42327
6470 IRR PLAC 2.6369 0.1097 0.0416 14.2212 3.341 2.3752 0.0588 0.4197 44.7317
6471 IRR PLAC 2.376 0.0975 0.041 5.8922 3.0948 2.1137 0.0728 0.4773 37.3907
6473 IRR PLAC 2.2582 0.0673 0.0298 1.9928 3.9723 2.1285 0.0723 0.4678 25.7534
6476 IRR PLAC 2.4001 0.099 0.0412 ‐0.2083 3.0913 1.7744 0.0765 0.5798 36.7233
6478 IRR PLAC 2.3684 0.0648 0.0274 2.7445 3.2637 1.8142 0.0666 0.551 21.0819
6486 IRR PLAC 2.603 0.0454 0.0174 0.5763 2.6618 1.3078 0.078 0.7745 19.8723
6487 IRR PLAC 2.1631 0.0603 0.0279 4.6229 3.5701 1.9493 0.0726 0.5176 43.3135
6497 IRR PLAC 2.5392 0.072 0.0284 4.726 3.5137 1.8632 0.0689 0.5368 24.5021
6503 IRR PLAC 2.1837 0.1213 0.0556 22.4389 2.6039 2.3142 0.059 0.4329 65.9623
MEAN 2.392067 0.081922 0.034477778 6.334055556 3.234733333 1.960055556 0.0695 0.5286 35.48124
ST DEV 0.173468 0.02565 0.011338185 7.37366741 0.434854461 0.324117873 0.006920079 0.106726449 14.779
6472 IRR ZOL 2.2495 0.9549 0.4245 99.5787 ‐3.3502 4.6049 0.0756 0.233 412.159
6475 IRR ZOL 2.5928 1.1758 0.4535 180.6913 ‐1.1868 5.9149 0.0874 0.1581 445.1103
6480 IRR ZOL 2.5465 1.1137 0.4374 108.5809 ‐2.2419 4.887 0.0821 0.2085 442.9831
6482 IRR ZOL 2.3491 1.0017 0.4264 137.4996 ‐2.8236 4.8056 0.0787 0.2276 411.4917
6488 IRR ZOL 2.4547 0.8025 0.3269 111.0107 ‐1.032 4.5071 0.0687 0.2275 336.3711
6489 IRR ZOL 2.2674 0.9827 0.4334 103.4234 ‐2.8535 4.8846 0.0819 0.2204 415.037
6490 IRR ZOL 2.0944 0.8507 0.4062 79.9768 ‐1.6407 4.5053 0.0847 0.23 409.865
6492 IRR ZOL 2.609 1.1785 0.4517 65.1595 ‐3.6276 4.3256 0.0964 0.2642 462.6287
6493 IRR ZOL 2.4007 0.927 0.3862 71.0208 ‐2.1468 4.1069 0.0828 0.2655 383.6291
6506 IRR ZOL 2.3203 1.2236 0.5273 65.5091 ‐4.9135 5.14 0.1026 0.2391 522.8585
MEAN 2.38844 1.02111 0.42735 102.24508 ‐2.58166 4.76819 0.08409 0.22739 424.2134
ST DEV 0.165509 0.145372 0.051255596 36.08303967 1.192177293 0.503254547 0.00974046 0.030165486 49.39204






Figure 5.3: Radiation+Zoledronate study example Mineral to Matrix 
Ratio mapping for FTIR data. Embedding material appears dark blue to 
light blue and bone spans roughly green to green from left to right. 





Figure 5.5: Example Raman MATLAB spectra of bone after 
baseline subtraction and PMMA subtraction (x-axis represents wave 
shift and y-axis represents intensity) 
Figure 5.4: Example MATLAB calculation of full-width half maximum (green circle) for 





Figure 5.6: Nanoindentation data collected for 14 day time point for Radiation+Zoledronate 
study 







Bone Cage Limb Sex VOX‐TV VOX‐BV VOX‐BV/TV Conn‐Dens. TRI‐SMI DT‐Tb.N DT‐Tb.Th DT‐Tb.Sp vBMD
7414 13‐0 R M 1.833 0.0953 0.052 87.8324 2.7951 3.6978 0.0331 0.2697 45.3897
7416 13‐1 R M 1.698 0.1069 0.063 91.5802 2.2672 3.4951 0.0339 0.2859 62.9226
7367 13‐2 R M 1.6946 0.1229 0.0725 129.5316 2.2456 4.0797 0.0325 0.2435 65.4398
7413 14‐0 R M 1.826 0.1028 0.0563 88.7189 2.58 3.5219 0.0347 0.2805 58.1488
7420 14‐1 R M 1.6891 0.0748 0.0443 42.923 3.052 3.4766 0.0339 0.2871 46.518
7366 14‐2 R M 1.6292 0.0919 0.0564 93.297 2.7265 3.5217 0.0343 0.2836 59.8848
7422 15‐0 R M 1.6871 0.0926 0.0549 88.3167 2.8021 3.3662 0.0365 0.2931 41.4838
7426 15‐1 R M 1.5996 0.0651 0.0407 42.5104 2.9666 3.4805 0.0339 0.2906 50.4239
7428 15‐2 R M 1.6838 0.0884 0.0525 73.3471 2.7559 3.3097 0.0353 0.3031 49.1219
7458 15‐3 R M 1.6055 0.0851 0.053 99.0358 2.7824 3.7237 0.0322 0.2681 51.2919
mean 0.05456 83.70931 2.69734 3.56729 0.03403 0.28052 53.06252
stdev 0.00888322 25.8629526 0.265244 0.22009 0.001284 0.016644 8.056933
7328 13‐0 L M 1.783 0.0784 0.044 47.6718 2.8025 3.4212 0.0325 0.2914 45.6501
7415 13‐1 L M 1.6307 0.0708 0.0434 49.0577 2.8075 3.043 0.0353 0.3301 39.5743
7329 13‐2 L M 1.663 0.084 0.0505 56.5249 2.7561 3.8719 0.0316 0.2582 48.5144
7417 14‐0 L M 1.7034 0.0597 0.035 27.5917 3.1216 3.394 0.0339 0.293 29.6794
7425 14‐1 L M 1.7027 0.0491 0.0288 16.1506 2.9853 3.2918 0.0291 0.3046 26.3812
7334 14‐2 L M 1.7334 0.0658 0.0379 30.8646 2.9104 3.1642 0.034 0.3166 40.6158
7421 15‐0 L M 1.6634 0.072 0.0433 47.1911 2.8912 3.3032 0.0333 0.3009 45.6501
7423 15‐1 L M 1.6927 0.056 0.0331 18.0185 3.0345 3.2768 0.0319 0.3051 32.2833
7427 15‐2 L M 1.6327 0.0558 0.0342 37.975 3.0519 3.3434 0.0308 0.3013 34.5401
7451 15‐3 L M 1.6209 0.0601 0.0371 41.6441 2.9536 3.5067 0.0299 0.2848 38.7063
mean 0.03873 37.269 2.93146 3.36162 0.03223 0.2986 38.1595
stdev 0.00647286 13.6922704 0.119943 0.221695 0.001953 0.019186 7.34882
Table 5.11: Hemophilia study 7 day male distal femur trabecular microCT raw data 
Bone Cage Limb Sex VOX‐TV VOX‐BV VOX‐BV/TV Conn‐Dens. TRI‐SMI DT‐Tb.N DT‐Tb.Th DT‐Tb.Sp vBMD
7454 16‐0 R F 1.7095 0.175 0.1024 120.2101 1.9585 3.8349 0.0407 0.2596 109.1854
7374 16‐1 R F 1.4997 0.1004 0.0669 89.0153 2.4882 3.4097 0.0373 0.2896 77.7649
7457 16‐2 R F 1.7614 0.1668 0.0947 125.751 1.9866 3.8142 0.0397 0.2581 101.9812
7375 17‐0 R F 1.3231 0.0626 0.0473 72.556 2.9536 3.6331 0.0326 0.2782 56.1525
7460 17‐1 R F 1.5061 0.1225 0.0814 111.546 2.1703 3.5247 0.037 0.284 95.2979
mean 0.07854 103.81568 2.31144 3.64332 0.03746 0.2739 88.07638
stdev 0.0220797 22.3937042 0.41642 0.183478 0.003137 0.014328 21.31048
7453 16‐0 L F 1.6412 0.127 0.0774 118.5138 2.2887 3.9052 0.0355 0.2515 74.4666
7288 16‐1 L F 1.4217 0.1072 0.0754 85.1108 2.4691 3.5806 0.039 0.2766 86.6182
7455 16‐2 L F 1.4755 0.1136 0.077 97.2564 2.4048 3.5951 0.0405 0.2781 78.0253
7286 17‐0 L F 1.3155 0.052 0.0395 57.3914 3.0084 3.6843 0.0295 0.2711 56.0657
7459 17‐1 L F 1.3088 0.0676 0.0517 67.2387 2.7132 3.2247 0.0373 0.3137 49.8163
mean 0.0642 85.10222 2.57684 3.59798 0.03636 0.2782 68.99842
stdev 0.01753468 24.2438277 0.286822 0.245705 0.004266 0.022506 15.46812


















7414 13‐0 M R 15.935242 6.02008 17.467581 5.85717 0.043325 0.912
7416 13‐1 M R 15.529947 5.888942 17.262119 5.739721 0.039813 0.900
7367 13‐2 M R 15.578012 5.684399 16.980193 5.531702 0.040866 0.917
7413 14‐0 M R 15.770549 5.923532 17.58263 5.768711 0.041651 0.897
7420 14‐1 M R 15.794462 5.985825 17.576474 5.825673 0.041269 0.899
7366 14‐2 M R 16.144063 6.048143 17.879661 5.85688 0.044736 0.903
7422 15‐0 M R 15.791216 5.914108 17.024336 5.793849 0.040796 0.928
7426 15‐1 M R 15.514881 5.783739 17.051712 5.623175 0.041938 0.910
7428 15‐2 M R 15.522461 5.901128 16.77438 5.750024 0.043214 0.925
7458 15‐3 M R 15.271797 5.486131 16.951362 5.322715 0.044172 0.901
7454 16‐0 F R 15.21752 5.512226 16.302387 5.368092 0.042091 0.933
7374 16‐1 F R 15.433214 5.723932 16.619615 5.575119 0.041149 0.929
7457 16‐2 F R 15.427561 5.9292 16.872918 5.780847 0.041608 0.914
7375 17‐0 F R 14.617586 5.077992 17.058505 4.905541 0.043512 0.857
7460 17‐1 F R 15.53902 5.899324 16.780721 5.753069 0.040945 0.926
7328 13‐0 M L 16.020544 5.868001 18.88933 5.677411 0.042577 0.848
7415 13‐1 M L 15.406064 5.615222 17.587608 5.467208 0.039159 0.876
7329 13‐2 M L 16.046998 5.793788 18.155318 5.595333 0.044627 0.884
7417 14‐0 M L 15.705087 5.703184 17.954761 5.545898 0.042495 0.875
7425 14‐1 M L 15.783726 5.669466 18.814291 5.43549 0.045349 0.839
7334 14‐2 M L 16.214891 5.752989 19.052503 5.508437 0.045871 0.851
7421 15‐0 M L 15.607848 5.689082 17.876303 5.536729 0.041026 0.873
7423 15‐1 M L 15.52975 5.630922 18.289615 5.439837 0.041915 0.849
7427 15‐2 M L 15.618022 5.584106 18.344345 5.381005 0.04423 0.851
7451 15‐3 M L 15.099106 5.369442 18.507771 5.197779 0.043725 0.816
7453 16‐0 F L 15.473143 5.351964 17.248178 5.138963 0.044752 0.897
7288 16‐1 F L 15.954524 5.485847 18.588345 5.231521 0.044667 0.858
7455 16‐2 F L 15.7042 5.726655 17.299066 5.544102 0.044207 0.908
7286 17‐0 F L 15.193716 5.172243 17.75293 4.95753 0.044175 0.856
7459 17‐1 F L 15.457235 5.476555 17.57182 5.27441 0.045937 0.880






Bone Cage Mouse Limb Sex VOX‐TV VOX‐BV VOX‐BV/TConn‐DenTRI‐SMI DT‐Tb.N DT‐Tb.Th DT‐Tb.Sp vBMD
7676 10 0 R M 1.6247 0.1195 0.0736 90.1716 2.6335 3.7168 0.0394 0.2664 78.5461
7678 10 1 R M 1.7326 0.1296 0.0748 97.8316 2.7855 3.8377 0.0419 0.2561 83.2331
7680 11 0 R M 1.7248 0.0966 0.056 70.7314 2.7008 3.4003 0.0357 0.2968 50.2503
7368 11 1 R M 1.6717 0.1075 0.0643 78.0655 2.7172 3.6206 0.0392 0.2791 66.2209
7369 12 0 R M 1.5412 0.0795 0.0516 66.5081 2.7725 3.6464 0.0346 0.2755 52.7674
7682 12 1 R M 1.7234 0.1068 0.062 94.5808 2.5817 3.6164 0.0357 0.2748 64.485
7684 12 2 R M 1.6247 0.0873 0.0537 78.4755 2.9325 3.5235 0.0367 0.2821 60.6659
7686 12 3 R M 1.5922 0.0722 0.0453 40.825 3.0452 3.5116 0.0371 0.2836 39.0535
mean 0.060163 77.14869 2.771113 3.609163 0.037538 0.2768 61.90278
stdev 0.010479 18.43007 0.153084 0.134092 0.002436 0.012083 14.63924
7674 10 0 L M 1.3056 0.0401 0.0307 39.0629 3.1144 3.3995 0.03 0.2963 36.6232
7677 10 1 L M 1.6787 0.13 0.0774 109.6105 2.6491 3.8867 0.0397 0.2561 82.0179
7679 11 0 L M 1.5393 0.0484 0.0315 24.6867 3.1479 2.8993 0.0359 0.3446 30.1134
7330 11 1 L M 1.3293 0.0391 0.0294 26.7054 3.2859 3.2141 0.0316 0.3113 36.4496
7331 12 0 L M 1.2716 0.0303 0.0238 23.5918 3.1305 3.115 0.0287 0.3252 24.298
7681 12 1 L M 1.2842 0.0343 0.0267 31.536 3.0528 3.1776 0.0282 0.3112 30.4606
7683 12 2 L M 1.5766 0.0564 0.0358 66.9141 2.7474 3.1577 0.0284 0.3188 36.0156
7685 12 3 L M 1.1417 0.0226 0.0198 13.5766 3.2103 2.521 0.0302 0.398 13.622
mean 0.034388 41.9605 3.042288 3.171363 0.031588 0.320188 36.20004
stdev 0.018059 31.60115 0.224683 0.390233 0.00412 0.040559 20.07474
Table 5.13: Hemophilia study 14 day male distal femur trabecular microCT raw data 
Bone Cage Mouse Limb Sex VOX‐TV VOX‐BV VOX‐BV/TConn‐DenTRI‐SMI DT‐Tb.N DT‐Tb.Th DT‐Tb.Sp vBMD
7589 7 1 R F 1.502 0.1708 0.1137 139.1512 1.8855 4.0568 0.0408 0.2434 117.3443
7373 7 2 R F 1.4002 0.1263 0.0902 130.3368 2.0548 3.9039 0.0374 0.2579 85.4898
7591 7 3 R F 1.6691 0.1076 0.0645 106.0471 2.5274 3.5334 0.036 0.2814 62.7491
7594 8 1 R F 1.6168 0.1315 0.0813 100.8154 2.0925 3.5732 0.0383 0.2768 94.3431
7605 8 2 R F 1.3991 0.1118 0.0799 112.9334 2.2095 3.3499 0.0381 0.2946 82.6255
7607 8 3 R F 1.3822 0.1321 0.0956 117.2024 1.9923 3.6323 0.0401 0.2752 91.4788
7636 9 1 R F 1.5108 0.0678 0.0449 51.9604 3.0427 3.4088 0.0351 0.2929 48.0804
7638 9 2 R F 1.6187 0.1139 0.0704 103.788 2.1566 3.3595 0.0359 0.3015 68.2173
mean 0.080063 107.7793 2.245163 3.602225 0.037713 0.277963 81.29104
stdev 0.020871 26.16315 0.373722 0.257495 0.002031 0.019537 21.41784
7588 7 1 L F 1.0508 0.082 0.0781 100.4 2.0164 3.3905 0.0381 0.2898 86.5314
7284 7 2 L F 0.9862 0.0606 0.0614 70.4695 2.4028 3.6841 0.0348 0.2711 71.3419
7590 7 3 L F 1.259 0.0531 0.0422 60.3667 2.7962 3.2676 0.0325 0.306 41.4838
7593 8 1 L F 1.1475 0.0595 0.0519 70.1535 2.5441 3.4633 0.0333 0.2936 62.3151
7604 8 2 L F 1.1757 0.0806 0.0686 92.2885 2.3667 3.5021 0.037 0.29 76.463
7606 8 3 L F 0.9232 0.067 0.0726 68.242 2.4825 3.5931 0.0433 0.277 85.4898
7635 9 1 L F 1.2826 0.0464 0.0362 31.5753 3.214 3.2571 0.0343 0.3073 38.5327
7637 9 2 L F 1.1202 0.0541 0.0483 74.091 2.4485 3.1738 0.0342 0.3067 60.4055
mean 0.057413 70.94831 2.5339 3.41645 0.035938 0.292688 65.3204
stdev 0.015093 20.71256 0.349352 0.177069 0.003501 0.013709 18.26816


















7676 10 0 R M 16.098166 6.047444 17.391649 5.869661 0.045113 0.926
7678 10 1 R M 15.981284 5.90761 17.199517 5.758027 0.041638 0.929
7680 11 0 R M 15.383531 5.605003 16.712122 5.439701 0.044463 0.921
7368 11 1 R M 15.63342 5.644888 16.860587 5.481152 0.043293 0.927
7369 12 0 R M 15.452936 5.644841 17.4741 5.509425 0.039099 0.884
7682 12 1 R M 15.609279 5.762726 16.905039 5.5999 0.043205 0.923
7684 12 2 R M 15.686686 5.822545 17.025737 5.652794 0.0432 0.921
7686 12 3 R M 15.384604 5.678585 16.933788 5.501412 0.045592 0.909
7589 7 1 R F 15.364798 5.607862 16.811148 5.455479 0.042253 0.914
7373 7 2 R F 15.188897 5.377226 16.512984 5.244473 0.040672 0.920
7591 7 3 R F 15.059866 5.406977 15.982573 5.283505 0.039834 0.942
7594 8 1 R F 15.571749 5.731568 16.548112 5.601631 0.041147 0.941
7605 8 2 R F 15.21272 5.595373 16.264817 5.440775 0.042714 0.935
7607 8 3 R F 15.119068 5.406036 16.021759 5.266476 0.042986 0.944
7636 9 1 R F 15.722841 5.919121 17.200876 5.746082 0.04449 0.914
7638 9 2 R F 15.772005 6.004556 17.047446 5.840286 0.044615 0.925
7674 10 0 L M 17.1404 6.220476 20.202814 5.969568 0.042672 0.848
7677 10 1 L M 16.134152 6.169273 17.427955 6.011589 0.043377 0.926
7679 11 0 L M 16.838521 5.826803 19.606438 5.545989 0.046242 0.859
7330 11 1 L M 16.718686 5.839458 19.087469 5.572811 0.042735 0.876
7331 12 0 L M 16.54382 5.776666 19.450437 5.512364 0.043866 0.851
7681 12 1 L M 16.394748 5.978959 18.263421 5.757444 0.04326 0.898
7683 12 2 L M 17.098638 6.358474 20.612176 6.084773 0.042432 0.830
7685 12 3 L M 16.008298 5.561242 18.549694 5.331015 0.044376 0.863
7588 7 1 L F 16.102916 5.519912 18.507427 5.270394 0.043771 0.870
7284 7 2 L F 16.428728 5.683327 18.739436 5.418552 0.045481 0.877
7590 7 3 L F 16.41398 5.776796 18.918011 5.530736 0.043699 0.868
7593 8 1 L F 16.857735 5.846204 19.098036 5.565243 0.045767 0.883
7604 8 2 L F 15.412229 5.66625 17.043661 5.509471 0.041147 0.904
7606 8 3 L F 16.47192 5.567927 18.977188 5.293517 0.044413 0.868
7635 9 1 L F 15.954027 5.629 17.641485 5.416272 0.044278 0.904
7637 9 2 L F 16.924822 5.983453 19.37751 6.650791 0.047231 0.873






Bone Cage Mouse Limb Sex VOX‐TV VOX‐BV VOX‐BV/TV Conn‐DenTRI‐SMI DT‐Tb.N DT‐Tb.Th DT‐Tb.Sp vBMD
7567 4 1 R M 1.5913 0.0685 0.0431 26.0788 3.2512 2.9599 0.0448 0.3339 42.699
7570 4 2 R M 1.7225 0.113 0.0656 71.9884 2.6072 3.3138 0.0416 0.3011 68.5645
7572 4 3 R M 1.7692 0.0724 0.0409 20.3486 3.3702 2.5776 0.049 0.3788 36.6232
7574 5 1 R M 1.6688 0.0999 0.0598 58.1262 2.7965 3.4334 0.0427 0.2902 63.7038
7580 5 3 R M 1.6284 0.1066 0.0655 65.0943 2.9069 3.2192 0.0465 0.3087 67.1757
7582 5 4 R M 1.6476 0.0698 0.0424 43.3954 3.0709 3.1035 0.0389 0.3191 36.1024
7584 6 1 R M 1.5573 0.0611 0.0392 52.334 3.1372 3.1984 0.0367 0.3137 34.2797
7587 6 2 R M 1.5185 0.0426 0.028 32.2681 3.0858 2.7721 0.0354 0.3703 27.4227
mean 0.0480625 46.20423 3.028238 3.072238 0.04195 0.326975 47.07138
stdev 0.013827709 18.81116 0.247662 0.286519 0.004766 0.032082 16.65221
7566 4 1 L M 1.6798 0.0439 0.0261 18.1565 3.6342 2.6495 0.0371 0.3771 11.1917
7569 4 2 L M 1.4695 0.0588 0.04 38.1079 3.1446 2.9861 0.0394 0.3385 50.6843
7571 4 3 L M 1.5875 0.0413 0.026 9.1339 3.5679 2.3076 0.0428 0.4377 21.1733
7573 5 1 L M 1.6195 0.0471 0.0291 22.2286 3.6058 2.8887 0.0362 0.353 24.298
7579 5 3 L M 1.6993 0.096 0.0565 37.6622 3.0774 3.037 0.0489 0.328 55.3713
7581 5 4 L M 1.6728 0.0622 0.0372 27.4995 3.2378 2.8884 0.0389 0.3465 35.2344
7583 6 1 L M 1.2673 0.0238 0.0187 6.3125 3.7806 2.7019 0.0339 0.3667 16.2259
7586 6 2 L M 1.5607 0.0495 0.0317 22.1058 3.3339 2.5745 0.0398 0.395 31.589
mean 0.0331625 22.65086 3.422775 2.754213 0.039625 0.367813 30.72099
stdev 0.011567681 11.69917 0.258036 0.243573 0.004592 0.035514 15.81685
Table 5.16: Hemophilia study 28 day male distal femur trabecular microCT raw data 
Bone Cage Mouse Limb Sex VOX‐TV VOX‐BV VOX‐BV/TV Conn‐Dens. TRI‐SMI DT‐Tb.N DT‐Tb.Th DT‐Tb.Sp vBMD
7484 1 1 R F 1.6929 0.1203 0.0711 96.5827 2.6333 3.3087 0.0425 0.3008 75.5082
7556 1 2 R F 1.5438 0.0785 0.0509 78.6999 2.6424 3.0643 0.0359 0.3272 45.7369
7558 2 1 R F 1.4737 0.0497 0.0337 48.177 3.1092 2.8407 0.0356 0.3449 40.5291
7560 2 2 R F 1.4811 0.0879 0.0593 73.5935 2.8001 3.0283 0.0407 0.333 65.0058
7372 3 1 R F 1.3955 0.0865 0.062 58.4028 2.5726 3.0401 0.0444 0.3321 66.5681
7563 3 2 R F 1.5182 0.0709 0.0467 68.8337 2.6519 3.041 0.0372 0.3402 49.4691
7565 3 3 R F 1.5015 0.1237 0.0824 84.2473 2.2598 3.4083 0.0436 0.2976 84.1879
mean 0.058014286 72.64812857 2.667043 3.104486 0.039986 0.325114 61.00073
stdev 0.016089586 16.13090996 0.254934 0.19113 0.003721 0.018631 16.22857
7483 1 1 L F 1.3174 0.0984 0.0747 82.7384 2.7438 3.3285 0.0442 0.3047 81.4104
7555 1 2 L F 1.185 0.082 0.0692 75.9466 2.4285 3.008 0.0438 0.3371 71.3419
7557 2 1 L F 1.2861 0.0507 0.0394 54.0382 2.9007 2.8764 0.0373 0.3559 40.3555
7559 2 2 L F 1.3163 0.0716 0.0544 66.8526 2.9787 3.3683 0.0418 0.2978 54.243
7283 3 1 L F 1.0685 0.0487 0.0455 32.756 2.7718 2.8097 0.044 0.3554 59.7979
7562 3 2 L F 1.3328 0.0524 0.0393 50.645 2.9077 3.0726 0.0348 0.3345 42.8726
7564 3 3 L F 1.0736 0.0834 0.0777 67.5294 2.2276 3.1793 0.0417 0.317 88.7013
mean 0.057171429 61.50088571 2.7084 3.091829 0.041086 0.328914 62.67466
stdev 0.016595553 16.95339146 0.278253 0.213504 0.003658 0.023182 18.58839


















7567 4 1 M R 15.464343 5.587304 16.731585 5.438365 0.042452 0.924
7570 4 2 M R 15.815441 5.851648 17.49438 5.681662 0.042858 0.904
7572 4 3 M R 15.599304 5.948141 17.405721 5.788374 0.041051 0.896
7574 5 1 M R 15.722147 5.953772 17.983744 5.781172 0.043075 0.874
7582 5 4 M R 15.57477 5.877714 17.115993 5.700062 0.043879 0.910
7584 6 1 M R 15.319872 5.641923 16.539148 5.499987 0.04257 0.926
7587 6 2 M R 15.116242 5.447719 16.80826 5.278989 0.044708 0.899
7484 1 1 F R 15.548997 5.712913 16.319816 5.520467 0.045507 0.953
7556 1 2 F R 14.948842 5.280682 16.004523 5.144027 0.041429 0.934
7558 2 1 F R 15.261264 5.539311 16.831307 5.385654 0.0412 0.907
7560 2 2 F R 15.03495 5.400912 16.189968 5.25637 0.043821 0.929
7372 3 1 F R 15.210144 5.525913 16.474981 5.372185 0.04313 0.923
7563 3 2 F R 15.37999 5.700497 16.97575 5.523308 0.043731 0.906
7565 3 3 F R 15.677605 5.82735 17.045368 5.646246 0.043885 0.920
7566 4 1 M L 17.757067 6.551532 20.833671 6.290814 0.042798 0.852
7569 4 2 M L 17.263769 6.311147 19.661657 6.047939 0.043862 0.878
7571 4 3 M L 16.872719 6.108522 18.676973 5.829409 0.044857 0.903
7573 5 1 M L 17.982778 6.840592 21.962639 6.548373 0.044767 0.819
7581 5 4 M L 16.814775 6.400316 19.549672 6.143586 0.042526 0.860
7583 6 1 M L 16.371559 5.659333 18.661996 5.440204 0.04219 0.877
7586 6 2 M L 15.548231 5.370789 17.233788 5.183357 0.04211 0.902
7483 1 1 F L 17.334766 6.269121 20.288576 5.947821 0.046036 0.854
7555 1 2 F L 15.810539 5.482948 17.524152 5.276077 0.042522 0.902
7557 2 1 F L 16.396863 5.85041 18.616133 5.606648 0.042529 0.881
7559 2 2 F L 17.459496 5.925364 20.693067 5.654189 0.041464 0.844
7283 3 1 F L 17.394983 5.810463 19.96115 5.534362 0.042032 0.871
7562 3 2 F L 16.676864 5.848213 18.865349 5.618741 0.041631 0.884
7564 3 3 F L 17.558508 6.239688 20.553942 5.986088 0.043017 0.854






Figure 5.8: Example setup for hemophilia study Raman spectroscopy array on uninjured limb 
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